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ABSTRACT 
Over the past few years, G-quadruplex DNA has been established as a potential target for anti-
cancer drugs. The formation of quadruplexes in the promoter region of certain oncogenes (such as c-
myc) is thought to play an important role in regulating their expression. Furthermore the 
stabilisation of quadruplex DNA in the telomeric region is thought to inhibit telomerase, an enzyme 
overexpressed in cancerous cells and related to cell proliferation. Therefore the development of 
small molecules with the ability to interact selectively with quadruplex DNA is receiving increasing 
attention. In particular metal complexes provide a novel approach for targeting quadruplex DNA. 
In this thesis a series of mono-, bi- and tri-nuclear metal(II)-terpyridine (with the metal being 
copper(II), platinum(II) and zinc(II)), and platinum(II)-phenanthroline complexes have been prepared 
and evaluated as quadruplex DNA (Htelo and c-myc DNA) binders. The metals complexes were 
designed to have planar geometries to π-π stack atop quadruplex DNA. Side arms were incorporated 
to provide additional interactions with the loops, grooves and phosphate backboneof DNA.  
Once prepared, the ability of the complexes to π-π stack in solid and solution state was probed using 
X-ray crystallography and 1H NMR and/or UV-Vis spectroscopy respectively.  This gave an insight into 
the propensity of the complexes to π-π stack with quadruplex DNA. Metal complex-quadruplex DNA 
interactions were studied using a number of well established biophysical techniques. Fluorescence 
intercalator displacement assays, UV-Vis, fluorescence, 1H NMR and circular dichroism spectroscopic 
studies were used to probe non-covalent interactions.  Several of the compounds were found to 
bind with high affinity and selectivity to quadruplex DNA (especially c-myc DNA). 1H NMR 
spectroscopic experiments with guanosine were used to investigate the potential of the complexes 
to form covalent bonds with DNA.  
A selection of the most potent quadruplex DNA binders were studied in cells. The MTS assay was 
used to determine the toxicity of the complexes towards cancer (U2OS and 293T) and normal 
(GM0575) cell lines. The IC50 values showed the potential of the metal complexes as anti-cancer 
drugs. To gain a better understanding of metal complex induced cell death, cellular uptake and DNA-
flow cytometric studies were carried out. Additionally, RT q-PCR was used to probe the ability of 
these metal complexes to regulated c-myc oncogene expression. 
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complexes (2eq., 10 µM). The bi-nuclear complexes, 18-20 displayed better stabilisation 
than the mono-nuclear platinum(II)complex, 8 or the terpyridine-DPA free ligand. 
 
Figure 3-8: The NMR spectra of d(TTAGGG) in KCl, phosphate buffer (1 mM) upon increasing 
equivalents of 8. The G4-6 imino signals are observed to shift upfield and under line 
broadening. 
 
Figure 3-9: Proposed binding modes adopted by 8, 15 and 20 upon interaction with 
d(TTAGGG). The G-A cleft in the preferred binding site (labelled primary binding position). 
 
Figure 3-10: Bar graph representing the upfield shift in the imino proton signals after the 
addition of five equivalences of 8, 15 and 20. The largest shift was observed for the G4 
imino proton. 
 
Figure 3-11: (a) Chemical structure of 20. (b) Chemical structure of guanosine mono-
phosphate, GMP. (c) A comparison of the 1H NMR spectra obtained for 20 and GMP + 20 
(after 2 h incubation at 37oC). (d) A comparison of the 31P NMR spectra obtained for GMP 
and GMP + 20. 
 
Figure 3-12: (a) The 1H NMR spectra of GMP upon increasing amounts of 19 (top to bottom; 
0-30 µM). (b) The 31P NMR spectra of GMP upon increasing amounts of 19 (top to bottom; 
0-30 µM). 
 
Figure 3-13: Proposed binding mode of the bi-nuclear complexes 20, to GMP.  
Figure 3-14: (a) Chemical structure of 10. (b) Chemical structure of guanosine. (c; bottom) 
1H NMR spectra obtained for guanosine (c; middle) 10 and (c; top) guanosine + 10 after 24 h 
incubation at 37oC. The H8 signal shifts downfield and the proton signals associated to the 
sugar moiety broaden significantly. 
 
Figure 3-15: The fluorescence spectrum of 29 (in Tris- KCl buffer) upon increasing 
concentration of c-myc DNA, λex = 430 nm.  At the point of saturation, [DNA/Pt] = 50, there 
is a 36-fold enhancement in emission. 
 
Figure 3-16: Bar chart depicting the enhancement in 29 emission (in Tris- KCl buffer) upon 
addition of 50 equivalents of various biomolecules. A clear optical selectivity for c-myc DNA 
is shown. 
 
Figure 3-17: Fluorescence microscopy image of U2OS cells after incubation with 29 (20 µM 
for 16 h). The platinum(II) complex (green patches) was not taken up by the cells, instead it 
formed crystals around the cell membrane.   
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Figure 3-18: Possible intra-cellular reaction between 10 and glutathione. The adduct is 
stable due to the formation of thermodynamically favourable Pt-S bond. 
 
Figure 3-19: (a) Chemical structure of 10. (b; bottom) 1H NMR spectra obtained for 
glutathione (b; middle) 10 and (b; top) glutathione + 10 after 24 h incubation at 37oC. The Ha 
signal shifts downfield and the proton signals associated to the thiol, H1 disappears. (c) The 
experimental ESI signal for the [10-glutathione adduct]+ molecular ion. (d) The theoretical 
signal for the [10-glutathione adduct]+ molecular ion, generated using 
http://fluorine.ch.man.ac.uk/research/mstool.php. The isotopic pattern obtained was the 
same as that predicted. 
 
Figure 3-20: (a) DFT calculated structure for the 10-glutathione adduct, it displays a non-
planar geometry. (b) FID displacement curves obtained for the 10-glutathione adduct and 
10 with Htelo and c-myc DNA. Comparison of the data show how planarity affects 
quadruplex DNA binding. Upon addition of 40 eq. of the 10-glutathione adduct, 50% 
displacement of TO was not achieved, therefore no DC50 values were obtained. 
 
 
Chapter 4: Cellular Studies 
Figure 4-1: IC50 values obtained for the mono-nuclear platinum(II)-terpyridine, pyridyl- and 
phenyl-phenanthroline complexes against U2OS (cancerous), 293T (cancerous) and 
GMO5757 (normal) cell lines. The values are an average of three independent 
measurements. The associated error for each value is represented in form of capped error 
bars. 
 
Figure 4-2: IC50 values obtained for the bi- and tri-nuclear copper(II) and zinc(II)-terpyridine-
DPA complexes against U2OS (cancerous), 293T (cancerous) and GMO5757 (normal) cell 
lines. The values are an average of three independent measurements. The associated error 
for each value is represented in form of capped error bars. 
 
Figure 4-3: The cellular uptake data for selection of platinum(II) poly-pyridyl complexes. The 
amount of platinum (ng) per protein (mg) is expressed for the whole cell, cytoplasm and 
nucleus.  
 
Figure 4-4: The cellular uptake data for the bi- and tri-nuclear copper(II)and zinc(II)-
terpyridine-DPA complexes. The amount of zinc or copper (ng) per protein (mg) is expressed 
for the whole cell, cytoplasm and nucleus. 
 
Figure 4-5: (a) A graphical representation of the relationship between cytotoxicity (IC50 
values) and uptake of the complexes into the cell as a whole. (b) A graphical representation 
of the relationship between cytotoxicity (IC50 values) and uptake of the complexes into the 
nucleus. 
 
Figure 4-6: Graphical representation of the expression of c-myc in U20S cells after treatment 
with a selection of metal complexes (10 µM). The expression values are normalised relative 
to the control gene, β-actin. The values are an average of three independent 
measurements. The associated error for each value is represented in form of capped error 
bars. 
 
Figure 4-7: Histograms resulting from flow cytometric analysis after 24 h of: (a) untreated 
U2OS cells; (b) U2OS cells treated with 10 µM of 16; (c) U2OS cells treated with 10 µM of 
19; (d) U2OS cells treated with 10 µM of cis-platin; (e) U2OS cells treated with 10 µM of 22; 
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(f) U2OS cells treated with 10 µM of 21. 
Figure 4-8: Histograms resulting from flow cytometric analysis after 48 h of: (a) untreated 
U2OS cells; (b) U2OS cells treated with 10 µM of 10; (c) U2OS cells treated with 10 µM of 
19; (d) U2OS cells treated with 10 µM of cis-platin; (e) U2OS cells treated with 10 µM of 22; 
(f) U2OS cells treated with 10 µM of 21. 
 
 
Appendix 
Figure A-1: 1H COSY NMR of 18 taken in DMSO-d6 at 298K  
Figure A-2: 1H COSY NMR of 20 taken in DMSO-d6 at 298K  
Figure A-3: 1H COSY NMR of 15 taken in DMSO-d6 at 298K  
Figure A-4: 1H COSY NMR of 16 taken in DMSO-d6 at 298K  
Figure A-5: 1H COSY NMR of 24 taken in DMSO-d6 at 298K  
Figure A-6: 1H COSY NMR of 29 taken in DMSO-d6 at 298K  
Figure A-7: The NMR spectra of d(TTAGGG) in KCl, phosphate buffer (1 mM) upon increasing 
equivalents of 20. The G4-6 imino signals are observed to shift upfield and undergo line 
broadening. 
 
Figure A-8: The NMR spectra of d(TTAGGG) in KCl, phosphate buffer (1 mM) upon increasing 
equivalents of 15. The G4-6 imino signals are observed to shift upfield and undergo line 
broadening. 
 
Figure A-9: Graphical representation of TO displacement from duplex 17-mer DNA, duplex 
26-mer DNA, c-myc quadruplex DNA and Htelo quadruplex DNA upon increasing 
concentration of 4 from 0.25 to 10 μM. 
 
Figure A-10: Graphical representation of TO displacement from duplex 26-mer DNA upon 
increasing concentration of 8 from 0.25 to 10 μM. Data for duplex 17-mer DNA, c-myc 
quadruplex DNA and Htelo quadruplex DNA were recorded during the MSci project and 
have been published. 
 
Figure A-11: Graphical representation of TO displacement from duplex 26-mer DNA upon 
increasing concentration of 10 from 0.25 to 10 μM. Data for duplex 17-mer DNA, c-myc 
quadruplex DNA and Htelo quadruplex DNA were recorded during the MSci project and 
have been published. 
 
Figure A-12: Graphical representation of TO displacement from duplex 17-mer DNA, duplex 
26-mer DNA, c-myc quadruplex DNA and Htelo quadruplex DNA upon increasing 
concentration of 13 from 0.125 to 5 μM. 
 
Figure A-13: Graphical representation of TO displacement from duplex 17-mer DNA, duplex 
26-mer DNA, c-myc quadruplex DNA and Htelo quadruplex DNA upon increasing 
concentration of 14 from 0.125 to 5 μM. 
 
Figure A-14: Graphical representation of TO displacement from duplex 17-mer DNA, duplex 
26-mer DNA, c-myc quadruplex DNA and Htelo quadruplex DNA upon increasing 
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concentration of 15 from 0.0625 to 5 μM. 
Figure A-15: Graphical representation of TO displacement from duplex 17-mer DNA, duplex 
26-mer DNA, c-myc quadruplex DNA and Htelo quadruplex DNA upon increasing 
concentration of 16 from 0.5 to 10 μM. 
 
Figure A-16: Graphical representation of TO displacement from duplex 17-mer DNA, duplex 
26-mer DNA, c-myc quadruplex DNA and Htelo quadruplex DNA upon increasing 
concentration of 18 from 0.125 to 10 μM. 
 
Figure A-17: Graphical representation of TO displacement from duplex 17-mer DNA, duplex 
26-mer DNA, c-myc quadruplex DNA and Htelo quadruplex DNA upon increasing 
concentration of 19 from 0.125 to 5 μM. 
 
Figure A-18: Graphical representation of TO displacement from duplex 17-mer DNA, duplex 
26-mer DNA, c-myc quadruplex DNA and Htelo quadruplex DNA upon increasing 
concentration of 20 from 0.125 to 5 μM. 
 
Figure A-19: Graphical representation of TO displacement from duplex 17-mer DNA, duplex 
26-mer DNA, c-myc quadruplex DNA and Htelo quadruplex DNA upon increasing 
concentration of 21 from 1.25 to 10 μM. 
 
Figure A-20: Graphical representation of TO displacement from duplex 17-mer DNA, duplex 
26-mer DNA, c-myc quadruplex DNA and Htelo quadruplex DNA upon increasing 
concentration of 22 from 0.25 to 10 μM. 
 
Figure A-21: Graphical representation of TO displacement from duplex 17-mer DNA, duplex 
26-mer DNA, c-myc quadruplex DNA and Htelo quadruplex DNA upon increasing 
concentration of 24 from 0.0625 to 5 μM. 
 
Figure A-22: Graphical representation of TO displacement from duplex 17-mer DNA, duplex 
26-mer DNA, c-myc quadruplex DNA and Htelo quadruplex DNA upon increasing 
concentration of 26 from 0.125 to 5 μM. 
 
Figure A-23: Graphical representation of TO displacement from duplex 17-mer DNA, duplex 
26-mer DNA, c-myc quadruplex DNA and Htelo quadruplex DNA upon increasing 
concentration of 27 from 0.0625 to 2.5 μM. 
 
Figure A-24: Graphical representation of TO displacement from duplex 17-mer DNA, duplex 
26-mer DNA, c-myc quadruplex DNA and Htelo quadruplex DNA upon increasing 
concentration of 28 from 1.25 to 2.5 μM. 
 
Figure A-25: Graphical representation of TO displacement from duplex 17-mer DNA, duplex 
26-mer DNA, c-myc quadruplex DNA and Htelo quadruplex DNA upon increasing 
concentration of 29 from 0.5 to 2.5 μM. 
 
Figure A-26: UV-Vis titration and reciprocal plot of D/∆εap versus D for 8 (20 µM) upon 
addition of Htelo DNA. 
 
Figure A-27: UV-Vis titration and reciprocal plot of D/∆εap versus D for 8 (20 µM) upon 
addition of ct-DNA. 
 
Figure A-28: UV-Vis titration and reciprocal plot of D/∆εap versus D for 8 (20 µM) upon 
addition of c-mycDNA. 
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Figure A-29: UV-Vis titration and reciprocal plot of D/∆εap versus D for 10 (20 µM) upon 
addition of Htelo DNA. 
 
Figure A-30: UV-Vis titration and reciprocal plot of D/∆εap versus D for 10 (20 µM) upon 
addition of ct-DNA. 
 
Figure A-31: UV-Vis titration and reciprocal plot of D/∆εap versus D for 10 (20 µM) upon 
addition of c-mycDNA. 
 
Figure A-32: UV-Vis titration and reciprocal plot of D/∆εap versus D for 13 (20 µM) upon 
addition of Htelo DNA. 
 
Figure A-33: UV-Vis titration and reciprocal plot of D/∆εap versus D for 13 (20 µM) upon 
addition of ct-DNA. 
 
Figure A-34: UV-Vis titration and reciprocal plot of D/∆εap versus D for 13 (20 µM) upon 
addition of c-myc DNA. 
 
Figure A-35: UV-Vis titration and reciprocal plot of D/∆εap versus D for 14 (20 µM) upon 
addition of Htelo DNA. 
 
Figure A-36: UV-Vis titration and reciprocal plot of D/∆εap versus D for 14 (20 µM) upon 
addition of ct-DNA. 
 
Figure A-37: UV-Vis titration and reciprocal plot of D/∆εap versus D for 14 (20 µM) upon 
addition of c-myc DNA. 
 
Figure A-38: UV-Vis titration and reciprocal plot of D/∆εap versus D for 15 (20 µM) upon 
addition of Htelo DNA. 
 
Figure A-39: UV-Vis titration and reciprocal plot of D/∆εap versus D for 15 (20 µM) upon 
addition of ct-DNA. 
 
Figure A-40: UV-Vis titration and reciprocal plot of D/∆εap versus D for 15 (20 µM) upon 
addition of c-myc DNA. 
 
Figure A-41: UV-Vis titration and reciprocal plot of D/∆εap versus D for 16 (20 µM) upon 
addition of Htelo DNA. 
 
Figure A-42: UV-Vis titration and reciprocal plot of D/∆εap versus D for 16 (20 µM) upon 
addition of ct-DNA. 
 
Figure A-43: UV-Vis titration and reciprocal plot of D/∆εap versus D for 16 (20 µM) upon 
addition of c-myc DNA. 
 
Figure A-44: UV-Vis titration and reciprocal plot of D/∆εap versus D for 26 (20 µM) upon 
addition of Htelo DNA. 
 
Figure A-45: UV-Vis titration and reciprocal plot of D/∆εap versus D for 26 (20 µM) upon 
addition of ct-DNA. 
 
Figure A-46: UV-Vis titration and reciprocal plot of D/∆εap versus D for 26 (20 µM) 
uponaddition of c-myc DNA. 
 
Figure A-47: UV-Vis titration and reciprocal plot of D/∆εap versus D for 24 (20 µM) upon  
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addition of Htelo DNA. 
Figure A-48: UV-Vis titration and reciprocal plot of D/∆εap versus D for 24 (20 µM) upon 
addition of ct-DNA. 
 
Figure A-49: UV-Vis titration and reciprocal plot of D/∆εap versus D for 24 (20 µM) upon 
addition of c-myc DNA. 
 
Figure A-50: UV-Vis titration and reciprocal plot of D/∆εap versus D for 27 (20 µM) 
uponaddition of Htelo DNA. 
 
Figure A-51: UV-Vis titration and reciprocal plot of D/∆εap versus D for 27 (20 µM) upon 
addition of ct-DNA. 
 
Figure A-52: UV-Vis titration and reciprocal plot of D/∆εap versus D for 27 (20 µM) upon 
addition of c-myc DNA. 
 
Figure A-53: UV-Vis titration and reciprocal plot of D/∆εap versus D for 28 (20 µM) upon 
addition of Htelo DNA. 
 
Figure A-54: UV-Vis titration and reciprocal plot of D/∆εap versus D for 28 (20 µM) upon 
addition of c-myc DNA. 
 
Figure A-55: UV-Vis titration and reciprocal plot of D/∆εap versus D for 29 (20 µM) upon 
addition of Htelo DNA. 
 
Figure A-56: UV-Vis titration and reciprocal plot of D/∆εap versus D for 29 (20 µM) upon 
addition of ct-DNA. 
 
Figure A-57: UV-Vis titration and reciprocal plot of D/∆εap versus D for 29 (20 µM) upon 
addition of c-myc DNA. 
 
Figure A-58: UV-Vis titration and reciprocal plot of D/∆εap versus D for 19 (20 µM) upon 
addition of Htelo DNA. 
 
Figure A-59: UV-Vis titration and reciprocal plot of D/∆εap versus D for 19 (20 µM) upon 
addition of ct-DNA. 
 
Figure A-60: UV-Vis titration and reciprocal plot of D/∆εap versus D for 19 (20 µM) upon 
addition of c-myc DNA. 
 
Figure A-61: UV-Vis titration and reciprocal plot of D/∆εap versus D for 20 (20 µM) upon 
addition of Htelo DNA. 
 
Figure A-62: UV-Vis titration and reciprocal plot of D/∆εap versus D for 20 (20 µM) upon 
addition of ct-DNA. 
 
Figure A-63: UV-Vis titration and reciprocal plot of D/∆εap versus D for 20 (20 µM) upon 
addition of c-myc DNA. 
 
Figure A-64: The CD spectra of Htelo DNA (10 µM) in the presence of potassium ions, upon 
addition of increasing amounts of 8. 
 
Figure A-65: The CD spectra of Htelo DNA (10 µM) in the presence of potassium ions, upon 
addition of increasing amounts of 15. 
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Figure A-66: The CD spectra of Htelo DNA (10 µM) in the presence of potassium ions, upon 
addition of increasing amounts of 18. 
 
Figure A-67: The CD spectra of Htelo DNA (10 µM) in the presence of potassium ions, upon 
addition of increasing amounts of 19. 
 
Figure A-68: The CD spectra of Htelo DNA (10 µM) in the presence of potassium ions, upon 
addition of increasing amounts of 20. 
 
Figure A-69: The CD spectra of Htelo DNA (10 µM) in the presence of potassium ions, upon 
addition of increasing amounts of L9. 
 
Figure A-70: The CD spectra of Htelo DNA (10 µM) in the presence of potassium ions, upon 
addition of increasing amounts of 26. 
 
Figure A-71: The CD spectra of Htelo DNA (10 µM) in the presence of potassium ions, upon 
addition of increasing amounts of 24. 
 
Figure A-72: The CD spectra of Htelo DNA (10 µM) in the presence of potassium ions, upon 
addition of increasing amounts of 27. 
 
Figure A-73: The CD spectra of Htelo DNA (10 µM) in the presence of potassium ions, upon 
addition of increasing amounts of L13. 
 
Figure A-74: The CD spectra of Htelo DNA (10 µM) in the absence of salts, with and without 
the addition of two equivalents of 8, 10 and 15. 
 
Figure A-75: The CD spectra of Htelo DNA (10 µM) in the absence of salts, with and without 
the addition of two equivalents of 18, 19, 20 and L9. 
 
Figure A-76: CD melting curves for c-myc DNA (5 µM) with and without the presence of 3 
and 4 (2eq., 10 µM).  
 
Figure A-77: CD melting curves for c-myc DNA (5 µM) with and without the presence of L4, 
10, 13, 14 and 15 (2eq., 10 µM). 
 
Figure A-78: CD melting curves for c-myc DNA (5 µM) with and without the presence of 24, 
26 and 27 (2eq., 10 µM). 
 
Figure A-79: CD melting curves for c-myc DNA (5 µM) with and without the presence of 21 
and 22 (2eq., 10 µM). 
 
Figure A-80: CD melting curves for c-myc DNA (5 µM) with and without the presence of 
TmPyP4 (2eq., 10 µM). 
 
Figure A-81: (a) Chemical structure of 20. (b) Chemical structure of guanosine. (c; bottom) 
1H NMR spectra obtained for guanosine (c; middle) 20 and (c; top) guanosine + 20 after 24 h 
incubation at 37oC.  
 
Figure A-82: (a) Chemical structure of 15. (b) Chemical structure of guanosine. (c; bottom) 
1H NMR spectra obtained for guanosine (c; middle) 15 and (c; top) guanosine + 15 after 24 h 
incubation at 37oC.  
 
Figure A-83: (a) Chemical structure of 13. (b) Chemical structure of guanosine. (c; bottom) 
1H NMR spectra obtained for guanosine (c; middle) 13 and (c; top) guanosine + 13 after 24 h 
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incubation at 37oC.  
Figure A-84: MTS assay profile for the platinum(II)-terpyridine complexes with the U2OS cell 
line. 
Figure A-85: MTS assay profile for the bi-metallic complexes with the U2OS cell line. 
Figure A-86: MTS assay profile for the tri-metallic complexes with the U2OS cell line. 
Figure A-87: MTS assay profile for the pyridyl-phenanthroline platinum(II) complexes with 
the U2OS cell line. 
Figure A-88: MTS assay profile for the phenyl-phenanthroline platinum(II) complexes with 
the U2OS cell line. 
Figure A-89: MTS assay profile for the platinum(II)-terpyridine complexes with the 293T cell 
line. 
Figure A-90: MTS assay profile for the di-metallic complexes with the 293T cell line. 
Figure A-91: MTS assay profile for the tri-metallic complexes with the 293T cell line. 
Figure A-92: MTS assay profile for the pyridyl-phenanthroline platinum(II) complexes with 
the 293T cell line. 
Figure A-93: MTS assay profile for the phenyl-phenanthroline platinum(II) complexes with 
the 293T cell line. 
Figure A-94: MTS assay profile for the platinum(II)-terpyridine complexes with the 
GMO5757 cell line. 
Figure A-95: MTS assay profile for the di-metallic complexes with the GMO5757 cell line. 
Figure A-96: MTS assay profile for the tri-metallic complexes with the GMO5757 cell line. 
Figure A-97: MTS assay profile for the pyridyl-phenanthroline platinum(II) complexes with 
the GM05757 cell line. 
Figure A-98: MTS assay profile for the phenyl-phenanthroline platinum(II) complexes with 
the GM05757 cell line. 
Figure A-99: Forward scatter - height (cell size) vs side scatter (cell texture) dot plot. The 
population of cells selected for study are shown by the gates. 
 
Figure A-100: Forward scatter - height vs forward scatter – area dot plot. The population of 
cells selected for study are shown by the gates. 
 
Figure A-101: An example of a histrogram respresenting the different phases of the cell 
cycle for the cells in the chosen population. 
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LIST OF ABBREVIATIONS 
A:   Adenine 
bp:   Base pairs 
BSA:   Bovine Serum Albumin 
C:   Cytosine  
CD:   Circular Dichroism 
cDNA:   Complementary Deoxyribonucleic Acid 
COSY NMR:  Correlation Spectroscopy Nuclear Magnetic Resonance 
ctDNA:   Calf Thymus DNA 
Ctr1:   Copper-transport 1 
DC50:   Displacement Concentration 
DNA:   Deoxyribonucleic Acid 
DPA:   Dipicolylamine 
EC50:   Half maximal Effective Concentration 
ESI-MS:   Electron Spray Ionisation Mass Spectroscopy 
FID:   Fluorescent Intercalator Displacement assay 
FRET:   Fluorescence Resonance Energy Transfer assay 
G:   Guanine 
GMP:   Guanosine monophosphate 
Htelo DNA:  Human Telomeric DNA 
hTERT:   Human Telomerase Reverse Transcriptase 
hTR:   Human Telomerase RNA 
HSA:   Human Serum Albumin 
IC50:   Half maximal Inhibitory Concentration 
ICP-MS:   Inductively Coupled Plasma Mass Spectrometry 
MLCT:   Metal to Ligand Charge Transfer 
MMLCT:  Metal – Metal to Ligand Charge Transfer  
mRNA:   Messenger Ribonucleic Acid 
MTS: 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium 
NHE III1:  Nuclear Hypersensitivity Element III1 
NMR:   Nuclear Magnetic Resonance 
PMS: Phenazinemethosulfate 
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POT1:   Protection of Telomeres 1 
Rap1:   Ras-related Protein 1 
RNA:   Ribonucleic Acid 
RT-qPCR:  Quantitative Real Time Polymerase Chain Reaction 
SPR:    Surface Plasmon Resonance 
T:   Thymidine 
TIN2:   TRF1-Interacting Protein 2 
TMPyP4:  5,10,15,20‐tetra(N‐methyl‐4‐ pyridyl) porphyrin 
TO:   Thiazole Orange 
TPP1:   Tripeptidyl-Peptidase 1 
TQMP: 5,10,15,20‐tetra[4-hydroxy-3-(trimethylammonium)methyl-phenyl] 
porphyrin 
TRAP-LIG:  Telomere Repeat Amplification Protocol – Ligand assay 
TRF1:   Telomeric Repeat Binding Factor 1 
TRF2:   Telomeric Repeat Binding Factor 2 
TRIS:   2-Amino-2-hydroxymethyl-propane-1,3-diol 
U:   Uridine 
UV-Vis:   Ultra Violet- Visible 
WHO:   World Health Organisation 
VC:   Variable Concentration 
vs.   Verus 
VT:   Variable Temperature 
VTCD:   Variable Temperature Circular Dichroism 
Å:   Angstrom  
a.m.u.   Atomic Mass Unit  
M:   Molar 
mM:   Milli-molar 
ppm:    Parts per Million 
δ :   Chemical Shift 
Δδ :   Change in Chemical Shift 
ε:   Molar Absorbtivity  
λ :   Wavelength 
Tm:   Melting Temperature  
ΔTm:   Change in Melting Temperature 
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CHAPTER 1 
 
 
INTRODUCTION 
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Cancer is a prevalent and potentially fatal disease affecting all age groups. The World Health 
Organisation (WHO) reported 7.6 million people to have died from cancer during 2008 worldwide.[1] 
Deaths from cancer are projected to continue increasing, reaching as estimated 12 million deaths in 
2030. This ominous statistic illustrates the deadly nature and sheer magnitude of the illness. Cancer 
occurs as a result of cells displaying undesirable characteristics such as uncontrollable growth, where 
cell growth and division transpires at levels beyond the normal programmed limits. Intrusion on and 
eradication of adjacent cells and metastasis are also common features exhibited by cancerous cells. 
Nearly all cancers arise from deformities in genetic material. Such malfunctions result from the 
effects of carcinogens, errors that occur during DNA replication and in some cases are inherited.  
Science holds the key to developing a cure for cancer and researchers have been exploring potential 
avenues for decades. More specifically, bio-inorganic chemistry has provided a number of 
breakthroughs in cancer treatment.[2] Metallo-drugs based on platinum, (cisplatin [Platinol®], 
carboplatin [Paraplatin®], nedaplatin [Aqupla®]) arsenic (arsenic oxide [Trisenox®]) and both iron 
and copper (bleomycin [Blenoxane®]) are already used clinically to treat tumours. The majority of 
these clinical agents function through interacting with nucleotide targets and prevent DNA 
synthesis/replication which ultimately leads to tumour cell death. The nature of both the metal 
centre and coordinated ligand(s) is highly significant as both influence the nature of the drug-DNA 
interaction. While cisplatin and other metallo-pharmaceuticals are extremely effective against solid 
tumours (ca. 60% treated with platinum complexes)[3], many cancers display intrinsic, acquired and 
cross-resistance against the drugs. It is therefore of great importance to develop new anticancer 
drugs that can treat a wider range of cancers. 
As indicated above, clinically approved metallo-drugs are proposed to act via their interaction with 
duplex DNA. More recently, G-quadruplex DNA has emerged as an attractive target for the 
development of novel anticancer agents. The inhibition of telomerase mediated by the stabilisation 
of quadruplex DNA has been one focal point in recent cancer research.[4] Another is the regulation 
of oncogenes expression by quadruplex DNA stabilisation.[5] 
 
1.1 DNA 
DNA is made up of nucleotides which are constructed from phosphate ions, pentose sugars and 
bases (see Figure 1-1). The nucleotides form phosphodiester linkages between adjacent phosphate 
groups and pentose sugars at the 3’ and 5’ positions to give DNA strands. 
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Figure 1-1: (a) Simplified chemical structure of a nucleotide. (b) Chemical structure of the four DNA bases. (c) Chemical 
structure of the phosphodiester linker that holds the DNA strands together. 
 
As was famously reported by Watson and Crick in 1953, DNA exists in living organisms as a pair of 
anti-parallel strands entwined around one another producing a double helical structure.[6] The 
double helix structure is stabilised by hydrogen bonds formed between complementary bases on the 
two strands. Adenine was found to bond to thymine via two hydrogen bonding interactions and 
cytosine to guanine via three. π-π stacking between bases is another very important supra-molecular  
interaction that contributes to the stability of duplex DNA. There are three different conformations 
of doubly stranded DNA, B-DNA, A-DNA and Z-DNA (see Figure 1-2). However under physiological 
conditions, B-DNA is the most common, this conformation can be described as a right-handed spiral 
with the sugars adopting C2’-endo geometries.[7] 
(a) 
(b) 
(c) 
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Figure 1-2: Structures of double helical DNA present in living organisms: (a) A-DNA: right handed with C3’-endo sugar 
geometry (b) B-DNA: right handed with C2’-endo sugar geometry (c) Z-DNA: left handed with C2’-endo and C2’-exo sugar 
geometry (taken from R. Wheeler). 
 
 
1.2 G-quadruplex DNA 
1.2.1 Structural Aspects 
Apart from the double helix, DNA is able to adopt a number of other biologically important 
secondary structures. Quadruplex DNA is one such structure and it is regarded as a potential anti-
cancer target. Quadruplex DNA results in guanine rich DNA sequences. The guanine units are able to 
form planar G-tetrads via Hoogsteen hydrogen bonding (Figure 1-3). The tetrads π-π stack forming 
quadruplex structures with vacant cavities occupied by Na+ and K+ ions. The metal ions are able to 
stabilise the structure by interacting (electrostatically) with the electronegative carbonyl groups 
present in each set of tetrads. The fact that the carbonyl groups are directed towards the centre of 
the G-tetrad makes such interactions more feasible.[8] 
 
 
 
 
(c) (a) (b) 
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Figure 1-3: (a) Structure of G-tetrad, four guanine bases are held together by hydrogen bonds and electrostatic 
interactions with the central cation (b) Three possible G-quadruplex topologies (l to r): tetra-, bi- and intra-molecular. 
Several book chapters and reviews have described the rich geometry and topology of quadruplex 
structures. The structures are generally classified in terms of their molecularity and strand 
orientation. Tetra-molecular quadruplexes result when four separate guanine rich strands 
assemble.[9, 10] When two strands are involved, dimerised guanine-guanine hairpins of several 
types have been observed. Furthermore the existence of antiparallel intramolecular quadruplexes 
has been reported for DNA sequences with either four guanine rich regions or long tracts.[11-13] 
The G-tetrads that make up the quadruplex structures are held in place by loops. Loops are 
intervening nucleotide sequences that are not involved in the make-up of the tetrads. There are four 
main types of loops (Figure 1-4)[14]: (1) edgewise or lateral type loops which connect two adjacent 
antiparallel strands, (2) diagonal loops which connect two opposing antiparallel strands, (3) double 
chain reverse or “propeller” loops which connect adjacent parallel strands and (4) V-shaped loops 
which connect two corners of a tetrad core. 
 
Figure 1-4: Schematic of the different classes of loops that exist in G-quadruplex DNA (taken from Ref. 14). 
(a) 
(b) 
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1.2.2 Biological Relevance 
Bio-informatic studies suggest the existence of ca. 370,000 putative quadruplex forming sequences 
in the human genome.[15, 16] Significantly, a large proportion of them appear in the promoter 
regions of genes hence it can be hypothesised that they have an important biological role in gene 
regulation. Since quadruplex structures readily form from the telomeric sequence under 
physiological conditions, it can be hypothesised that they also play a role in vivo, associated with the 
recognition of telomere ends and proteins as well as the inhibition of telomerase. 
 
1.2.3 Human Telomeric DNA 
The telomere is a region of highly repetitive non coding DNA at the ends of eukaryotic 
chromosomes. The telomere is usually 5-8 kilo-bases long.[17] It is largely doubly stranded but 
consists of a short singly stranded overhang at the 3’ terminus (100-200 bases). The overhang is 
guanine rich (made up of 30-40 repeats of TTAGGG in vertebrates) and therefore has the propensity 
to form quadruplex structures.The telomere is protected by the shelterin complex, which is made up 
of six proteins subunits (TRF1, TRF2, Rap1, TIN2, TPP1 and POT1).[18] The protein complex folds the 
telomere into a closed t-loop structure.  In fact the shelterin complex binds in such a way that the 
overhang folds back on itself, forming an additional triplex D-loop structure with the telomeric 
double stranded region.[19] This closed system prevents degradation of the overhang and end-to-
end chromosome fusion, which both lead to cell senescence and apoptosis.[20, 21] 
35 
 
 
Figure 1-5: Schematic showing the location of the telomere within a normal cell. A simplified model of its structure is 
also displayed[22] (taken from Ref. 22). 
 
During DNA replication, DNA polymerase is unable to replicate the chromatid fibres (the sequences 
present at the end of the chromosomes i.e. the telomere) therefore genetic information contained 
in these portions is lost (50-200 bases are lostduring each replication cycle).[4] After several 
replication processes, the telomere is shortened to a level that is harmful to cells, this is known as 
the Hayflick limit.[23] Beyond this point cells undergo apoptosis or cell death.[24] Therefore the cell 
lifespan is controlled by the telomere length. The telomere length is maintained in cancer cells (also 
stem and germline cells) through telomerase over-expression (85% of all malignant tumours have 
been reported to over-express the enzyme). This enzyme is deactivated in normal somatic cells.[25, 
26] Telomerase is a ribonucleoprotein holoenzyme which is made up of a reverse transcription 
protein (hTERT) and a RNA subunit (hTR). hTR is a 11-mer sequence complementary to the telomeric 
overhang. The hTERT protein catalyses the addition of nucleotides to the telomere ends using the 
RNA template (hTR) which results in elongation of the telomeric overhang. Telomerase activity in 
cancerous cells means that the telomere lengths are maintained at reasonable lengths, allowing 
long-living cells with the ability to proliferate. Therefore inhibiting telomerase is a potential way of 
tackling cancer. A number of approaches have been explored to do so; (1) inhibiting the enzyme 
directly by targeting the hTERT or hTR subunits[27-30]; (2) promoting the formation of the shelterin 
protein complex, thereby protecting the telomeric overhang through the formation of t- and D-loop 
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structures[31]; (3) targeting the c-myc gene which encodes the transcriptional regulation protein, c-
Myc, which has a number of roles including the activation of hTERT[32]; (4)inducing the formation of 
quadruplex structures in the telomeric region.[33] This approach relies on the inability of telomerase 
to bypass the folded form of DNA. 
 
 
Figure 1-6: (a) Diagram depicting the t-loop and D-loop structures formed upon binding of the shelterin complex to the 
telomeric overhang (b) Simplified diagram showing the action of telomerase (hTERT and hTR) on the telomere (taken 
from Ref. 21). 
 
1.2.4 Structure of Human Telomeric DNA 
The structure of human telomeric DNA has been resolved using both X-ray crystallography (solid 
state) and NMR spectroscopy (solution state). NMR spectroscopy was used to resolved the structure 
of the 22-mer sequence, d[AGGG(TTAGGG)3]  in sodium solution.[34] The structure displayed an 
anti-parallel intramolecular arrangement with three stacked G-tetrads interconnected by one 
diagonal and two lateral loops (Figure 1-7). In potassium solution the same sequence was found to 
adopt a number of distinctive topologies.[35] The structure determined by Neidle and co-workers 
using X-ray crystallography found a parallel intramolecular orientation with propeller type loops 
(a) 
(b) 
37 
 
linking the G-tetrads. More recently Patel et al. reported a different structure in the presence of K+ 
ions, using NMR spectroscopy; the telomeric sequence was found to give a 3+1 strand fold topology 
where one guanine in each quartet was oriented opposite to the other three.[36] Another Htelo 
sequence (26-mer), resolved by NMR spectroscopy, was found to adopt a mixture of parallel and 
anti-parallel topologies (a hybrid) with propeller and lateral loops.[37] Due to the structural diversity 
of the telomeric sequence in potassium solution, a universal agreement on its absolute orientation is 
yet to be reached. Currently the general consensus is that in the presence of potassium ions, it 
adopts a hybrid structure. 
The above mentioned human telomeric structures were resolved in physiological buffer however 
this doesn’t account for the molecular crowding experienced within a cellular environment. The 
crowded intracellular environment can affect the structure, stability and activity of quadruplex DNA. 
Therefore it is of importance to know the conformation of Htelo DNA in crowded cell-like 
environments. The first high resolution structure of Htelo DNA in “crowded” solution was resolved 
using NMR spectroscopy by Phan et al. in 2011.[38] In potassium ion containing molecular crowded 
solution (40% (v/v) PEG 200 was used as the crowding agent), Htelo DNA was found to adopt a 
parallel structure with propeller-type loops. The structure was proposed to result as a direct result of 
water depletion. The structure resembles that resolved using X-ray crystallography. Comparsion of 
the two structures found the tetrads to be similar and the loops to be slightly different. The crytals 
representation found a flatter loop orientation in comparsion to the NMR “crowded” structure. 
 
 
Figure 1-7: (a) NMR resolved quadruplex structure for intramolecular human telomeric DNA formed in sodium solution 
(b) Simplified diagram representing the same structure (taken from Ref. 34). 
 
(a) (b) 
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1.2.5 Promoter Region: c-myc DNA 
Promoter regions are sections of DNA that regulate and control transcription of a particular gene. It 
is generally located near the gene it controls, on the same strand and usually upstream. Potential 
quadruplex forming sequences are over-represented in the promoter regions of many oncogenes 
(such as c-myc, c-kit, Bcl2 and VEGF). The inhibition of oncogene transcription through quadruplex 
formation and stabilisation is an anti-cancer methodology that is currently receiving a lot of 
attention.  The c-myc oncogene is the most thoroughly studied system and will be one of the 
quadruplex sequences studied in this thesis.[39, 40] c-myc is related to cellular proliferation and cell 
growth regulation and its overexpression has been associated to a broad range of cancers, therefore 
suppression of this gene is thought to be one way of treating cancer.[41-43] 
Unlike telomeric DNA, the quadruplex sequence in the c-myc promoter region (the 33-mer guanine 
rich nuclear hypersensitivity element, NHE III1) is double stranded.[44] However during the 
transcription process, negative superhelicity in the c-myc promoter region resulting from the 
movement of duplex DNA through the transcriptional protein complex of RNA polymerase, leads to 
exposure of the single strands.[45] At this point the guanine- and complementary cytosine-rich 
regions can fold into quadruplex and i-motif structures (an intercalated structure formed by 
association in a head to tail orientation of two parallel duplexes whose strands are held together by 
hemi-protonated cytosine-cytosine+ pairs) respectively. Detailed studies have identified that the 
NM23-H2 protein unfolds these secondary structures, thereby returning the DNA to its original state 
which allows the re-binding of transcription factors (Sp1, CNBP, HNRNP K, RNA POL II) and 
continuation of transcription.[46-48] On the other hand the nucleolin protein was found to stabilise 
the quadruplex structure and hence prevent transcription.[40] Therefore by inducing the formation 
of quadruplex structures in the NHE III1 region, c-myc transcription and expression can be controlled. 
As a result, small molecules that have the ability to stabilise and selectivity interact with c-myc DNA 
are receiving huge interest as potential anti-cancer drugs. 
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Figure 1-8: Schematic showing the role of quadruplex structures in controlling the transcription of c-myc DNA. It also 
shows the role played by NM23-H2, nucleolin and quadruplex binders in stabilising and de-stabilising these quadruplex 
structures[49] (taken from Ref. 49). 
 
1.2.6 Structure of c-myc DNA 
To date, no solid state structures have been reported for the c-myc sequence. However two 
independent NMR spectroscopic studies in potassium solution have been carried out. Both found 
the c-myc sequence to fold into a quadruplex structure with parallel topology.[50] In the most recent 
report, Yang et al. proposed the existence of a stable intramolecular parallel structure with three 
tetrads and three well defined side loops (Figure 1-9).[51] The stability of the structure was 
attributed to the shortness of the loops. The loops were found to be made up of either one or two 
nucleotides. Further studies have shown the c-myc parallel structure exists as a dynamic mixture of 
four different loop isomers, with the isomers differing by the number of nucleotides making up the 
loops.[52, 53] 
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Figure 1-9: (a) NMR resolved quadruplex structure for intramolecular c-myc DNA formed in potassium solution. (b) 
Simplified diagram representing the same structure (taken from Ref. 51). 
 
1.2.7 Human Telomeric and c-myc DNA  
As discussed above both Htelo and c-myc sequences are guanine-rich and have been shown to fold 
into quadruplex structures in vitro. The conformation of Htelo DNA is highly dependent on the 
conditions under which they are studied (for example the cation present and loop sequence), 
whereas the c-myc structure is more predictable (only parallel topologies have been reported).  
In a biological sense the two quadruplex sequences are related. As discussed in detail above, the G-
rich region in the promoter of c-myc can form quadruplex structures that can regulate its 
transcription. The c-myc oncogene encodes the transcriptional regulation protein, c-Myc which 
controls a number of other genes involved in the proliferation aptitude of cells.[54] Importantly, c-
Myc also activates the telomerase protein, hTERT and binds to proteins that protect the telomere 
(such as TRF1).[55] Therefore the c-myc gene indirectly influences the elongation of the telomere. 
Activation of hTERT and binding to TRF1 by c-Myc leads to telomere elongation in vivo. This in turn 
can result in cell senescence or cell proliferation, both of which have detrimental effects.[56] 
Therefore by inducing quadruplex formation in the promoter region of the c-myc oncogene, not only 
is the expression of the c-Myc protein suppressed but the elongation of the telomere is also 
prevented.[57] 
 
(b) (a) 
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Figure 1-10: Schematic describing the cellular relationship between Htelo and c-myc DNA (modified from image in Ref. 
57). 
 
1.3 Quadruplex DNA Binders 
1.3.1 Organic Molecules 
As discussed earlier, high resolution NMR spectroscopic and X-ray crystallographic studies have 
given great insight into the structures of quadruplex DNA.[10, 35, 58] These investigations have 
shown a number of structures and topologies to exist, depending on the DNA sequence involved and 
the conditions under which they are examined. The structural features of quadruplex DNA have 
provided the basis for rationalising the properties required for good stabilisers. In order for small 
molecules to act as strong quadruplex binders they are required to contain: (1) π-delocalised 
moieties that are able to interact with the face of the guanine quartet via non-covalent π-π 
interactions, (2) a partial positive charge that is able to occupy the centre of the guanine quartet and 
thus stabilised the structure by electrostatic interactions and (3) positively charged or readily 
protonated side chains which are able to interact favourably with the loop/ grooves/ negatively 
charged phosphate backbone of DNA.  
Using these principles many planar organic molecules have been developed as good quadruplex 
stabilisers. Comprehensive reviews and book chapters of organic based quadruplex DNA binders 
have been published previously. In this section the most notable quadruplex binders will be 
presented.  
The 2,6-diamindoanthraquinone family was one of the first series of organic molecules to show 
effective quadruplex stabilisation and telomerase inhibition (Figure 1-11).[59] These molecules were 
designed to have a planar geometry with two protonable side arms to afford π-π stacking and 
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electrostatic interactions. However the anthraquinones were found to have poor selectivity for 
quadruplex DNA (over duplex DNA). Development of the core and side chains led to the preparation 
of a series of di-subsituted acridines. These polyaromatic molecules were shown to have significantly 
improved selectivities.[60, 61] A member of this family, BSU6039,was crystallised with dimeric anti-
parallel telomeric DNA, d(GGGGTTTTGGGG), derived from Oxytricha nova.[62] The X-ray crystal 
structure found the acridine moiety bound to one end of the quadruplex structure, shielded by the 
thymine loop. The compound was proposed to bind by a combination of π-π interactions (with the 
G-tetrads) and specific hydrogen bonds (with the thymine bases). BSU6039 was improved further to 
give one of the best G-quadruplex stabilisers known to date, BRACO-19 (Figure 1-11).[63, 64] The 
crystal structure of BRACO-19 complexed with bimolecular human telomeric quadruplex DNA, 
d(TAGGGTTAGGGT)2, found the compound sandwiched between two separate quadruplex 
structures (see Figure 1-11).[65] BRACO-19 was found to interact with the guanine tetrad of one 
quadruplex and the TATA tetrad of another (through π-π interactions). Furthermore, this tri-
substituted acridine exhibited a 31-fold preference for quadruplex DNA over duplex DNA. Selectivity 
was attributed to its three side arms which hinder intercalation between base pairs in duplex DNA. 
 
Figure 1-11: Chemical structures of early organic molecules known to bind to quadruplex DNA. (a) Bis-
amindoantraquinone. (b) BRACO-19, a tri-substituted acridine compound found to bind very strongly to Htelo DNA . (c) 
The X-ray crystal structure of BRACO-19 bound to bi-molecular Htelo DNA,d(TAGGGTTAGGGT)2 (taken from Ref. 64). 
 
 
(a) 
(b) 
(c) 
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Another acridine derivative, the pentacyclic RHPS4 (a methosulfate salt with two fluoro and three 
methyl substituents) was reported to induce quadruplex formation in the 3’ single-stranded 
telomeric overhang and significantly inhibit telomerase activity (sub-micromolar telEC50 values were 
obtained from the cell-free TRAP assay).[66] Cellular studies showed the compound can displace the 
telomerase catalytic subunit (hTERT), leading to DNA-damage signalling and chromosome fusion.  
Telomere dysfunction in cancerous cells resulted in potency against a range of common human 
tumours. As a result of its promising toxicity profile, RHPS4 became the first quadruplex binder to 
enter clinical trials.[67] 
 
Figure 1-12: The chemical structure of the petacyclic acridine compound, RHPS4. This was the first quadruplex binder to 
enter clinical trials. 
 
A number of other organic compounds with extended π-systems have also been reported to stabilise 
quadruplex DNA. Heterocyclic aromatic compounds such as TMPyP4 and telomestatin are some of 
the most promising examples (Figure 1-13). TMPyP4 is a water soluble cationic porphyrin with N-
methylated aromatic moieties. Methylation is proposed to facilitate more favourable π-π stacking 
interactions with quadruplex DNA, as it reduces electron density in the aromatic part. As reported by 
Hurley et al. TMPyP4 has high affinity for quadruplex DNA and is very active as a telomerase 
inhibitor.[68, 69] However it was also found to be non-selective.[70] TMPyP4 was shown by X-ray 
crystallography and NMR spectroscopic studies to have a diverse range of binding modes. As well as 
the expected end-stacking mode, intercalation between adjacent tetrads was also seen. This 
tendency for the porphyrin to intercalate between nucleotide units is thought to be the reason for 
its poor selectivity. A selective porphyrin, TQMP was reported by Zhou et al. (Figure 1-13).[71] The 
improved selectivity of this porphyrin was attributed to the presence of four flexible cationic side 
chains. The side arms were shown to disrupt intercalation into duplex DNA and at the same time 
facilitate favourable electrostatic interaction with the loops and grooves of quadruplex DNA. 
Furthermore the four hydroxyl groups were thought to allow effective hydrogen bonding to the DNA 
scaffolds. 
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Another polyaromatic macrocycle that has shown to stabilise quadruplex DNA is telomestatin. 
Telomestatin is a natural occurring molecule isolated from Streptomyces anulatus.[72] This poly 
heteroaromatic compound is currently the best telomerase inhibitor known with an IC50 value of 
5nM. It has been shown to significantly stabilise quadruplex DNA and display a 70-fold selectivity 
over duplex DNA. Selectivity is proposed to arise from its inherent neutral and cyclic nature. The 
major drawback of telomestatin is its lack of availability. Although the total synthesis of the natural 
product has been recently reported it is not conducive to large scale preparation.[73, 74] 
 
 
Figure 1-13: Heterocyclic aromatic examples of quadruplex stabilisers: (a) TMPyP4; (b) TQMP; (c) Telomestatin.  
A family of quindolines (a derivative of the natural product, cryptolepine) have been reported by 
Huang et al. to specifically target c-myc DNA (see Figure 1-14).[52] The compounds were found to 
induce and stabilise the formation of quadruplex structures in the NHE III1 section, thereby down-
regulating the transcription of c-myc in cancer cell lines (Hep G2). Recently the solution structure of 
a 2:1 complex of one of the quindoline derivatives (see Figure 1-14) and c-myc DNA was resolved by 
NMR spectroscopy.[75] The compound was found to bind in an “induced-fit” manner, whereby upon 
binding (by π-π stacking interactions with the 3’ and 5’ ends) the flanking sequences alter to form a 
new binding pocket. A series of berberine derivatives (an alkaloid isolated from Chinese herbs) were 
also identified to target c-myc DNA (see Figure 1-14).[53] These compounds were designed to have 
N+-containing aromatic moieties suitable for π-π stacking interactions with quadruplex DNA, 
furthermore they were functionalised with side chains containing terminal amino groups to afford 
electrostatic interactions with the phosphate backbone. The side arms also provided selectivity over 
duplex DNA. 
 
 
(a) (b) (c) 
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Figure 1-14: (a) The chemical structure of the berberine derivatives. (b) Chemical structure of the quindoline derivatives. 
(c) Solution structure of two molecules of a quindoline derivative bound to c-myc DNA. The structure was solved by 
NMR spectroscopy (taken from Ref. 75). 
 
Organic quadruplex stabilisers generally exhibit planar π-delocalised surfaces however this is not a 
necessity. Balasubramanian et al. reported 1,2,3-triazole-linked diethynylpyridine amides and 
trisubstituted diethynyl-pyridine amides as promising quadruplex binding ligands (see Figure 1-
15).[76] Unlike other quadruplex stabilisers these compounds are not co-planar, instead they have 
free rotation about the triple bond. Structural flexibility was proposed to enhance quadruplex 
binding (Kd constants measured by SPR were in the µM range and ΔTm obtained from the FRET assay 
were between 10-33oC) and more remarkably provide specificity between intramolecular promoter 
quadruplex-forming sequences. One of the compounds was found have a 50-fold preference for c-
myc and c-kit1 quadruplex DNA over c-kit2 and k-ras DNA. Very recently the di-alkyne compounds 
were cyclised to form a series of bis-indole carboxamides which displayed a 3-5 fold preference for 
c-kit2 over Htelo DNA.[77] One compound in this series induced the formation of a single anti-
parallel conformation of Htelo DNA in the presence or absence of salts. In this case the chirality of 
the Htelo structure was transferred to the achiral compound and the preferred ligand atropisomer 
was observed.  
A series of disubstituted triazole-linked acridine compounds were shown by Neidle et al. to bind very 
strongly to Htelo DNA.[78] The lead compounds (see Figure 1-15) displayed selectively over duplex 
DNA as well as both c-kit sequences (c-kit1 and c-kit2). Selectivity was attributed to the dimensions 
of the triazole-acridine unit and the separation of the alkyl-amino terminal groups. Two compound 
(a) 
(b) 
(c) 
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from this family displayed inhibitory effects on the proliferation of cancer cell lines and one was 
shown to inhibit telomerase (using the TRAP-LIG assay).  
 
 
 
Figure 1-15: (a) Chemical structures of 1,2,3-triazole-linked diethynylpyridine amides and trisubstituted diethynyl-
pyridines, these compounds were found to selectively bind to the c-myc and c-kit1 quadruplex sequence. (b) Chemical 
structures of bis-indole carboxamides which exhibited selectivity for the c-kit2 sequence. (c) Chemical structure of 
triazole linked acridine compounds which displayed selectivity for the Htelo sequence. 
 
1.3.2 Metal Complexes 
More recently our group and others have shown metal complexes to be exceptional quadruplex 
binders. The presence of a metal can be advantageous in a number of ways.[79] For instance, the 
metal can play a fundamental role in organising the ligand(s) into an optimal geometry in order to 
interact with quadruplex DNA. Furthermore, the electron-withdrawing properties of the metal can 
reduce the π-electron density of the chelated ligand(s) and thus promote more effective π-π 
interactions. Additionally, the metal can theoretically position itself over the central cationic channel 
of quadruplex DNA, increasing electrostatic stabilisation. A review on metal complex interactions 
with quadruplex DNA was recently published by our group, the most noteworthy examples will be 
covered in this section. 
Copper(II)[80, 81], Manganese(II) and Nickel(II)[82, 83] TMPyP4 complexes were the first reported 
examples of metal complex stabilisers. In each case the metals ions were found to occupy the 
(a) (b) 
(c) 
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central cavity. The addition of the metals was seen to impart only a moderate enhancement in the 
quadruplex stabilisation relative to TMPyP4 (organic analogue). The presence of the metal restricted 
the number binding modes to quadruplex DNA, thus improving the selectivities of the porphyrins. 
The copper(II) TMPyP4 derivative was reported to have a solvent molecule coordinated axially, this 
was thought to force the complex to bind via the external G-tetrad only. Intercalation between 
adjacent tetrads as reported for TMPyP4 did not occur. The axially bound solvent molecule in the 
manganese(II) example was shown to disrupt many of the common binding modes, including 
interaction via the external G-tetrad. This complex was observed to bind via the quadruplex grooves, 
giving the best selectivity in the TMPyP4 series, a 10-fold preference for quadruplex DNA. Another 
porphyrin based complex, a highly cationic manganese(III) derivative (Figure 1-16) was designed to 
include side chains.[84] This was shown to facilitate very strong electrostatic interactions with the 
quadruplex grooves and this gave rise to an extraordinary selectivity of 10000-fold (over duplex 
DNA). It also demonstrated excellent levels of telomerase inhibition, with a IC50 value in the nano-
molar range.   
 
 
Figure 1-16: First reported metal complex G-quadruplex stabilisers: (a) Metal-TMPyP4 and (b) a modified metal 
porphyrin complex which was found to be very selectivity for quadruplex DNA. 
 
Metal (copper, nickel and zinc) phthalocyanines complexes present larger π surfaces compared to 
porphyrins, allowing more favourable π-π stacking interactions with the external G-tetrad (Figure 1-
17).[85, 86] Interestingly, the inherent charge of the complexes was found to improve quadruplex 
binding and telomerase inhibition. Furthermore these complexes were shown by CD spectroscopy to 
induce quadruplex formation and allow conversion between the different quadruplex topologies. In 
particular a zinc(II) cationic phthalocyanine complex with guanidinium side arms (Zn-DIGP, see Figure 
1-17) was shown by Luedtke et al. to bind very strongly to c-myc quadruplex DNA (in fact it is the 
(a) (b) 
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strongest binding interaction reported for a small molecule to date, Kd < 2 nM).[87, 88] The complex 
displayed increased luminescence upon binding to c-myc DNA and at the same time down regulated 
c-myc RNA expression. Its luminescent properties allowed imaging studies to be carried out in 
cellulo.  
Copper and manganese corrole complexes are another type of macro-cyclic quadruplex 
stabilisers.[89-91] This is quite surprising considering their “saddle” type geometry (non- planar). The 
corroles were designed with pyridinium and amine side arms, allowing greater interactions with the 
quadruplex loops and grooves. Like the phthalocyanines complexes, the corroles were also found to 
promote changes between quadruplex conformations.  
 
 
Figure 1-17: (a) Chemical structure of the zinc(II)-phthalocyanine, Zn-DIGP complex found to bind extremely strongly 
with c-myc DNA and (b) metal corroles containing positively charged pyridinium side arms. 
 
More recently metal complexes involving non-cyclic polypyridyl planar ligands have attracted great 
interest as potential quadruplex stabilizers. Pioneering work conducted in our group has shown 
nickel- and copper-salphen complexes to be excellent quadruplex binders (Figure 1-18).[79, 92] The 
salphen complexes were functionalised with cyclic amine side chains to allow interactions with the 
quadruplex grooves. Additionally an electron withdrawing fluoride group was attached to the ligands 
to reduce the electron density of the aromatic group and thereby promote more effective π-π 
stacking. The nickel complexes displayed some of the highest degrees of stabilization recorded by 
the FRET assay (at best ΔTm= 33
oC at 1 µM). The complexes also displayed considerable selectively 
over duplex DNA (50-fold). Furthermore, based on data from the TRAP-LIG assay, several of the 
complexes were found to be very good telomerase inhibitors (low micromolar telEC50 values 
reported). A comparative study of nickel(II), copper(II), zinc(II), and vanadyl complexes with the same 
(a) (b) 
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salphen ligand illustrated the significance of complex geometry for improved binding to Htelo 
DNA.[93] Square planar complexes typically appeared superior to square pyramidal ones. 
Very recently the first crystal structure of quadrupelx DNA interacting with a metal complex was 
reported by our group in collaboration with Neidle.[94] The study found the nickel(II) and copper(II) 
salphen complexes to π-π stack atop quadruplex DNA, proving the proposed binding mode. A very 
similar series of square planar platinum(II)salphen and salen complexes were reported later by Che 
et al.[95] Some of the complexes in this family were found to regulate c-myc activity in cell-free 
systems as well as in cancer cells. 
 
 
Figure 1-18: (a) Chemical structure of one of the most potent quadruplex stabilisers, this complex was synthesised by 
our group in 2006. (b) The X-ray structure of the nickel(II) complex with Htelo DNA, it shows the complexes to π-π stack 
on both external G-tetrads (taken from Ref. 94). 
A number of octahedral ruthenium(II) complexes have been shown to bind to quadruplex DNA. The 
reported complexes are generally made up of bidentate aromatic nitrogen ligands which are 
proposed to π-π stackor intercalate between the G-tetrads (the metal itself is not considered to 
contribute to these interactions). The complexes as a whole are positively charged and are thought 
to bind to the negatively charged loops and grooves of quadruplex DNA. One example has two 
phenathroline units and a pyridine ligand attached to a porphyrin motif, to enhance its lipophilicity 
and bioavailability (see Figure 1-19).[96] This particular complex was found to bind with high affinity 
to Htelo DNA and as a result de-stabilise its parallel conformation. A series of luminescent bimetallic 
RuII complexes with the ditopic ligands, tetrapyridophenazine and tetraazatetrapyridopentacene 
(see Figure 1-19) were reported by Thomas et al. to bind quadruplexDNA, giving rise to significant 
emission enhancements.[97] Upon addition of quadruplex DNA, the metal to ligand charge transfer 
(MLCT) band was observed to increase 150-fold (with a blue shift), which is 2.5 times more than that 
for duplex DNA. The complexes were proposed to bind via “end-pasting” or threading through the 
(a) (b) 
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lateral loops, while partial intercalation remained a possibility, considering the highly dynamic 
nature of quadruplex structures. Members of this series have been used for in vivo direct imaging of 
nuclear DNA, including quadruplex DNA, in eukaryotic and prokaryotic cells.[98] 
 
 
Figure 1-19: (a) Chemical structure of a quadruplex DNA binding octahedral Ru
II
 complex, functionalised with a 
porphyrin to enhance its lipophilicity and bioavailability. (b) Chemical structure of a Ru
II
 complex with ditopic ligands 
which was used for in vivo imaging of nuclear DNA in eukaryotic and prokaryotic cells. (c) Cellular localisation of the Ru
II
 
complex shown by transition electron microscopy. The complex was found to accumulate within the nucleus and show 
strong heterochromatic staining (taken from Ref. 98). 
The same group reported another ruthenium(II) bi-metallic probe for quadruplex DNA. The probe 
featured two [Ru(bipy)3]
2+ units connected by an azo linker (Figure 1-20).[99] Mixing the complex 
with Htelo DNA, AG3(T2AG3)3 resulted in an instant colour change (from purple to blue). The shift in 
colour was attributed to a change in environment of the azo moiety upon binding of the complex to 
quadruplex DNA.  
 
Figure 1-20: (a) Chemical structure of the Ru
II
 based probe. (b) The colour change (from purple to blue) observed upon 
addition of quadruplex Htelo DNA to the probe (taken from Ref 99). 
(a) (b) 
(c) 
(a) (b) 
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Another bi-metallic complex, Hannon’s triple-helical cylinder made up of three ditopic ligands and 
two metal ions (either nickel or iron)[100], was reported by Qu and co-worker to selectively 
recognize Htelo DNA (see Figure 1-21).[101] Only the P-enantiomer is able to interact specifically 
with the Htelo quadruplex, and convert its antiparallel form (in the presence of sodium ions) to a 
hybrid form. S1 nuclease cleavage assays suggest that the supramolecular complex protects the 
Htelo sequence from cleavage at the two ends, indicating some type of end binding mode. The 
authors propose that the cylinders stack atop the quadruplex through its extensive hydrophobic 
exterior and at the same time the metal centers engage in ionic interactions with the loops and 
grooves. Recent studies on this system found the P-enantiomer induces Htelo quadruplex formation 
in salt deficient conditions.[102] Formation was reported to be fast, efficient (did not require a large 
excess of the cylinder) and loop sequence dependent. Furthermore the complex was found to 
exhibit selectivity for Htelo DNA over duplex DNA as well as over other quadruplex forming 
sequence (namely c-myc and c-kit DNA).  
 
 
Figure 1-21: (a) Chemical structure of the ditopic ligand used to form the bi-metallic triple-helical cylinders, the nitrogen 
atoms participate in covalent bonds to the divalent metal ions, nickel(II) and iron(II). (b) The two chiral antipodes of the 
[Ni2(ligand)3]
4+
 chiral cylinder. Only the P enantiomer stabilises Htelo DNA. (c) An illustration of the P enantiomer 
inducing the formation of a hybrid quadruplex structure from single stranded Htelo DNA under salt deficient conditions 
(taken from Ref. 102). 
 
(a) (b) 
(c) 
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Work carried out by our group in collaboration with Lippert, described the first gold complex (with 
pyrazolylpyridine ligands) found to interact with quadruplex DNA (both c-myc and Htelo DNA).[103] 
The complex displayed very high affinity for quadruplex DNA. Remarkably it was able to template 
the formation of a quadruplex structure from a singly-stranded human telomeric sequence in the 
absence ofpotassium or sodium salts. The complex was proposed to interact by π-π stacking 
interaction only, as it was not functionalised with sides arm to enable interactions with the loops 
and grooves. 
 
Figure 1-22: Chemical structure of the gold(III) pyrazolylpyridine complex 
 
1.3.3 Platinum(II) Complexes 
Platinum (II) phenanthroline complexes are promising quadruplex stabilisers.[104] Work conducted 
in our group, showed the complexes effectively stabilise Htelo DNA (ΔTm,1 µM = 20
oC using the FRET 
assay) and inhibit telomerase(telEC50 = 49.5 µM using the TRAP assay). The phenanthroline complexes 
were modified with pendant cyclicamine or pyridine side arms through a single amide linkage to 
allow favourable interactions with the loops and grooves of quadruplex DNA. Control tests 
performed with the free ligands found limited interactions demonstrating the important role played 
by metals in quadruplex DNA binding of these compounds. Work undertaken by Sissi et al. also 
highlighted the significance of metals.[105] Transition metals (copper and nickel) were shown to 
assemble functionalised phenanthrolines ligands into optimal structures that were able to recognise 
specific quadruplex conformations. The uncoordinated ligands did not have the capacity to do 
likewise. Further evidence for the binding of phenanthrolines complexes (platinum, nickel and 
ruthenium) to quadruplex DNA was provided by Ralph et al. using electrospray ionisation mass 
spectrometry (ESI-MS) and circular dichroism spectroscopy (CD).[106] 
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Figure 1-23: (a) Chemical structure of one of the platinum(II)-phenanthroline complexes prepared in our group (b) and 
by others which have been shown to bind to quadruplex DNA. 
 
A metallo-supramolecular complex made up of four platinum-ethylene diamine components held 
together by bipyridine linkers (Figure 1-24), was found by Sleiman and co-workers to bind strongly to 
quadruplex DNA (ΔTm (at 0.75 µM) = 34.5
oC using the FRET assay) and at the same time inhibit 
telomerase activity (telIC50 = around 0.2 µM using a modified TRAP assay).[107] Binding to quadruplex 
DNA was attributed to a combination of factors including the square arrangement of the four 
bipyridine units, the overall electropositive nature of the complex and the hydrogen bonding ability 
of the Pt-ethylene diamine components. Molecular dynamics simulations were conducted to probe 
the quadruplex DNA interaction further. The bipyridine groups were found to be not co-planar with 
respect to the tetrad hence π-π stacking was not proposed as the main binding mode. Electrostatic 
and hydrogen bonding interactions of the terminal platinum atoms and the ethylene diamine groups 
with the phosphate backbone were thought to be predominant modes of binding.    
 
(a) (b) 
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Figure 1-24: (a) The chemical structure of the platinum(II) supramolecular “square” complex. (b) A molecular modelling 
illustration depicting the interaction between the complex and the external tetrad of quadruplex DNA (taken from Ref. 
107). 
 
Other platinum complexes such as those containing dipyridophenazine and C-
deprotonatedphenylpyridine ligands have also been found to interact strongly with quadruplex 
DNA.[108] Using photophysical techniques, these complexes were shown to bind via the expected 
external end-stacking mode with affinities in the region of 107 dm3 mol-1. Their ability to inhibit 
telomerase in vitro was demonstrated using the biotinylated-primer extension telomerase assay 
(telIC50 = 760 µM). One of these complexes displayed a 293-fold increase in its photoluminescence 
upon binding to quadruplex DNA (Figure 1-25). As a similar enhancement was not observed upon 
interacting with other DNA structures, the complex was presented as a selective luminescent probe 
for quadruplex DNA.  
 
Figure 1-25: (a) The chemical structure of the platinum(II) dipyridophenazine-phenylpyridine complex. (b) Emission 
spectrum showing the increase in its photoluminescence upon binding to quadruplex DNA (taken from Ref. 108). 
 
(a) (b) 
(a) (b) 
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More recently the same group reported a series of platinum(II) 2,6-bis-(benzimidazol-2-yl)pyridine 
(bzimpy) complexes capable of stabilising c-myc DNA.[109] NMR spectroscopy and molecular 
modelling studies showed that the complexes to interact with c-myc DNA via an external end-
stacking mode (through π-π interactions). Furthermore, UV-Vis absorption and competition dialysis 
experiments found the complexes bind preferable to c-myc DNA (over duplex DNA), with binding 
constants ranging between 106 and 107 dm3 mol-1. As a results some of the complexes displayed very 
strong inhibition of c-myc expression in cell-free (IC50 = 2.2 µM) and in vivo (IC50 = 17 µM) systems. 
Interestingly one of the complexes exhibited a 38-fold enhancement in photoluminescence (λmax= 
622nm) upon binding to c-myc DNA.  
 
Figure 1-26: (a) Chemical structure of platinum(II)-bzimpy complexes. The chloride complex was found to have the 
highest affinity for c-myc DNA and at the same time exhibit the highest potency for the inhibition of c-myc expression in 
cell-free and in vivo systems. The alkyne complex displayed “turn-on” luminescence in the presence of c-myc DNA. (b) 
Molecular modelling images showing the end-stacking of a platinum(II)-bzimpy complex with c-myc DNA. Both the top 
and side views are shown (taken from Ref. 109). 
 
Another luminescent probe, a water soluble alkynylplatinum(II) terpridine complex was recently 
reported by V. Yam et al.[110] The positively charged complex was found to interact electrostatically 
with single stands of negatively charged G-rich DNA. When potassium ions were added the G-rich 
strands were observed to align into tetra-molecular quadruplex structures thereby providing a 
framework for the electrostatically bound platinum(II)-complexes to aggregate and form 
intermolecular Pt-Pt and π-π interactions. Aggregation gave rise to MMLCT absorption and emission 
bands (at 550nm and 800nm). The MMLCT bands were monitored by UV-Vis and fluorescence 
spectroscopy respectively. Therefore by monitoring enhancements in the MMLCT bands the 
formation of quadruplex DNA was photo-physically probed.  
(a) (b) 
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Figure 1-27: Schematic showing how the formation of quadruplex DNA leads to the aggregation of the platinum(II)-
terpyridine complexes and therefore induces the formation of MMLCT bands (taken from Ref. 110). 
 
Using FRET and FID assays, Fichou et al. recognized the potential for metal terpyridine complexes to 
act as good quadruplex binders.[111] Their affinity and selectivity for quadruplex DNA was shown to 
be dependent on the metal geometry. Terpyridine complexes of copper(II), platinum(II), zinc(II) and 
ruthenium(III) were studied. The square planar platinum(II) and square pyramidal copper(II) 
complexes were shown to give the most noteworthy stabilisations. Whereas the trigonal bipyramidal 
zinc(II) and octahedral ruthenium(III) complexes displayed little stabilisation. The work 
demonstrated the necessity for quadruplex stabilisers to have at least one planar surface to form 
effective π-π stacking interactions with the external tetrad. Interestingly the copper(II) complex 
showed the best selectivity. The presence of an apical substituent was thought to impede duplex 
DNA intercalation and thus impart selectivity. 
 
 
Figure 1-28: (a) Chemical structure of the square pyramidal copper(II)-terpyridine complex with an apical nitro group 
which impedes duplex base pair intercalation and (b) the square planar platinum(II)-terpyridine complexes. Both 
complexes displayed good G-quadruplex stabilisation. 
(a) (b) 
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Detailed long term studies conducted on a series of platinum(II) terpyridine complexes by the same 
group (see Figure 1-29) suggest that they interact with Htelo-like quadruplex structures through site-
selective platination of certain adenine bases (present in either the lateral or diagonal loops).[112] 
Therefore platinum(II) terpyridine complexes are proposed to interact with quadruplex DNA, initially 
via non-covalent means (π-π or electrostatic interactions) and then, after longer exposure,by 
formation of covalent bonds. 
 
Figure 1-29: Chemical structures of platinum(II)-terpyridine complexes found to covalently bind to adenine bases 
present on the quadruplex DNA loops. 
 
Following this, work carried out in our group showed that by adding side chains comprising of cyclic 
amine head-groups to platinum(II) terpyridines, a moderate enhancement in binding can be 
achieved.[113] This forms the starting point for my thesis and will be discussed extensively in the 
upcoming chapters.  
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1.4 Aims and Objectives 
The overall aims of this study were to design and synthesise a series of metal complexes and to 
demonstrate their ability to selectively stabilise quadruplex DNA. In particular, interactions with 
human telomeric and c-myc DNA were to be studied, as these sequences have been identified as 
potential anti-cancer targets. 
This study hopes to builds on previous work carried out as part of my MSci final year research 
project, in which platinum(II)-terpyridine complexes (8-10) were studied as potential quadruplex 
DNA stabilisers.The compounds to be studied in this thesis are mono-, bi- and tri-nuclear metal(II)-
terpyridine and platinum(II)-pyridyl- and phenyl-phenanthroline complexes functionalised with cyclic 
amine (piperidine, pyrrolidine and morpholine) or metal(II)-dipicolyl side arms. The complexes were 
designed to have planar cores to π-π stack atop quadruplex DNA and side arms to allow electrostatic 
interactions with the loops, grooves and phosphate backbone of DNA. 
In order to achieve the overall goals the following objectives were targeted: 
1. SYNTHESIS OF mono-, bi- and tri-nuclear metal(II)-terpyridine and platinum(II)-pyridyl- and 
phenyl-phenanthroline complexes.   
2. CHARACTERISATION OF the complexes via spectroscopic, analytic and structural techniques.  
3. AN EVALUATION OF the ability of the complexes to π-π stack in solid and solution states using X-
ray crystallography, 1H NMR and UV-Vis spectroscopy. This would give an indication of their 
propensity to interact with quadruplex DNA via π-π interactions. 
4. AN ASSESSMENT OF the ability of the complexes to bind non-covalently to quadruplex (Htelo and 
c-myc) and duplex DNA using fluorescence intercalator displacement assays, UV-vis, fluorescence, 1H 
NMR and circular dichroism spectroscopic studies. 
5. AN ASSESSMENT OF the potenial of the complexes to bind covalently (i.e. direct metal 
coordination) to DNA by monitoring over time the 1H NMR spectra of selected complexes incubated 
with guanosine. 
6. For the most promising complexes, DETERMINTAION OF their cytoxicity (IC50 value) towards 
cancer and normal cell lines using the MTS assay. 
7. Cellular uptake and DNA-flow cytometric studies, to gain a better understanding of metal complex 
induced cell death, 
59 
 
8. Finally, to determine the ability of a selection of complexes to regulate c-myc oncogene 
expression using the q-PCR assay. This was to be carried out in collaboration with Mr. George 
Stephen and Dr. David Mann.  
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CHAPTER 2 
 
 
SYNTHESIS AND 
CHARACTERISATION 
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2.1 Overview  
Two different classes of metal complexes were synthesised and characterised: a) Mono, bi and tri-
nuclear platinum(II), copper(II), zinc(II) and gold(III)-terpyridine complexes; and b) platinum(II) 
pyridyl- and phenyl-phenanthroline complexes. In this chapter, a brief discussion on the complexes’ 
design and a detailed description of their syntheses will be given. The complexes were fully 
characterised using 1H, 13C and 31P NMR and UV-Vis spectroscopy, ESI mass spectrometry and 
elemental analysis. The X-ray crystal structures of some of the terpyrdine based complexes were 
resolved, giving an insight into theirgeometry and binding potential to quadruplex DNA. Furthermore 
the ability of the complexes to π-π stack in solid and solution state was probed using X-ray 
crystallography and 1H NMR and/or UV-Vis spectroscopy.   
 
2.2 Complex Design 
Based on quadruplex DNA structures reported to date (using high resolution NMR spectroscopy and 
X-ray crystallography), criteria for effective quadruplex stabilisers have been established. As 
discussed in the introductory chapter, good quadruplex binder generally have: (1) π-delocalised 
moieties that are able to stack on the face of the guanine quartet; (2) a partial positive charge that is 
able to occupy the centre of the guanine quartet thus stabilising the structure by electrostatic 
interactions in a similar way to sodium and potassium ions which reside at this site under 
physiological conditions; (3) positively charged or readily protonated side chains which are able to 
interact favourably with the loops, grooves and negatively charged phosphate backbone of 
quadruplex DNA. The latter is also important for retaining water solubility, which allows for 
biophysical and cellular studies to be carried out. A particularly important issue when designing 
quadruplex DNA binders, is to introduce features that enhance their selectivity over duplex DNA. 
This can be achieved by, for example, incorporating side arms that hinder intercalation between 
base pairs in duplex DNA and at the same time promote quadruplex DNA binding. 
 
Using these principles a series of mono- and di-functionalised, mono-nuclear platinum(II), copper(II), 
zinc(II) and gold(III)-terpyridine complexes were designed and synthesised (see Figure 2-1). The 
terpyridine core contains aromatic moieties, which when planar can effectively stack atop 
quadruplex DNA via π-π interactions (see Figure 2-1). The ligands were designed to include 
heterocyclic amine side chains to allow additional interactions with the loops, grooves and 
negatively charged phosphate backbone of quadruplex DNA. Three different side chains were used: 
piperidine, pyrrolidine and morpholine were attached to the terpyridine core via a three atom 
spacer (two carbon atoms and one oxygen atom). Different metals were used to determine the 
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relationship between complex geometry and quadruplex DNA affinity. From studies conducted in 
our group and those reported elsewhere, a planar surface is known to be essential for effective π-π 
stacking interactions with quadruplex DNA. Therefore the platinum(II), copper(II)and gold(III)-
complexes (those with at least one planar face) were expected to bind strongly with quadruplex 
DNA. On the other hand, the zinc(II) complex was expected to bind weakly and hence was 
synthesised and studied for comparison. The platinum(II) and gold(III) complexes were 
functionalised further to include two side arms. This was achieved by: (i) attaching one arm to the 
terpyridine core (π-π stacking component) and one to the metal centre (through direct coordination, 
see thiol- functionalised platinum(II) terpyridine complexes section) or (ii) attaching both arms to the 
terpyridine core. The extra side arm was envisaged to enhance selectivity by sterically hindering 
intercalation between base pairs in duplex DNA. 
 
 
 
 
Figure 2-1: (a) Mono- and di-functionalised terpyridine ligands. (b) Qualitative docking of 8 (the crystal structure of 
which was obtained during my MSci project) atop Htelo DNA in potassium solution (PDB: 1KF1). The external guanine 
tetrad is represented as CPK. The image was created using Maestro Schrodinger. 
 
(a) 
(b) 
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A series of platinum pyridyl- and phenyl-phenanthrolines were also designed and synthesised (see 
Figure 2-2). The extra aromatic ring (compared to the terpyridine complexes) was envisaged to 
improve π-π stacking interactions with quadruplex DNA and at the same time prevent intercalation 
in-between base pairs in duplex DNA. Cyclic amine side arms were included to impart further 
selectivity for quadruplex DNA. 
 
 
Figure 2-2: Mono-functionalised pyridyl- and phenyl-phenanthroline ligands. 
 
Zinc(II) and copper(II)-dipicolylamine complexes have been reported to interact strongly with 
phosphate ions and phosphoester groups on proteins.[114, 115] So as an alternative to conventional 
organic side arms, the use of metal dipicolylamine side arms was proposed. The metal-DPA side 
arms were expected to bind strongly with the phosphate backbone ofquadruplex DNA. To test this 
hypothesis, a series of bi- and tri-nuclear terpyridine-DPA platinum(II), zinc(II) and copper(II) 
complexes were designed and synthesised (see Figure 2-3). Given the size of the metal-DPA unit, the 
side arms were also predicted to enhance selectivity over duplex DNA by sterically hindering 
intercalation between base pairs. 
 
 
 
Figure 2-3: Mono- and di-functionalised terpyridine-DPA ligands. 
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2.3 Synthesis 
2.3.1 Non- and Mono- Functionalised Metal Terpyridine Complexes 
The un-substituted zinc(II), copper(II)and platinum(II)-terpyridine complexes (1, 2 and 7) were 
prepared according to literature procedures.[116, 117] The platinum complexes, 8, 9 and 10 (with 
cyclic amine functionalities) were prepared during my MSci project and the method has since been 
published.[113] The new copper(II), 4 and 6, and zinc(II), 3 and 5 complexes were synthesised using 
the same methodology employed for the un-substituted metal terpyridine complexes. The 
respective terpyridine ligands were reacted with 1.1 equivalents of the appropriate metal chloride 
salt (ZnCl2 and CuCl2·2H2O respectively) in methanol. Upon stirring the reaction mixtures at room 
temperature for 24h, the products precipitated out. Blue and white powders were obtained for the 
copper and zinc complexes respectively. The solids were washed with methanol and diethyl ether 
and dried. No further purification was necessary for the zinc complexes. The copper complexes 
required a re-crystallisation step whereby acetone was allowed to slowly diffuse into a concentrated 
aqueous solution of the complex over 3 days. This induced crystallisation of the corresponding 
complexes yielding 4 and 6 as blue crystalline solids. 
 
 
Scheme 2-1: Reaction scheme for the synthesis of zinc(II)-terpyridine and copper(II)-terpyridine complexes, 1-6. 
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Scheme 2-2: Reaction scheme for the synthesis of platinum(II)-terpyridine complexes, 7-10. 
 
The non- and mono- substituted (II), copper(II)and platinum(II) complexes were characterised by 1H 
NMR spectroscopy (except the copper complexes due to their paramagnetic nature), mass 
spectrometry, elemental analyses and in some cases X-ray crystallography. The 1H NMR spectra of 
the platinum and zinc complexes displayed the expected chemical shifts and splitting patterns. The 
aromatic signals in each case were seen to shift downfield relative to the corresponding ligand, 
indicative of metal coordination to terpyridine. For the appropriate complexes, resonances in the 
aliphatic region corresponding to the amine side arms were also observed.  
A different approach was used to prepare the gold(III) derivatives, 11and 12.[118] The gold 
complexes were synthesised by reacting the corresponding terpyridine ligand with KAuCl4 (1:1 ratio) 
in aqueous conditions. The optimum pH for chelataion was found to be 3. At pH 1, the terpyridine 
nitrogens’ were found to be protonated preventing metal coordination, furthermore various gold 
anions (such as AuCl2
-, AuCl4
-, assigned using elemental analysis) formed, meaning purification 
proved difficult. At high pH, gold(III) reduced to give gold(0) metal. The reaction was carried at 50oC 
for 2 h and 85oC for a further 2 h. Upon completion of the reaction, a saturated aqueous solution of 
NaPF6 was added to precipitate the products as pink solids. The solids were washed thoroughly with 
water and diethyl ether and dried. No further purification was required.  1H NMR spectroscopy was 
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used to confirm the formation of the products. All the expected signals were observed with the 
correct intensities and multiplicities. Interestingly an extra peak was observed in the aliphatic region 
(for 11 and 12). This peak was tentatively assigned to the proton on the protonated amine side arm 
(piperidine and pyrrolidine; Hh in Figure 2-4) which is not suprising considering that the reaction was 
carried out at an acidic pH. Elemental analysis was used to confirm the purity of the compounds. 
 
 
Scheme 2-3: Reaction scheme for the synthesis of gold(III)-terpyridine complexes, 11 and 12. 
 
 
 
Figure 2-4: 
1
H NMR spectrum of 9 in DMSO-d6. The spectrum revealed that the pyrrolidine side arm was protonated. 
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2.3.2 Thiol- Functionalised Platinum Terpyridine Complexes 
The thiol substituted platinum complexes, 13-15 were prepared from the corresponding 
platinum(II)-terpyridine-chloro derivatives.[119] The mono-functionalised complex, 13, was 
prepared by reacting 7 with 4 equivalents of L18 (which was prepared by modification of a reported 
procedure,[120] see Section 6.3) in water at 25oC for 48 h. During this period the solution was 
observed to change colour from red to dark purple. Upon completion of the reaction, excess thiol 
was removed by diethyl ether extraction. The solvent was then removed and after several washings 
with diethyl ether, the desired complex was isolated as a deep purple solid.  It was not possible to 
isolate the other complexes (14 and 15) as pure chloride salts using the same method (reacting 8 
and 9 with L18). In these cases an additional counter-anion exchange step was required, so the 
chloride ion could be exchanged for a PF6 ion. This was achieved by dissolving the crude chloride 
salts in a minimum amount of DMSO and adding a saturated aqueous solution of NaPF6. This 
produced an orange precipitate (in both case) which was filtered, thoroughly washed with water and 
diethyl ether and dried. Using this strategy, 14 and 15 were isolated as pure PF6 salts. 
 
 
 
Scheme 2-4: Reaction scheme for the synthesis of platinum(II)-terpyridine complexes substituted with a thiol unit on the 
fourth position, 13- 15. 
 
The platinum(II)-thiol complexes were fully characterised by 1H, 31P NMR, UV-Vis spectroscopy, mass 
spectrometry and elemental analysis. The aromatic proton signals (assigned using 1H-1H COSY NMR) 
were observed to shift downfield (ranging from 0.2-0.8ppm) relative to the corresponding 
platinum(II)-chloro complexes, clearly demonstrating coordination of the thiol arm to the fourth 
position of the platinum(II)-terpyridine motif. The largest shift was observed for the Ha terpyridine 
peak (0.8ppm downfield, see Figure 2-5), likely to result from the magnetic anisotropy of the 
neighbouring platinum-sulphur bond. The appearance of a LMCT band (charge transfer from the 
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sulphur p orbital to the platinum d orbital) at ca. 500nm in the UV-visible spectrum provided further 
evidence for the successful attachment of the thiol moiety.[121] For 14 and 15, the amine units on 
both arms were found to be protonated (determined from 1H NMR spectroscopy). This can be 
explained by the proposed mechanism for product formation depicted in Scheme 2-5. In aqueous 
conditions the cyclic amine on the platinum(II)-chloro complex is proposed to extract a proton from 
the thiol, forming a nucleophilic thiolate ion. This is then proposed to attack the platinum centre, 
displacing the chloride and forming the desired platinum(II)-thiol product (with a thermodynamically 
favoured “soft-soft” Pt-S bond). The platinum(II)-thiol is then able to deprotonate another thiol, 
giving a doubly protonated complex and at the same time re-generating the thiolate ion. 
 
Figure 2-5: (a) Chemical structure of 8. (b) Chemical structure of 14. (c) A comparison of the 
1
H NMR obtained for the 
chloro (top) and thiol (bottom) substituted platinum(II)-terpyridine complexes. (d) UV-Vis spectrum of 14. 
 
 
 
 
(a) 
(b) 
(c) 
(d) 
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Scheme 2-5: Proposed mechanism for the formation of the di-functionalised platinum(II)-terpyridine complexes, 14 and 
15. Both cyclic amine side arms are protonated in the final product. 
 
2.3.3 Di- Functionalised Metal-Terpyridine Complexes 
The platinum(II) and gold(III) complexes, 16 and 17 (see Scheme 2-7) were prepared from the di-
functionalised terpridine ligand, L7. Two different reaction methodologies were used to prepare the 
ligand. The first, involving four steps is a modification of the Kröhnke synthesis (represented in 
Scheme 2-6).[122] This reaction involves ring closure of two 1,5-diketone intermediates by 
ammonium acetate in n-propanol. The 1,5-diketones were prepared by Michael addition of an 
unsaturated ketone (obtained from the amine cleavage of L5, which was prepared from the amino 
alkylation of 6-pyridine dicarboxaldehyde, with a pyridinium salt. This was followed by a one pot 
oxidation-hydrolysis reaction (achieved by the loss of pyridinium) to give L6, predominately in the 
pyridone form (assigned using 1H NMR spectroscopy). The poly-pyridyl compound was then 
functionalised with cyclic amines under basic conditions to yield the final ligand. Although the 
desired compound was isolated using this approach, the overall yield was not practically useful (6%). 
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Scheme 2-6: Reaction scheme for the four step synthesis of L
7
. The major disadvantage of this route was its very poor 
overall yield (6%). 
 
The second and simpler approach involves a single step. Dibromo-terpyridine was reacted with 2 
equivalents of 1-(2-hydroxyethyl)piperidine in DMSO under strong basic conditions (powdered KOH) 
at 85oC for 24 h. An alkoxy nucleophile is generated by deprotonation of the hydroxyl group which 
subsequently undergoes a nucleophilic aromatic substitution reaction with dibromo-terpyridine. This 
results in displacement of the peripheral bromines to give the desired product. The product was 
extracted into dichloromethane, washed several times with water and isolated after solvent 
removal. The resultant brown solid was fully characterised by 1H and 13C NMR spectroscopy, mass 
spectrometry and elemental analysis. The attachment of the side arms was clearly illustrated by the 
downfield shift of the carbon signal corresponding to the site of substitution (from 157 ppm for 
dibromo-terpyridine to 163 ppm for L7). The mass spectrum obtained by ESI, produced a signal 
corresponding to the expected molecular ion, this confirmed the formation of the desired product. 
In contrast to the previously described procedure, this single step method had a considerably higher 
yield (52%) and was the preferred option.  
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Scheme 2-7: Reaction scheme for the synthesis of di-functionalised platinum(II) and gold(III)-terpyridine complexes, 16 
and 17. 
 
16 and 17 were prepared using analogues methods to those used for the mono-functionalised 
platinum and gold complexes (depicted in Scheme 2-7). The metal complexes were characterised by 
1H and 31P NMR spectroscopy, mass spectrometry and elemental analysis. Upon metal coordination 
the aromatic signals were observed to shift downfield relative to the free ligand (a greater difference 
was seen for 16 compared to 17). Unlike the previously discussed platinum(II) and gold(III) 
complexes, the amine side chains were not protonated (determined using 1H NMR spectroscopy). 
 
 
2.3.4 Bi-metallic Terpyridine-Dipicolylamine Complexes 
L9 was prepared by reacting L8 (synthesised according to literature procedure[123]) with 4-chloro 
terpyridine in the presence of KOH (Scheme 2-8). The reactants were stirred in degassed DMSO at 
60oC for 4 h before being extracted into dichloromethane. After several aqueous washings, the 
solvent was removed to yield a brown solid. 1H and 13C NMR spectra of the product provided clear 
evidence for the successful formation of L9. Nine different proton peaks (of equal integration) were 
observed in the aromatic region, consistent with the successful attachment of the dipicolyl side arm. 
This was supported by; (a) the absence of a broad hydroxyl signal associated to the starting material, 
N,N-bispicolyl-2-ethanol amine and (b) the downfield shift of the triplet peak associated to the -
OCH2-protons (from 3.70 ppm for L
8 to 4.40 ppm for L9). A similar downfield shift was also observed 
for the terminal methylene carbon in the 13C NMR spectrum. 
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Scheme 2-8: Reaction scheme for the two step synthesis of the terpyridine-dipicolylamine ligand, L
9
. 
 
The di-zinc(II), di-copper(II) and di-platinum(II) complexes 18, 19 and 20 were prepared using a 
similar method to that described for the mono-metallic complexes (adding 2 equiv of the 
corresponding MCl2 salt to a methanol or DMSO solution of L
9). For 20, an additional purification 
step (counter-anion exchange using saturated aqueous NaPF6) was required. The complexes were 
fully characterized by spectroscopic and analytic techniques (1H, 13C, 31P NMR spectroscopy, mass 
spectrometry and elemental analysis). 
 
Scheme 2-9: Reaction scheme for the synthesis of the bi-nuclear zinc(II) and copper(II)-terpyridine-DPA complexes, 18 
and 19. 
 
Scheme 2-10: Reaction scheme for the synthesis of the bi-nuclear platinum(II)-terpyridine-DPA complex, 20. 
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1H NMR analysis of 18 proved conclusive, all the expected peaks with the right integration and 
splitting patterns were observed. The aromatic region displayed nine distinctive signals, all of which 
showed a 0.1-0.4ppm downfield shift relative to the corresponding signals in the ligand, L9 (see 
Figure 2-6). These shifts can be accredited to the coordination of zinc to terpyridine and dipicolyl 
amine. The mass spectrum obtained by ESI provided further evidence for the successful formation of 
18. A peak (with the appropriate isotopic distribution) corresponding to the expected molecular ion 
of 18 (m/z = 673 a.m.u.) was detected. 
 
 
 
Figure 2-6:  (a) Chemical structure of L
9
. (b) Chemical structure of 18. (c) A comparison of the 
1
H NMR spectra of L
9
 and 
18. Upon metal coordination the aromatic proton signals were observed to shift downfield. Those associated to the DPA 
unit displayed significant line broadening. 
 
 
Complex 19 was not analysed by NMR spectroscopy due to its paramagnetic nature. However the 
mass spectrum displayed the expected molecular ion peak with the correct isotopic pattern (See 
Figure 2-7). The purity of 19 was established by elemental analysis.  
(a) 
(b) 
(c) 
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Figure 2-7: (a) The experimental ESI signal for the [19-2Cl]
+
 molecular ion. (b) The simulated signal for the [19-2Cl]
+
 
molecular ion, generated using http://fluorine.ch.man.ac.uk/research/mstool.php.The isotopic pattern obtained was 
the same as that predicted. 
 
The 1H NMR spectrum of 20 displayed similar characteristics to that of 18. The aromatics peaks were 
observed to shift downfield relative to the ligand, an indication of successful metal chelation. It is 
also worth pointing out that for 20, the dipicolyl methylene singlet (observed in the ligand’s 1H NMR 
spectrum) splits into two doublets. This phenomenon, which has been previously reported for metal 
dipicolyl complexes, illustrates the structural rigidity imposed by platinum upon coordination to the 
side arm.[124] The ESI mass spectrum displayed the expected molecular ion peak and isotopic 
pattern, indicating the successful formation of 20.   
 
Ideally, platinum would be coordinated to the terpyridine core, to provide a square planar geometry 
(the optimal structure for effective π-π interactions with quadruplex DNA) and zinc to the dipicolyl 
side arm, to afford strong interactions with the phosphate backbone. Therefore it was of interest to 
synthesis the hetero-nuclear platinum(II)-zinc(II) complex shown in Figure 2-8. Preliminary NMR 
experiments found the dipicolyl unit to have a higher affinity for platinum over zinc. So preparation 
of the proposed complex directly from L9 (with the metals being coordinated to the desired sites) 
was not feasible. Therefore a number of other synthetic possibilities were investigated and are 
summarised in Table 2-1. The starting materials were recovered from methods 1 and 2. This can be 
explained by the poor reactivity (leaving ability) of the chloro substituent on 31 (prepared using 
literature procedure[125] and analysed by 1H NMR spectroscopy). Using method 3a, L9 was isolated 
(confirmed by 1H NMR spectroscopy). De-coordination of zinc was attributed to reaction with KOH. 
Taking this into account, a milder, more sterically hindered base (KOtBu) was tried (method 3b). 
(a) (b) 
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However the same outcome was observed. Therefore it was not possible to isolate the desired 
platinum(II)-zinc(II) complex. The experimental details of the attempted methods are reported in 
Section 6.4.1. 
 
 
Figure 2-8: Chemical structure of the proposed hetero-nuclear platinum(II)-zinc(II)-terpyridine-DPA complex. 
 
Table 2-1: Synthetic possibilities investigated in order to synthesis the proposed hetero-nuclear 
platinum(II)-zinc(II)-terpyridine-DPA complex. 
Method  Reagents Conditions Results 
1 
 
DMSO (solvent), 
KOH (base)  
Starting materials 
recovered 
2 
 
DMSO (solvent), 
KOH (base) 
Starting materials 
recovered 
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3a  
 
DMSO (solvent), 
KOH (base) 
Isolated 
 
3b  
 
DMSO (solvent), 
KOtBu (base) 
Isolated 
 
 
 
2.3.5 Tri-metallic Terpyridine-Dipicolylamine Complexes 
L10 was synthesised using the method described for L7 (in this case L8 was used as the nucleophilic 
component). The compound was characterised by 1H NMR spectroscopy and mass spectrometry. 
The 1H NMR spectrum provided clear evidence for the formation of the desired product (nine 
aromatic and three aliphatic signals with the appropriate multiplicities and intensities were 
observed). Elemental analysis was not carried out as the product was isolated as an oily solid. 
 
Scheme 2-11:  Reaction scheme for the single step synthesis of L
10
. 
 
The tri-metallic complexes were prepared following an analogous procedure to that for the mono- 
and bi- metallic complexes (in these cases 3 equivalents of the corresponding metal salts were used). 
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The tri-metallic complexes were fully characterised using various spectroscopic and analytic 
techniques. For the zinc(II) and platinum(II) complexes (21 and 23) the terpyridine and DPA NMR 
proton signals were observed to shift downfield, suggestive of successful metal coordination to both 
N-tridenate modalities. The ESI mass spectra of the three tri-metallic complexes displayed the 
expected molecular ion peaks and isotopic patterns. The purity of 21 and 22 was confirmed by 
elemental analysis.  An elementally pure sample of 23 was not obtained. 
 
 
Scheme 2-12: Reaction scheme for the synthesis of the tri-nuclear zinc(II) and copper(II)-terpyridine-DPA complexes, 21 
and 22. 
 
 
Scheme 2-13: Reaction scheme for the synthesis of the tri-nuclear platinum(II)-terpyridine-DPA complex, 23. 
 
2.3.6 Pyridyl-phenanthroline Platinum(II) Complexes 
The mono-functionalised pyridyl-phenanthroline ligand, L12 was prepared using a two step approach. 
5-chloro-1,10-phenanthroline was reacted with 1-(2-hydroxyethyl)piperidine and KOH in degassed 
DMSO to yield L11 (the conditions used were equivalent to that used to functionalise dibromo-
terpyridine, discussed earlier). The substituted phenanthroline was then coupled with 2-bromo-
pyridine using nbutyl-lithium (as a base) in THF under an inert atmosphere. Upon extraction into 
DCM, re-oxidation using MnO4 and alumina column chromatography purification with 
THF:hexane:Et3N  (5:1:0.02) as elutants, the desired ligand was isolated as a brown oily solid. The 
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ligand was characterised by 1H NMR spectroscopy and ESI mass spectrometry. The aromatic protons 
were observed to shift downfield relative to the starting material, indicative of product formation. 
Furthermore, formation of the desired C-C bond was clearly shown by the disappearance of one 
ortho-phenanthroline proton signal. A distinctive molecular ion peak was observed in the ESI 
spectrum (m/z = 384 a.m.u.), providing further evidence for product formation.  
 
Scheme 2-14: The reaction scheme for the synthesis of the mono-functionalised pyridyl-phenanthroline platinum(II) 
complex, 24 and the proposed route to prepare the di-functionalised pyridyl-phenanthroline platinum(II) complex 25. 
The corresponding platinum(II) complex, was synthesised by reacting L12 with an equimolar amount 
of [Pt(COD)Cl2]. The reaction was carried out in water at 75
oC for 3 h. This produced a yellow 
solution. A saturated aqueous solution of NaPF6 was added to the solution to precipitate the desired 
complex as an orange PF6 salt. The complex was characterised by 
1H and 31P NMR spectroscopy, 
mass spectrometry and elemental analysis. The aromatic peaks were observed to shift downfield 
(between 0.2-0.5ppm) relative to the ligand, indicative of successful platinum coordination. The 
expected molecular ion peak and isotopic pattern were observed in the ESI mass spectrum, 
indicating the successful formation of 24. Furthermore 31P NMR spectroscopy confirmed the 
presence of the PF6
- counter-anion.  
Two different methods were used in the attempted synthesis of 25. The procedures involved either 
one or two steps. The single step method was analogous to that used to prepare the platinum(II)-
terpyridine-thiol complexes. The two-step method involved: (a) generation of a sodium thiolate salt 
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corresponding to L18 (using NaH) and (b) reaction of this salt with the platinum species. The starting 
materials were recovered from the two-step method, whereas the one-step approach proved more 
promising. In this case the product was observed to form (monitored by 1H NMR spectroscopy), 
however only as a mixture with other side products (unidentified compounds). Elevating the 
reaction temperature (from 25oC to 60oC) improved the desired product-to-side product ratio, 
however full conversion was not achieved. At even higher temperatures (>70oC), a yellow precipitate 
was observed to form (assigned as an inorganic salt as no peaks were observed from the 1H and 13C 
NMR spectra in D2O). This made purification even more difficult, therefore the desired product was 
not isolated. The experimental details of the attempted methods are reported in Section 6.4.2. 
 
The non- and mono-substituted pyridyl-phenanthroline platinum(II) complexes, 26 and 27 were 
prepared using the procedure depicted in Scheme 2-15. The ligand was prepared by coupling 
phenanthroline and 2-bromopyridine (using the same conditions described for L12). Reacting the 
tridentate ligand with [Pt(COD)Cl2] in water at 75
oC for 3 h, yielded 26 (isolated as a red chloride 
salt). 26 was reacted further with excess L18 in water to produce 27 (using an analogous method to 
that used to prepare the equivalent platinum(II) terpyridine thiol complex, 13). The platinum 
complexes were fully characterised by 1H and 31P NMR spectroscopy, mass spectrometry and 
elemental analysis. The large downfield shift observed for the ortho proton signal (0.8 ppm 
difference between 26 and 27) signified the successful attachment of the thiol moiety. 
 
Scheme 2-15: Reaction scheme for the synthesis of the cholro and thiol substituted pyridyl-phenanthroline platinum(II) 
complexes, 26 and 27 respectively. 
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2.3.7 Phenyl-phenanthroline Platinum(II) Complexes 
L14-16 were prepared by coupling 2-bromobenzene or L19 (synthesised by refluxing 2-bromophenol, 
chloroethyl-piperidine and K2CO3 in acetone for 16 h) with 1,10-phenanthroline or L
11. The reaction 
conditions used were the same as that described for L12 however a different purification method was 
used. Silica column chromatography using petroleum ether: ethyl acetate:Et3N  (9:1:0.02) as elutants 
was required to isolate the compounds. L14 was isolated as a white solid whereas L15 and L16 were 
obtained as off-white oily solids meaning elemental analysis was not possible. All three compounds 
were characterised by 1H NMR spectroscopy and ESI spectrometry.  
 
Scheme 2-16: Reaction scheme for the synthesis of phenyl-phenanthroline platinum(II) complexes, 28-30 
 
A number of methods were tried prior to successful formation of the corresponding cyclo-metallated 
platinum(II) complexes (the conditions used are summarised in Table2-2). The starting materials 
were recovered from method 1. Some product formation was observed (monitored by 1H NMR 
spectroscopy) using method 2 however full conversion was not achieved. Attempts to isolate the 
product using alumina column chromatography (neutral) were unsuccessful. Method 3a again 
resulted in a mixture of product and side products however upon increasing the reaction 
temperature (by 10oC) and time (by one day), full conversion to the desired product was achieved 
(method 3b). This method was used to successfully synthesis all three platinum complexes 28-30. 
The platinum complexes were fully characterised by 1H NMR spectroscopy, mass spectrometry and 
elemental analysis (except for 30). Chelation of platinum to the two nitrogen atoms was shown by a 
downfield shift of the aromatic proton signals, especially the ortho-phenanthroline proton signal. 
Formation of the cyclometalled Pt-C (aromatic) bond was confirmed by the disappearance of the 
ortho phenyl proton signal.  
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Table 2-2: Synthetic methods used to prepare the cyclo-metallatedphenyl-phenanthroline 
platinum(II) complexes, 28-30. 
Method  Reagents Conditions Purification  
1 php ligand, K2PtCl4, glacial 
acetic acid (solvent) 
120oC, 3 days Filter precipitate and 
wash thoroughly with 
H2O, MeOH, Et2O. 
2 php ligand, K2PtCl4, 
MeCN:H2O 1:1 (solvent) 
Heat at 90oC until 
all the MeCN 
evaporates 
Filter precipitate and 
wash thoroughly with 
H2O, MeOH, Et2O. 
3a php ligand, K2PtCl4, NaOAc, 
DMSO, MeCN (solvent) 
50oC, 2 days Filter precipitate and 
wash thoroughly with 
H2O, MeOH, Et2O. Then 
re-crystallise from 
DCM and hexane 
3b php ligand, K2PtCl4, , 
NaOAc, DMSO, MeCN 
(solvent) 
60oC, 3 days Filter precipitate and 
wash thoroughly with 
H2O, MeOH, Et2O. Then 
re-crystallise from 
DCM and hexane 
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Figure 2-8: (a) A comparison of the 
1
H NMR spectra obtained for L
14
 (bottom), the result of method 3a (middle) and 3b 
(top). (b) Chemical structure of 28. (c) Chemical structure of L
14
. 
 
2.4 X-ray Crystal Structures of Metal-Terpyridine Complexes 
The X-ray crystal structures where resolved by Dr. A.J.P. White (Imperial College London) 
In order to fully probe the geometry of the metal-terpyridine unit, X-ray crystal structures of a 
selection of the synthesised platinum(II), zinc(II), copper(II) and gold(III) complexes were resolved.  
We have previously shown by X-ray crystallography that the mono-functionalised platinum(II) 
terpyridine complexes 8 and 10 adopt square planar geometries, ideal for π-π stacking with 
quadruplex DNA.[113] In order to compare this to the thiol substituted complexes, crystals of 13 
were grown (from a methanol/diethyl ether mixture) for X-ray crystallographic study. 13 crystallised 
as red needles with two methanol molecules and two chloride counter-anions in the P-1 space group 
(see Figure 2-10). Platinum was found to coordinate the ligand via a well-defined triple chelation. 
The Pt-N bond distances show the normal variation, 1.972(3)-2.044(4) Å) with that to the bridgehead 
nitrogen being ca. 0.07 Å shorter than those to the side atoms. The N-Pt-N angles agree with those 
reported for other platinum(II) terpyridyl complexes[125-127] and the Pt-S bond distance, 
2.3131(10) Å is similar to that reported for [Pt(terpy)(SCH2CH2OH)]PF6.[119] Therefore the structural 
parameters of 13 generally confer with the norm. The Pt(1) atom is seen to reside in the plane 
defined by the terpyridine unit and hence conveys a square planar geometry (comparable to 8 and 
10). The square planar structure is demonstrated by (a) an almost linear N(1)-Pt(1)-S(19) angle of 
(a) (b) 
(c) 
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178.18(10)o and (b) an average bond angle around Pt (1) of 89.997o i.e. the average value for the 
N(1)-Pt(1)-N(14), N(1)-Pt(1)-N(8), N(14)-Pt(1)-S(19) and N(8)-Pt(1)-S(19) bond angles. Interestingly 
due to a Pt(1)-S(19)-C(20) angle of 103.57(15)o the piperidine arm is projected almost perpendicular 
to the Pt-terpyridine motif. It is also worth pointing out the presence of a protonated piperidine unit 
(also observed by 1H NMR spectroscopy), which results in a doubly charged complex with two 
chloride counter anions rather than one. This finding supports the proposed mechanism of complex 
formation (discussed earlier). 
 
 
Figure 2-9:  X-ray crystal structure of the platinum(II) complex 13.Front view of an ortep plot (thermal ellipsoids shown 
at 50% probability).  It provided confirmation of the proposed formulation and displays the presence of two chloride 
counter anions and two methanol molecules. The hydrogen atoms are omitted from the structure for clarity. 
 
Crystals of 5 suitable for single-crystal X-ray diffraction study were obtained by slow evaporation 
from a DMSO solution over 2 days. 5 crystallised as colourless blocky needles in the P-1 space 
group (see Figure 2-11). 5 displays the expected molecular structure with zinc coordinated to L4 and 
two chlorides atoms, one of which occupies an apical position, τ=0.20. The Zn-N bonds distances 
displayed the normal variations, 2.1049(14)-2.2017(15) Å with that to the central nitrogen being 
shortest.[117] The structure of 5 resembles a distorted trigonal bi-pyramid (non-planar).[128] Its lack 
of planarity is illustrated by (a) the Zn atom not residing in the basal plane defined by the terpyridine 
ligand [Cl(2),N(1),N(8),N(14)], the metal lies about 0.62 Å out of this plane and (b) the non-
perpendicular nature of the Cl(1)-Zn(1)-Cl(2) angle, 119.25(2)o. Furthermore the three pyridyl rings 
and O(19) are noticeably more distorted from planarity than in either the copper or platinum species 
(the metal and Cl(2) lie about 0.25 and 1.18 Å out of this plane respectively). In terms of DNA 
binding, the nonexistence of an accessible planar surface suggests 5 would not be suitable to 
interact with quadruplex DNA (via π-π interactions). 
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Figure 2-10: X-ray crystal structure of the zinc(II) complex 5. Front view of an ortep plot (thermal ellipsoids shown at 50% 
probability).  It provided confirmation of the proposed formulation. The complex displays a distorted trigonal bi-
pyramidal geometry. The hydrogen atoms are omitted from the structure for clarity. 
 
Crystals of 6 suitable for a single-crystal X-ray diffraction study were obtained by slow diffusion of 
acetone into a concentrated aqueous solution of the compound over 3 days. 6 crystallised as blue 
thin plates with one water molecule in the P2(1)/c space group (see Figure 2-12). The solid state 
structure exhibits the expected molecular structure with copper adopting a square base pyramidal 
coordination geometry (bonding to L4 and two chlorides).The geometry is demonstrated by (a) 
almost linear N(14)-Cu(1)-N(8) and N(1)-Cu(1)-Cl(2) angles of 157.30(7)o and 164.60(6)o respectively 
and (b) N(1)-Cu(1)-Cl(1), N(8)-Cu(1)-Cl(1) and N(14)-Cu(1)-Cl(1) angles close to 90o. As previously 
reported for Cu(terpyridine)Cl2, the geometry can be more accurately described an “apical 
elongated” square pyramid as the apical chloride is only weakly coordinated.[129-131] This is clearly 
demonstrated for 6, the axial Cu-Cl bond distance is ca. 0.28 Å greater than the equatorial. 
Interestingly the apical chloride was less distorted (τ = 0.11)[128] compared to the zinc analogue. 
The complex has one open planar face accessible for π-π stacking. Therefore 6 could be envisaged to 
interact strongly with quadruplex DNA (via π-π stacking interactions). Furthermore the presence of 
an apical chloride is beneficial in terms of selectivity over duplex DNA as it hinders intercalation 
between base pairs. 
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Figure 2-11: X-ray crystal structure of the copper(II) complex 6. Front view of an ortep plot (thermal ellipsoids shown at 
50% probability). It provided confirmation of the proposed formulation. The complex displays an “apical elongated” 
square pyramidal geometry. The hydrogen atoms are omitted from the structure for clarity. 
 
Crystals of the gold(III)-terpyridine derivative 12 were also resolved by single-crystal X-ray 
diffraction. The crystals were obtained by slow diffusion of diethyl ether into a concentrated 
acetonitrile solution of the compound over 2 days. 12 crystallised as pale yellow thin plates with two 
acetonitrile solvates and three hexafluorophosphate counter-anions in theP-1 space group (see 
Figure 2-13). The gold atom was found to bind via three bonds (varying in length from 1.990(5)-
2.026(6) Å) to L3 and through a longer bond to chloride (2.2586(18) Å), giving an overall square 
planar geometry. This was clearly shown by (a) almost linear N(14)-Au(1)-N(8) and N(1)-Au(1)-Cl(1) 
angles of 161.8(3)o and 177.89(14)o respectively and (b) an average bond angle around Au (1) of 
90.01(5)o i.e. the average value for the N(1)-Au(1)-N(8), N(1)-Au(1)-N(14), N(14)-Au(1)-Cl(1) and N(8)-
Au(1)-Cl(1) bond angles. As with the platinum case 13, the amine side arm (pyrrolidine unit) in 12 
was found to be protonated (this was also observed by 1H NMR spectroscopy). Protonation results in 
an overall +3 charge. The planarity and positive charge of the complex make it ideal for quadruplex 
DNA binding via π-π stacking and electrostatic interactions respectively. 
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Figure 2-12:  X-ray crystal structure of the gold(III) complex 12. Front view of an ortep plot (thermal ellipsoids shown at 
50% probability). It provided confirmation of the proposed formulation. The complex displays as square planar 
geometry. The three hexafluorophosphate counter anions, two acetonitrile molecules and the hydrogen atoms are 
omitted from the structure for clarity. 
 
2.5 π-π stacking Interactions in Solid State 
Intermolecular π-π stacking interactions in solid state usually occur through different geometric 
configurations.  The most thermodynamically stable is the parallel displaced conformation. In this 
type, the aromatic rings are displaced in a parallel direction, with a typical centroid to centroid 
distance of 3.3-3.8 Å. The X-ray crystal structures of 5, 12 and 13 show these complexes to π-π stack 
with a parallel displaced conformation. Contrastingly the solid state structure of 6 shows it to form a 
hydrogen bonded network, lacking π-π stacking interactions. 
The planarity of 13 allows adjacent centrosymmetically related complexes to form an extended 
stacking network along the a axis through a series of π-π interactions. The packing pattern is such 
that ring A in one platinum complex is placed on top of another ring A in another C2-related complex. 
The centroid-to-centroid and mean interplanar distances (about 3.689 and 3.340 Å respectively) are 
comparable to those reported for other π-π stacked systems. Additionally ring B in one complex 
overlays ring C in another rotationally related complex and vice versa (ring C overlays ring B), 
forming a continuous ···B···C···B···C··· array. The centroid to centroid and mean interplanar distances 
(about 3.810 and 3.379 Å respectively) in this case are also indicative of π-π stacking interactions. In 
terms of relative symmetry, the ring planes are parallel but slightly offset, implying the existence of 
aparallel displaced π-π stacking conformation. It is also worth pointing out that the Pt···Pt 
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separations (4.498 and 6.789 Å) suggests that additional metallophilic interactions do not occur. 
Overall the solid state crystal structure of 13 clearly demonstrates the complexes ability to self π-π 
stack and is suggestive of its the potential to interact with quadruplex DNA via π-π interactions. 
 
Figure 2-13: (a) Molecular structure of 13. The three poly-pyridyl rings are labelled A, B and C. (b) Part of the π-π stacked 
network of 13, along the crystallographic a axis direction. The centroid-to-centroid distances are 3.689 and 3.810 Å. 
 
Despite the non-planar nature of 5, in solid state, the complex packs in a manner that displays three 
distinctive π-π stacking interactions. The packing pattern is such that ring A in one complex overlays 
ring B in another Ci related complex and vice versa (ring B overlays ring A). The centroid–to-centroid 
and mean interplanar separations (about 3.61and 3.37 Å respectively) fall within the range usually 
associated to π-π stacking interactions. Furthermore ring C is in close proximity to another ring C in 
an adjacent inversed complex in the opposite direction to the one involved in the AB and BA ring 
interactions. In this case the centroid-to-centroid and mean interplanar separations (about 3.82 and 
3.37 Å respectively) also suggest a case for intermolecular π-π interactions. On the account of 
thecentre of symmetry, the ring planes are perfectly parallel. Therefore the π-π interactions can be 
considered to occur through a parallel displaced conformation. 
 
 
 
 
 
 
 
(a) (b) 
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Figure 2-14: (a) Molecular structure of 5. The three poly-pyridyl rings are labelled A, B and C (b) Part of the π-π stacked 
network of 5, along the crystallographic c axis direction. The centroid to centroid distances are 3.822 and 3.610 Å. 
 
Although 6 displays a square based pyramidal geometry capable of forming intermolecular π-π 
stacking interactions, its packing structure is dominated by hydrogen bonding interactions. The 
hydrogen bonding network involves the solvate water molecule. The O(30) atom on the water 
molecule serves to link adjacent complexes in the b axis direction through hydrogen bonding 
interactions to the equatorial Cl(1) atom in one complex [O···Cl 3.2006(19) Å, H···Cl 2.34 Å, O-H···Cl 
161o] and the morpholine N(22) atom in another lattice translated complex [O···N 2.986(3) Å, H···N  
2.09 Å, O-H···N 173o]. The fact that 6 forms a stable hydrogen bonded lattice in the solid state (in the 
presence of water), suggests that it may be less available to interact with quadruplex DNA via π -π 
stacking interactions. 
(a) (b) 
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Figure 2-15: Part of the hydrogen bonded network of 6, along the crystallographic b axis direction. The water solvate 
serves to link the equatorial chloride atom in one complex to the morpholine nitrogen atom in another adjacent 
complex by hydrogen bonding interaction. 
 
The gold(III) complex, 12 forms an extended stacking network along the c axis. The packing pattern is 
such that ring B in one gold complex stacks atop ring C on another translated complex and vice versa 
(ring C overlays ring B), in a similar fashion to 5. Two centroid-to-centroid distances are obtained for 
the ring B···C interactions (4.033 and 4.492 Å), both of which are slightly above the distances usually 
associated to π-π stacking interactions. It is also worth pointing out that the Au···Au separations 
(6.917 and 9.429 Å) suggest that additional metallophilic interactions do not occur. Overall the solid 
state structure of 12 clearly demonstrates its propensity to interact with quadruplex DNA via π-π 
interactions. 
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Figure 2-16: (a) Molecular structure of 12. The three poly-pyridyl rings are labelled A, B and C. (b) Part of the π-π stacked 
network along the crystallographic c axis direction. The centroid to centroid distances are 4.033 and 4.492 Å. 
 
 
2.6 π-π Stacking Interactions in Solution State 
The majority of quadruplex DNA stabilisers are known to interact through π-π interactions. In order 
to interact in this manner, a planar coordination geometry is necessary. This is a characteristic 
inherent to platinum(II) and gold(III)-terpyridine complexes. To semi-quantitatively establish the 
existence of intermolecular π-π stacking interactions in solution, variable concentration (VC) and 
temperature (VT) 1H NMR spectroscopic and variable concentration UV-Vis spectroscopic studies 
were undertaken. Molecules that are able to self π-π stack are more likely to stack with other 
components i.e. the face of the terminal G-tetrad.  
 
The detection of π-π interactions by VC and VT 1H NMR spectroscopy relies on the concentration and 
temperature dependence of certain aromatic protons’ chemical shifts.[132] As the concentration is 
increased or the temperature is lowered there is a higher tendency for the molecules to come into 
close contact (aggregate). This facilitates π-π interactions, thus protons associated to the π-ring 
systems become shielded. This results in an upfield shift of the proton signals. 
 
We have previously shown, by variable concentration and temperature 1H NMR spectroscopy, that 8 
and 9 aggregate in solution via π-π stacking.[113] Upon increasing the temperature (from 25 to 
(a) (b) 
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100oC) and concentration (from 0.002 M to 0.014 M) the resonances associated to the aromatic 
protons shifted to higher and lower field respectively. This was consistent with intermolecular π-π 
stacking interactions. It was therefore of interest to analyse whether other polypyridyl-platinum(II) 
complexes would behave in similar manner. VC and VT 1H NMR spectroscopic studies were carried 
out for the di-functionalised platinum(II) complexes, 13-15 (in D2O) and 16 (in DMSO-d6). In all four 
cases the aromatic proton signals (i.e. those involved in π-π stacking) were seen to shift downfield 
upon dilution (from 0.02 M to 0.00125 M) or increasing temperature (from 298 K to 373 K), 
indicative of self-aggregation (see Figure 2-18).  
 
 
 
Figure 2-17: (a) Chemical structure of 14. (b) Graphical presentation of the changes in aromatic proton chemical shifts 
upon increasing temperature. (c) The 
1
H NMR spectra of 14 upon increasing temperature, 298-363 K (bottom to top). 
 
Similar 1H NMR spectroscopic studies were carried for the pyridyl- and phenyl-phenanthroline 
platinum(II) complexes, 24, 27 and 29 (with larger aromatic surfaces). Upon increasing the 
concentration of the platinum complexes in DMSO-d6, the aromatic proton signals were seen to shift 
upfield, symptomatic of aggregation (see Figure 2-20). The phenanthroline proton signals 
(particularly Ha and Hb for 27, 24 and 29 see Figure 2-19) displayed the most significant shifts. 
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Therefore these protons can be proposed to function as the π-σ attraction component which 
contributes to π-π interactions. Comparing these VC studies to those of the terpyridine complexes 
it is evident that by increasing aromatic surface, the potential to π-π stack is not enhanced but 
preserved. 
 
Figure 2-18: Chemical structure of 27, 24 and 29. The highlighted phenanthroline protons were found to display the 
highest shifts upon changes to temperature and concentration. 
 
 
 
Figure 2-19: (a) The 
1
H NMR spectra of 27 upon increasing concentration, 0.00125-0.0165 M (top to bottom). (b) 
Graphical presentation of the changes in aromatic proton chemical shifts upon increasing concentration. 
 
 
The bi-metallic platinum(II)-platinum(II) complex, 20 and its corresponding ligand, L9 were also 
analysed by VT 1H NMR spectroscopy (in DMSO-d6). For the free ligand, no significant changes in the 
aromaticregion were observed upon increasing the temperature. This indicates that the free ligand 
does not display π-π stacking interactions, which is not surprising since the pyridine groups of the 
free ligand are not necessarily coplanar. In contrast, significant shifts in the resonances of the 
aromatic protons were observed for 20 upon increasing the temperature from 298 to 373K (see 
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Figure 2-22). Interestingly, not all the aromatic protons follow the same trend. While some shifted 
downfield upon increasing temperature others shifted in the opposite direction. This suggests that 
only some of the aromatic protons are involved in π-π stacking interactions (namely, Ha, Hb, He, Hg, 
and Hi; see 2D NMR spectra for assignments/connectivity). Interestingly, these protons are not all in 
the terpyridine fragment but also on the DPA group. This is in contrast to the mono-platinum(II) 
terpyridine complexes (8 and 9) which from previous studies  were shown to be fully engaged in π-π 
stacking interactions (i.e., all the protons on the terpyridineligand are displaced to higher chemical 
shifts upon increasing the temperature). Besides the above observations consistent with π-π 
stacking, some protons shiftupfield upon increasing temperature, suggesting thatthey are not 
involved in π-π stacking interactions but more likely in some form of hydrogen bonding that upon 
increasing the temperature is broken (and hence these protons become more shielded). The most 
likely source of this interaction is with the polar DMSO solvent; it is well established that when 
dissolved in polar solvents, protons tend to shift upfield if temperature increases because of reduced 
solvation interactions with the solvent. Another possible explanation for these observations is that 
the two platinum units interact with each other (either intra- or inter-molecularly) via π-π stacking 
interactions (see figure 2-21). Since the coordination environments of the two platinum(II) units are 
different, their stacking will not be symmetric and therefore not all the protons will be affected in 
the same way by the aromatic ring currents associated to the shielding of protons. To gain some 
more insight into the nature of these interactions, VC 1H NMR was carried out. Unexpectedly, 
practically no changes were observed when the concentration was increased from 0.0005 M to 
0.008 M. This suggests that the π-π stacking interactions are likely to be the consequence of small 
aggregates (e.g., dimers of 20) that are not modified by concentration. Another explanation could be 
that the pyridine rings of the terpyridine and DPA ligands interact intramolecularly; however, this is 
unlikely since the spacer between the two moieties is not long/ flexible enough to allow them to be 
placed “face-to-face”in an effective manner. An X-ray crystal structure would help clarify the nature 
of these interactions; however, all attempts to grow single crystals have so far failed. 
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Figure 2-20: Proposed dimers of 20, held together by inter-molecular π-π interactions between the terpyridine and 
dipicolyamine ring systems. (a) Head to tail dimer. (b) Dimer adopting a “pacman” conformation. 
 
 
 
 
Figure 2-21:  (a) Chemical structure of 20. (b) Graphical presentation of the changes in aromatic proton chemical shifts 
upon increasing temperature. (c) The 
1
H NMR spectra of 20 upon increasing temperature, 298-413 K (bottom to top). 
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As a comparison VT 1H NMR spectroscopic studies were also conducted for 18 (in DMSO-d6 solvent).  
Upon increasing the temperature the aromatic peaks were seen to shift upfield (terpyridine and 
DPA). The shifts can be attributed to a number of reasons including: (a) the exchange of Zn ions 
between binding sites at high temperatures; (b) structural changes occurring as a result of solvent 
coordination to the Zn centre; (c) the dissociation of Zn from the ligand. Nevertheless the 1H NMR 
signal shifts detected for 18, are not consistent with π-π interaction. This is expected considering the 
non-planar geometry of 18 (see X-ray crystal structure of 5, Figure 2-11). 
 
To confirm the ability of poly-pyridylplatinum(II) complexes to π-π stack in solution state, variable 
concentration UV-Vis studies were also conducted with a selection of the complexes (8, 10 and 
20).[133-135] At high concentrations, a low energy (>500nm) MMLCT band (metal-to-metal-to-
ligand charge transfer) was observed. MMLCT bands are usually associated to π-π stacking and 
platinum(II)-platinum(II) interactions in planar platinum(II) complexes. To rationalise whether the 
band was a manifestation of aggregation or simply a trait associated to the concentration increase 
(Beer’s law), the absorption at various concentrations was monitored. The absorption intensity of 
the MMLCT band (500nm for 8 and 10 and 505nm for 20) was plotted against concentration to see 
whether the relationship obeyed Beer’s law (linear) or displayed aggregation characteristics 
(exponential increase). 
 
 
 
Figure 2-22: (a) The absorption spectra of 20 upon increasing concentration from 0.00125 to 0.04 M. (b) Plot of 
concentration of 20 vs. absorbanceat 505nm. The graph shows aggregation characteristics for this system. 
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There was a non-linear relationship observed for 8, 10 and 20 (see Figure 2-23). Therefore the lower 
energy bands observed in the UV-Vis spectra were assigned to those corresponding to metal-metal / 
π-π interactions (MMLCT). The UV-Vis data obtained supports the 1H NMR spectroscopic studies and 
confirms the ability of the platinum(II) complexes 8, 10 and 20 to π-π stack in solution state.  
For the thiol functionalised platinum(II) complexes 13-15, a distinctive band was observed at low 
frequency (ca. 500nm). However, upon plotting the absorption of this band against varying 
concentrations of the complexes, a linear correlation was obtained. Therefore the low energy band 
in this case was assigned to LMCT rather than MMLCT (see Figure 2-24). π-π and metallophilic 
interactions (as shown by VT and VC 1H NMR studies and the solid state structure of 13) may still 
occur for the platinum(II)-thiol complexes, 13-15 however it cannot be detected by UV-Vis studies. 
This is due the presence of the LMCT band in the same region as the expected MMLCT band. 
 
 
Figure 2-23: (a) The absorption spectra of 15 upon increasing concentration, 0.000625-0.04 M. (b) Plot of concentration 
of 15 vs. absorption at 500nm. The plot shows that the system obeys Beer’s principles. 
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CHAPTER 3 
 
 
BIOPHYSICAL DNA BINDING 
STUDIES 
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3.1 Overview 
In order to determine the ability of the synthesised complexes to interact with DNA, a number of 
biophysical studies were carried out. The Fluorescent Intercalator Displacement (FID) assay was used 
to semi-quantitatively determine the affinity and selectivity of the complexes for quadruplex DNA 
(both Htelo and c-myc sequences).  In order to obtain more quantitative data, UV-Vis titration 
studies were carried out. Binding constants for quadruplex and duplex DNA were obtained using this 
technique.  It was also used to determine the binding mode of the complexes to quadruplex DNA. 
Variable Temperature Circular Dichroism (VTCD) studies were conducted to evaluate the capacity of 
the complexes to stabilise c-myc DNA. Circular Dichroism (CD) titration experiments were carried out 
to monitor (quadruplex DNA) conformational changes induced by the complexes. It was also used to 
assess the ability of the complexes to template the formation of quadruplex DNA (from singly 
stranded DNA). 1H NMR titration experiments with the tetra-molecular Htelo DNA sequence, 
d(TTAGGG) were conducted for a selection of compounds. This gave further insight into the binding 
mode of the complexes.  
During the above mentioned biophysical studies (FID, UV-Vis, CD and NMR), the complexes were 
incubated with DNA for short times (less than 2 h), therefore these methods can be considered to 
probe non-covalent interactions only. To investigate the potential of the complexes to interact 
covalently (i.e. by direct metal coordination), long term (over 24 h) 1H NMR spectroscopic 
experiments with guanosine were carried out. In the next sections, details of the data obtained with 
each of these techniques are provided. 
 
3.2 Fluorescent Intercalator Displacement (FID) 
The complexes were first screened using the Fluorescent Intercalator Displacement (FID) assay. This 
technique allows a quick, semi-quantitative assessment of the test compounds’ ability to bind to 
DNA.[70, 136-138] This method is based on the luminescent properties of thiazole orange (TO). 
When free in aqueous solution, TO luminescence is completely quenched. However when bound to 
DNA (quadruplex or duplex) TO becomes strongly luminescent. In the added presence of a strong 
DNA binder, TO is displaced and a subsequent loss in fluorescence is observed. This loss in 
fluorescence provides an approximate measure of the affinity of a given compound for DNA. To 
quantify the TO displacement (loss in fluorescence), DC50 values can be calculated. This is defined as 
the concentration of compound required to displace 50% of TO bound to DNA i.e. decrease TO 
fluorescence by 50%.  DC50 values of 0.5 μM and below are generally associated to very good DNA 
99 
 
binders. Selectivity for quadruplex DNA (over duplex DNA) was calculated by dividing the DC50 values 
of the 17-mer and 26-mer duplex sequences by those obtained for Htelo and c-myc quadruplex DNA.  
If selectivity is 10 or more (above the threshold) the test compound can be considered selective for 
that particular DNA sequence. 
 
Figure 3-1: Schematic representation of the FID assay. Quadruplex DNA has been shown as the oligonucleotide in this 
example. 
Four different DNA sequences were investigated: two quadruplex forming sequences (Htelo 22-mer 
and c-myc 20-mer) and two duplex DNA sequences (with 17bp and 26bp). DC50 values were 
determined for all the compounds and the results are summarised in Table 3-1, 3-2 and 3-3.  First 
the mono-nuclear platinum(II), copper(II), zinc(II) and gold(III) terpyridine complexes, and a selection 
of the corresponding ligands were analysed. Several trends were observed: the compounds that 
displayed the highest affinity for quadruplex DNA (Htelo and c-myc) were the platinum(II) 
complexes. The DC50 values obtained for 7-10 and 13-16 were in the nM range and are comparable 
to (and in some cases better than) previously reported quadruplex DNA binders with high binding 
affinities.[138] This can be attributed to their square planar geometry (see X-ray crystal structure of 
13, Figure 2-10) which allows effective π-π stacking interactions with quadruplex DNA. Interestingly 
the majority of platinum complexes favoured c-myc over Htelo DNA. It is also worth pointing out 
that the piperidine functionalised complexes were found to be considerably better quadruplex 
binders than their unsubstitued analogues (or those functionalised with pyrrolidine or morpholine 
groups). 
In terms of selectivity for quadruplex DNA (over duplex DNA), the mono-functionalised platinum 
complexes exhibited good selectivity (especially for c-myc DNA, where selectivity was above the 
threshold previously established for the FID assay) whereas the doubly substituted thiol complexes 
displayed little discrimination between the two DNA topologies. The addition of an extra substituent 
was initially envisaged to enhance selectivity by sterically hindering intercalation between duplex 
DNA base pairs. However given the FID data it is evident that addition of the second substituent (in 
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the given position) leads to poorer selectivity. The extra charge resulting from the protonation of the 
side arms is one potential explanation. Complex 16 on the other hand, which has two unprotonated 
side arms, displays very good selectivity for quadruplex DNA. 
Table 3-1: DC50 values obtained for the mono-nuclear platinum(II) and copper(II) terpyridine 
complexes. The values are an average of three independent measurements. All error values are 
within 5%. 
 TO Displacement Selectivity 
Compound 
HteloDC50 
(μM) 
cmycDC50 
(μM) 
ds17DC50 
(μM) 
ds26DC50 
(μM) 
ds26DC50 / 
HteloDC50 
ds26DC50 / 
cmycDC50 
7 1.46 0.86 > 2.5 > 2.5 2.0 2.9 
8 1.25 0.26 3.46 2.44 2.0 9.4 
9 1.44 0.46 4.11 > 2.5 1.7 5.4 
10 2.24 1.01 4.48 > 2.5 1.1 2.5 
13 0.46 0.30 0.41 0.68 1.5 2.3 
15 0.48 0.30 0.78 1.18 2.5 3.9 
14 0.33 0.49 0.84 1.17 3.5 2.4 
16 2.81 1.34 > 5 > 10 ---- ---- 
4 1.32 2.45 > 10 2.16 1.6 ---- 
 
Considering the square pyramidal geometry of the copper(II)-terpyridine core (see X-ray crystal 
structure of 6, Figure 2-12) one may have predicted the copper complexes to π-π stack strongly with 
quadruplex DNA (via its unhindered π-surface). However the results proved quite surprising, both 
HteloDC50 and 
cmycDC50 values were >10 µM (except for 4 which exhibited reasonable binding), implying 
very weak binding to quadruplex DNA. This can be explained by the tendency of copper(II)-
terpyridine complexes to form; (a) octahedral complexes or (b) hydrogen bonded networks upon 
coordination to donating solvents (such as water) (as seen in the solid state packing structure of 6, 
Figure 2-16).  
For the zinc(II) terpyridine complexes, (1, 3 and 5) weak binding was observed (no DC50 values were 
obtained up to a complex concentration of 10 µM). This was expected bearing in mind their trigonal 
bi-pyramidal structure (with no accessible planar surface). Furthermore, the corresponding free 
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ligands (L1, L2 and L3) were also found to be very weak quadruplex binders (no DC50 values were 
obtained). This was expected taking into account their non-planarity and structural flexibility in 
solution (see Section 2.6). The FID assay was not carried out for the gold(III) complexes, 11, 12 and 
17 due to their instability in the buffer used (K+ cacodylate 10 mM KCl 50 mM). Upon monitoring the 
complexes in solution by UV-Vis spectroscopy, there was a significant drop in the intensity of the 
absorption bands over a 4 h period (the MLCT band fell by 27%). The main source of instability could 
be de-coordination of the metal from the tridenate ligand via gold(III) to gold(I) reduction. 
Although structurally similar, platinum(II) pyridyl- and phenyl-phenanthroline complexes gave 
contrasting DC50 values. The pyridyl-phenanthroline complexes were found to interact very strongly 
with quadruplex DNA (both c-myc and Htelo DNA, DC50 values < 0.5 µM) whereas as the cyclo-
metallated complexes displayed considerably weaker binding; this can be explained by the 
difference in charge between the cyclometallated (neutral) and N-tridenate (positive) complexes. 
Both series of platinum complexes exhibited reasonable selectivity over duplex DNA (in the 3-7 
range, which is similar to that reported for the bisquinolinium dicarboxamide derivatives).[138] 
Comparing the DC50 values of the platinum(II) pyridyl-phenanthroline  complexes with the 
terpyridine family, it is evident that by increasing the aromatic π-surface, higher quadruplex DNA 
binding is achieved (significantly lower DC50 values).  
Table 3-2: DC50 values obtained for the platinum(II) pyridyl- and phenyl-phenanthroline complexes. 
The values are an average of three independent measurements. All error values are within 5%. 
 TO Displacement Selectivity 
Compound 
HteloDC50 
(μM) 
cmycDC50 
(μM) 
ds17DC50 
(μM) 
ds26DC50 
(μM) 
ds26DC50 / 
HteloDC50 
ds26DC50 / 
cmycDC50 
26 0.66 0.27 0.92 1.18 1.8 4.4 
27 0.40 0.13 0.32 0.71 1.8 5.5 
24 1.01 0.25 1.24 1.77 1.8 7.1 
28 5.06 2.57 4.78 > 10 ---- ---- 
29 1.88 1.12 5.62 > 10 ---- ---- 
 
The di- and tri-metallic terpyridine-DPA complexes were also tested using the FID assay. From all the 
compounds tested the di- and tri-nuclear copper(II) (19 and 22) and platinum(II) (20) complexes 
displayed the highest affinity and selectivity for quadruplex DNA (c-mycDC50 < 0.5 μM and selectivity 
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>10). In fact the values obtained were better than those obtained for previously reported 
quadruplex DNA binders with high binding properties (such as quinacridines and bisquinolinium 
derivatives). The results can be attributed to the metal-DPA component, which can be envisaged to 
promote quadruplex DNA binding through electrostatic interactions or direct coordination with the 
phosphate backbone and provide selectivity by sterically hindering duplex DNA intercalation. Even in 
the case of the di- and tri- zinc(II) complexes 18 and 21, good G4DC50 and selectivity values were 
observed (better than those for anyof the mono-metallic zinc-terpyridine complexes). 
Table 3-3: DC50 values obtained for the di- and tri-metallic terpyridine-DPA complexes. The values 
are an average of three independent measurements. All error values are within 5%. 
 
 TO Displacement Selectivity 
Compound 
HteloDC50 
(μM) 
cmycDC50 
(μM) 
ds17DC50 
(μM) 
ds26DC50 
(μM) 
ds26DC50 / 
HteloDC50 
ds26DC50 / 
cmycDC50 
18 2.25 1.63 9.23 > 2.5 1.6 2.9 
19 0.25 0.17 2.03 1.53 6.1 9.0 
20 0.48 0.26 2.58 > 2.5 5.8 10.9 
21 7.80 3.72 > 10 > 10 ---- ---- 
22 0.71 0.48 2.65 5.43 7.6 11.3 
103 
 
 
Figure 3-2: DC50 values for each of the complexes, the DNA sequence are Htelo (blue), c-myc (red), duplex 17bp (green) 
and duplex 26bp (purple). The dotted line represents the threshold previously reported for good DNA binders. 
 
3.3 UV-Vis Spectroscopic DNA Titrations  
UV-Vis spectroscopic titration experiments were carried with a selection of compounds and DNA 
(Htelo, c-myc and ct-DNA – the later as an example of duplex DNA), using a previously established 
protocol.[139] In order to perform these studies the test compounds were required to have an 
absorption maximum above 300nm (higher than the Amax of DNA, 260nm) and show optical changes 
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when interacting with DNA. As the free ligands did not have absorption bands above 300nm, only 
the metal complexes were tested. Upon addition of aliquots of DNA (in the mM range) to the 
corresponding metal complex solutions of known concentration, the absorption maximum was seen 
to decrease. From the absorption values, the concentration of bound and unbound metal complex 
were calculated and extrapolated to determine the binding constants. This was done by fitting the 
data to a reciprocal plot of D/Δεap versus D using the following equation: D/Δεap=D/Δε + 1/(Δε× K) 
where the concentration of DNA, D is expressed in terms of base pairs (determined by measuring 
the absorption at 260 nm and the appropriate extinction coefficients), the apparent molar extinction 
coefficient εa = Aobserved / [Complex], Δεap = [εa - εf] and Δε = [εb -εf]. εb is the extinction coefficient of 
the DNA bound complex, and εf is the extinction coefficient of the free complex. UV-Vis 
spectroscopic titrations were also used to probe the binding mode. Red shifts in absorption bands 
above 300 nm (those corresponding to MLCT or intraligand π-π* transitions) are signatory of π-π 
interaction with DNA bases. This is generally suggestive of an intercalative (for duplex DNA) or end 
stacking (for quadruplex DNA) binding mode.[97, 140-142] 
The addition of Htelo DNA to 8, 10 and 13 (mono-functionalised platinum(II) complexes) resulted in 
considerable hypochromicity of the metal perturbed intraligand π-π* band (ranging from 22-33%). A 
noticeable red shift (4-6 nm) was also observed for the complexes. These spectral features are 
suggestive of an end-stacking binding mode. Interestingly upon addition of c-myc DNA to 8, 10 and 
13, reduced hypochromicity (9-15%) and very small red shifts (1-2 nm) were observed. The latter 
suggests binding to c-myc DNA may not necessarily be restricted to end-stacking but could also 
involve supplementary interactions with the DNA’s loops and phosphate backbone. All three 
complexes demonstrated large hypochromicity (>30%) upon interaction with ct-DNA (duplex DNA); 
however only very small red shifts (1-2 nm) were observed. This suggests binding to ct-DNA may 
involve intercalation as well as other modes such as minor or major groove binding. The intrinsic 
binding affinity toward the different DNA sequences was determined and are summarised in Table3-
4. The three mono-functionalised platinum(II) complexes interact strongly with quadruplex DNA 
(both Htelo and c-myc), with binding constants comparable to those of other compounds reported 
to be good quadruplex DNA binders (in the range 106-107 M-1). 8 and 10 displayed reasonable 
selectivity for quadruplex DNA (one order of magnitude; higher for c-myc DNA) whereas 13 showed 
little discrimination between duplex and quadruplex DNA. The data indicates a clear correlation 
between side arm position and quadruplex DNA selectivity. Positioning the side arm on the 
terpyridine core (π-π stacking component) increases selectivity while coordination of the side-arm 
directly to the metal centre reduces selectivity. 
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Table 3-4: Binding constants obtained for the mono-functionalised platinum(II) terpyridine 
complexes. The values are an average of three independent measurements. 
Compound c-mycK (M–1) HteloK  (M–1) ct-DNA K (M–1) 
8 6.33 ± 0.32 × 106 1.83 ± 0.57 × 106 9.24 ± 0.72 × 104 
10 1.64 ± 0.32 × 107 1.75 ± 0.53 × 106 2.18 ± 0.23 × 105 
13 4.87 ± 0.44 × 107 1.95 ± 0.29 × 106 1.10 ± 0.23 × 106 
    
 
Figure 3-3: The UV-Vis spectra obtained from the addition of Htelo DNA to 8. The absorption band at ca. 320 nm displays 
hypochromicity and red shift, indicative of an end-stacking binding mode. The arrows indicate the change upon DNA 
addition. 
 
The di-functionalised platinum(II) complexes 14, 15 and 16 produced similar spectral changes upon 
interaction with DNA.  Addition of Htelo DNA resulted in hypochromicity (ranging from 15-23%) as 
well as energy shifts (by 2-7 nm) suggestive of an end-stacking binding mode (similar to the mono-
functionalised platinum(II) derivatives). c-myc DNA and ct-DNA produced large hypochromicity (from 
15-28%) but limited red shift, indicative of a complex binding mode (possibly two or more 
interaction modes). All three complexes were found to bind with very high affinity (107 M-1 range) 
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and selectivity (over a 100-fold) for c-myc DNA. Interestingly 16 displayed internal quadruplex 
selectivity, the binding constant for c-myc DNA was one order of magnitude higher than that for 
Htelo DNA. 
Table 3-5: Binding constants obtained for the di-functionalised platinum(II) terpyridine complexes. 
The values are an average of three independent measurements. 
Compound c-mycK (M–1) HteloK  (M–1) ct-DNA K (M–1) 
14 1.32 ± 0.42 × 107 1.06 ± 0.11 × 107 1.95 ± 0.52 × 105 
15 6.85 ± 0.24 × 107 1.60 ± 0.72 × 107 5.46 ± 1.10 × 105 
16 9.20 ± 0.42 × 106 8.78 ± 0.12 × 105 6.10 ± 0.94 × 104 
 
Addition of DNA (both quadruplex and duplex) to the platinum(II) pyridyl- and phenyl-
phenanthroline complexes resulted in large hypochromicity (ranging from 18-38%) but no red shift. 
This suggests binding may not exclusively result from π-π stacking interactions. In general, the 
complexes bind with high affinity to quadruplex DNA. The unsubstituted and thiol-functionalised 
complexes 26, 27 and 28 displayed reasonable selectivity for quadruplex DNA (around one order of 
magnitude). 24 and 29 on the other hand were very selective (over two orders of magnitude for c-
myc DNA). The data obtained for this series of complexes clearly shows, as was previously noticed 
for the mono-functionalised platinum(II) terpyridine complexes, a relationship between the 
positioning of the side arm and quadruplex vs. duplex DNA selectivity. 
Table 3-6: Binding constants obtained for the platinum(II) pyridyl- and phenyl-phenanthroline 
complexes. The values are an average of three independent measurements. 
Compound c-mycK (M–1) HteloK  (M–1) ct-DNA K (M–1) 
26 1.42 ± 0.10 × 107 6.21 ± 1.56 × 106 5.20 ± 1.32 × 105 
24 5.52 ± 0.42 × 106 8.00 ± 1.23 × 105 4.35 ± 1.19 × 104 
27 1.14 ± 0.22 × 107 1.46 ± 0.15 × 106 1.07 ± 0.21 × 106 
28 1.17 ± 0.21 × 107 8.76 ± 0.45 × 106 1.36 ± 0.68 × 106  
29 6.72 ± 0.65 × 107 1.27 ± 0.08 × 107 4.02 ± 1.12 × 105 
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Upon addition of quadruplex DNA (both Htelo and c-myc sequences) the di-metallic complexes (19 
and 20) displayed hypochromicity (15-20%) but only very small red shifts. These traits are suggestive 
of more than one binding mode. The complexes can be envisaged to bind via π-π stacking 
interactions atop quadruplex DNA (with the metal-terpyridine part) as well as through electrostatic 
or covalent means to the phosphate backbone (with the metal-DPA component). The complexes 
interact strongly with quadruplex DNA (binding constants in the 106-107 molar range). The di-
metallic platinum(II) complex, 20 displayed reasonable selectivity (1 order of magnitude).The di-
copper(II) complex on the other hand exhibited 100-fold selectivity for quadruplex versus duplex 
DNA.  
 
Table 3-7: Binding constants obtained for di-nuclear platinum(II) and copper(II) terpyridine-DPA 
complexes. The values are an average of three independent measurements. 
Compound c-mycK (M–1) HteloK  (M–1) ct-DNA K (M–1) 
19 1.79 ± 0.82 × 107 7.79 ± 0.33 × 106 6.71 ± 0.71 × 104 
20 9.69 ± 1.41 × 106 3.28 ± 0.34 × 106 1.31 ± 0.61 × 105 
 
3.4 Circular Dichroism (CD) 
Once binding to quadruplex DNA was firmly established (using FID and UV-Vis titrations), it was of 
interest to know whether binding led to any structural changes. To do this, circular dichroism (CD) 
was used. CD provides a quick and reliable way of empirically determining quadruplex structure. CD 
results from the interaction of chiral entities (e.g. quadruplex DNA) with circularly polarised 
electromagnetic rays. DNA studies are usually conducted in the ultraviolet region, where DNA bases 
absorb light. Quadruplex DNA absorbs right and left handed circularly polarised light to differing 
degrees. This difference is plotted against the various wavelengths of light to give a CD spectrum.  
Signature CD spectra have been reported for the different quadruplex structures.[143] A positive 
ellipticity in the 290 nm region in addition to a negative ellipticity around 260 nm represents an anti-
parallel quadruplex structure. On the other hand a maximum at 260 nm and a minimum at 240 nm 
denote a parallel quadruplex structure.[144-147] 
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3.4.1 Htelo DNA CD Titrations (in the presence of K+ ions) 
The structure of Htelo DNA in the presence of K+ ions is a topical subject. The general consensus is 
that it forms a mixture of anti-parallel and parallel structures. To see whether the complexes bind 
preferentially to one of the two conformations, CD spectra were recorded for mixtures of the test 
compound and Htelo DNA (0.5-10 ratios) in Tris-HCl (10 mM, pH 7.4)/KCl (150 mM) buffer (the 
spectra obtained for 19 are shown in Figure 3-4). 
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Figure 3-4: The CD spectra of Htelo DNA (10 µM) in the presence of potassium ions, upon addition of increasing amounts 
of 19. The signal at 295 nm increases and the one at 260 nm reduces, producing a new signal with negative ellipicity. 
 
As expected, the CD spectrum of Htelo DNA alone is indicative of an anti-parallel/ parallel mixture (a 
maximum band ca.290 nm with a shoulder in the 265 nm region; black line in Figure 3-4). Similar CD 
spectral changes were observed upon addition of the mono- and di-functionalised platinum(II) 
complexes 8 and 15. An increase in ellipticity at 295 nm and a decrease at 265 nm were observed. 
Intensification of the 295 nm band is characteristic of anti-parallel stabilisation and attenuation of 
the 265 nm band illustrates de-stabilisation of the parallel structure. Therefore the platinum(II) 
terpyridine complexes (under these conditions) bind preferentially to the anti-parallel conformation. 
 
According to Vorlickova and co-workers, similar spectral changes were noted upon addition of 
sodium ions to Htelo DNA in the presence of potassium ions.[148] The authors suggest that the 
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structure of Htelo DNA in K+ buffer is not a hybrid but an anti-parallel structure. Therefore the study 
proposes that the addition of sodium merely changes the stacking of the tetrad “due to specific K+ 
ions coordination” rather than inducing a conformational change. A non-coorperative process is put 
forward, whereby structural changes occur within a single conformational state.  In light of this 
study, the complexes studied can be considered to change the stacking pattern of the tetrads in 
Htelo DNA as well as its conformation. 
 
CD studies were also conducted for the platinum(II) pyridyl-phenanthroline and di-metallic 
complexes 24, 26, 27, 19 and 20. In general, the results resemble those of the platinum(II) 
terpyridine complexes, however there was an important difference. Upon addition of 3 eq. (or 
greater) of complex, the peak at 260 nm (corresponding to the parallel conformation) was seen to 
completely diminish, giving rise to a new signal with negative ellipticity. This suggests complete 
conversion to the anti-parallel motif (possibly through stronger interactions).  
 
The CD spectra obtained from the titration of 18 (to Htelo DNA) were more complicated. Upon 
increasing complex concentration, the bands at 260 and 290 nm were seen to decrease. After 
addition of a large excess of 18, an anti-parallel structure can be conferred. However preference for 
the anti-parallel conformation is usually accompanied by an intensification of the 290 nm band (not 
a reduction). This reduction in CD signal can be explained by electrostatic neutralisation of negative 
charged DNA by the positively charged complex. This irregularity was previously reported for the 
porphyrin, TMPyP4.[86] 
 
It should be noted that addition of increasing amounts of the poly-pyridyl ligands L9 and L13 did not 
bring about any changes in the CD spectrum. This highlights the important role played by the metals 
in quadruplex DNA binding of these systems. 
 
3.4.2 Htelo DNA CD Titrations (in the absence of K+ ions) 
It was of interest to assess the ability of these complexes to template the formation of quadruplex 
DNA from singly stranded DNA. For this, two equivalents of the test compound were added to a 
solution of singly stranded Htelo DNA (10 μM) in Tris-HCl buffer (which did not contain potassium 
ions) and changes in the CD spectra recorded. In the absence of potassium ions, the CD spectrum of 
Htelo DNA shows two maxima: one centred at ca. 250 nm which is associated to the unfolded 
sequence and an equally/ less intense one centred at ca. 295 nm (which corresponds to some of the 
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DNA being already folded into a quadruplex structure due to the presence of traces of cations in the 
DNA sample). 
 
Upon addition of the mono- and di-functionalised platinum(II) complexes 8, 10 and 15, only minor 
spectral changes were observed. A small amplification of the 295 nm band and an equally small 
reduction in the 250 nm band were seen. This suggests that upon addition of the complexes, the 
singly stranded Htelo sequence has a slight tendency to fold into an anti-parallel quadruplex 
structure (but not fully convert). 
 
Upon addition of two equivalents of the platinum(II) pyridyl-phenanthroline or di-metallic complexes 
24, 26, 27, 19 and 20,  the band at 250 nm was observed to completely disappear and the one 
centred at 295 nm increased. This indicates that even in the absence of potassium ions, these 
complexes can induce the formation of quadruplex DNA (largely the anti-parallel conformation).  
Comparing these spectra to those obtained for the platinum(II)-terpyridine complexes, it is evident 
that by increasing the π-surface or by incorporating metallic side arms (rather than cyclic amines), 
the formation of Htelo quadruplex DNA can be template (the spectra obtained for L13, 26, 24 and 27 
are shown in Figure 3-5). 
240 260 280 300 320 340 360
-2
-1
0
1
2
3
4
5
m
 d
e
g
s
Wavelength/ nm
 Htelo
 Htelo + L
13
 Htelo + 27
 Htelo + 24
 Htelo + 26
 
Figure 3-5: The CD spectra of Htelo DNA (10 µM) in the absence of salts, with and without the addition of two 
equivalents of platinum(II) pyridyl-phenanthroline complexes, 24, 26 and 27. 
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3.4.3 c-myc DNA CD and VTCD (in the absence of K+ ions) 
Similar CD studies were carried out with c-myc DNA, which exists as a parallel structure (both in the 
absence and presence of K+ ions) giving a maximum CD signal at 260 nm and a minimum at 240nm 
(see solid black line in Figure 3-5). Upon addition of a selection of complexes (2 eq. of 8, 10, 15, 19 
and 20) to c-myc DNA (5 μM), the CD spectrum remained unchanged suggesting that the complexes 
were unable modify the conformation of c-myc DNA. This was not surprising considering the 
structural stability of this sequence (see Chapter 1).  
 
CD spectroscopy can also be used to determine the melting temperature of quadruplex DNA in the 
presence/absence of a given compound. In turn, changes in melting temperature provide a good 
indication of the affinity of a given compound for DNA. Thus, variable temperature CD spectra were 
recorded for mixtures of c-myc quadruplex DNA (5 µM) and test compound (2 equivalents) and ΔTm 
values determined (see Figures 3-6 and Table 3-8) by monitoring the loss in ellipticity at 260 nm 
(signal corresponding to the parallel conformation). It is defined as the temperature at which half 
the original c-myc ellipticity is lost. It should be noted that analogous VTCD experiments using Htelo 
quadruplex DNA were not carried out. Although it is clearly possible to melt such structures upon 
increasing temperature, due to the equilibrium between the parallel and anti-parallel topologies the 
meting curves are not easy to interpret; this in turn can lead to considerable errors in the 
determination of ∆Tm values. 
112 
 
 
Figure 3-6: (a) The CD melting spectra of c-myc DNA (5 µM) in Tris-HCl buffer. (b) Pictorial representation of c-myc DNA 
unfolding during the CD melting experiment. 
 
In general, the ∆Tm values are in agreement with data obtained from the FID and UV assays. Within 
the mono-functionalised metal complex series, the platinum(II) complexes 8, 10 and 13 gave the 
highest ∆Tm values (8, 12 and 18
oC respectively). The copper(II) and zinc(II) derivatives, 5 and 6 
provided limited stabilisation (∆Tm = 2 and 3 respectively). The contrasting values can be explained 
by the planarity of the respective metal terpyridine complexes. The di-functional platinum(II) 
terpyridine complexes 14, 15, and 16 produced very high ∆Tm values. In fact 14 gave the highest ∆Tm 
value (21oC) recorded. This highlights the important role played by side arms in quadruplex DNA 
stabilisation. The platinum(II) pyridyl- phenanthroline complexes, 24, 26 and 27 displayed high ∆Tm 
values, proving that an increase in π-surface is beneficial in terms of quadruplex DNA binding. The di- 
and tri- nuclear metal complexes, 21 and 22 were also found to bind with high affinity (∆Tm= 8 - 
17oC). The ∆Tmvalues obtained for some of the compounds are in fact higher than that determined 
for TMPyP4 (a porphyrin previously reported to interact very strongly with quadruplex DNA).[49, 
149] These studies also showed that the free ligands, L4 and L9 are very poor quadruplex DNA 
binders (∆Tm = 2 and 3 respectively). This highlights the important played by the metal centres in 
quadruplex DNA binding. 
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Table 3-8: Melting temperatures for c-mycquadruplex DNA (5 µM) in the presence of 2 equivalents 
of different molecules.The values are an average of two independent measurements. 
Compound Tm (
oC) ∆Tm
a(oC) 
L4 56 3 
L9 55 2 
3 56 3 
4 57 4 
8 61 8 
10 65 12 
13 71 18 
14 74 21 
15 68 15 
16 62 9 
18 61 8 
19 70 17 
20 68 15 
21 65 12 
22 66 13 
24 66 13 
26 67 14 
27 61 8 
TmPyP4 64 11 
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Figure 3-7: CD melting curves for c-myc DNA (5 µM) with and without the presence of the complexes (2eq., 10 µM). The 
bi-nuclear complexes, 18-20 displayed better stabilisation than the mono-nuclear platinum(II) complex, 8 or the 
terpyridine-DPA free ligand. 
 
 
3.5 Nuclear Magnetic Resonance (NMR) Spectroscopic Studies – Quadruplex 
DNA 
To gain further insight into the structural binding mode of a selection of complexes (8, 15 and 20), 
NMR spectroscopic titration studies were conducted using a single repeat of the human telomeric 
sequence, d(TTAGGG). Native Htelo (multiple repeats of TTAGGG) and c-myc sequences were not 
used due to their poor NMR resolution. In the presence of potassium ions, d(TTAGGG) folds into a 
tetra-molecular parallel quadruplex, d(TTAGGG)4 therefore the studies were performed in 300 mM 
KCl, 50 mM phosphate buffer (pH 7.0). This produced three clear imino resonances in the 10.3-11.1 
ppm region corresponding to the three G-tetrads making up the quadruplex architecture. A series of 
well defined signals in the 7-8.5 ppm region were also observed, corresponding to the aromatic 
protons on the various DNA bases (assigned using literature).[150-152] Upfield shifts (due to ring 
current shielding) in the imino signals upon addition of test compounds are usually associated to 
end-stacking atop quadruplex DNA. On the other hand significant line broadening without a marked 
shift in resonance is suggestive of groove binding. 
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Upon addition of the complexes 8, 15 and 20 to d(TTAGGG) similar spectral changes were observed. 
The imino protons were generally observed to shift upfield (Figure 3-8 and 3-10), suggestive of end-
stacking. The largest shift was observed for the G4-tetrad imino signal (∆δ = 0.19 ppm), it also 
displayed considerable line broadening. These observations are indicative of binding to the G4-A3 
cleft. This notion was supported by the broadening of the A3H2 and A3H8 proton peaks. Interestingly, 
beyond one equivalence (of complex to quadruplex DNA), the four strands of DNA become 
magnetically inequivalent, giving rise to three (for 8 and 20) and two (for 15) new imino peaks. This 
can be attributed to a secondary binding event, possibly to the free G-tetrad on the opposite end of 
the quadruplex structure (3’ end). This binding event can be proposed to kink the quadruplex 
structure, thus leading to a slight disruption in DNA symmetry. Similar spectral changes were 
reported for the binding of distamycin A with tetra-molecular quadruplex DNA, d(TGGGGT).[153, 
154] The extra peaks were also observed to shift upfield upon further addition of the respective 
complexes (from 1- 5 equivalents). This suggests that the second binding mode also involves π-π 
interactions. Figure 3-9 depicts two possible binding modes that the complexes can adopt with 
d(TTAGGG)DNA. 
 
Figure 3-8: The NMR spectra of d(TTAGGG) in KCl, phosphate buffer (1 mM) upon increasing equivalents of 8. The G4-6 
imino signals are observed to shift upfield and under line broadening. 
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Figure 3-9: Proposed binding modes adopted by 8, 15 and 20 upon interaction with d(TTAGGG). The G-A cleft in the 
preferred binding site (labelled primary binding position). 
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Figure 3-10: Bar graph representing the upfield shift in the imino proton signals after the addition of five equivalences of 
8, 15 and 20. The largest shift was observed for the G4 imino proton. 
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3.6 NMR Spectroscopic Studies – Guanosine Monophosphate 
To gain a better understanding of the binding mode of the bi-nuclear complexes, 19 and 20 to 
quadruplex DNA, 1 H NMR spectroscopic studies were carried out with guanosine monophosphate 
(GMP). The NMR experiments were performed in a 1:1 mixture of DMSO-d6 and D2O. Under these 
conditions GMP gave very distinctive proton and phosphorus signals corresponding to the guanosine 
base and phosphate ion respectively (see Figures 3-11). Following addition of 20 (one equivalent) 
and 2 h incubation at 37oC, the aromatic proton signals associated to the complex  and the aliphatic 
proton signals associated to guanosine were observed to broaden and shift downfield. This was 
indicative of interactions with the base and sugar moieties. Furthermore the GMP 31P resonance 
shifted upfield from 2.33 ppm to -1.07 ppm. This was suggestive of additional electrostatic or 
covalent interactions with the phosphate group. Similar resonances shifts were reported for the 
electrostatic binding of a zinc(II)-terpyridine derivative to adenosine triphosphate (ATP) (Δδ = ca. 2-3 
ppm).[155] Collectively the NMR data suggests 20 can bind to quadruplex DNA via a combination of 
π-π stacking (with the DNA bases) and electrostatic (with the phosphate and sugar backbone) 
interactions (see Figure 3-13).  
 
 
 
 
 
 
 
 
 
Figure 3-11: (a) Chemical structure of 20. (b) Chemical structure of guanosine mono-phosphate, GMP. (c) A comparison 
of the 
1
H NMR spectra obtained for 20 and GMP + 20 (after 2 h incubation at 37
o
C). (d) A comparison of the 
31
P NMR 
spectra obtained for GMP and GMP + 20. 
 
Upon addition of increasing amounts of 19 to GMP, the H8 proton signal (corresponding to the imine 
proton on the guanine base) was observed to undergo significant line broadening. The proton signals 
associated to the sugar moiety were relatively unaffected. The phosphorus signal broadened 
indicative of electrostatic or covalent interactions with the phosphate ion (Figure 3-12). Analogous 
(a) 
(b) 
Ha Hb Hc Hd He 
Hf Hg 
Hh Hi 
Pa 
(d) (c) 
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NMR data was reported for the interaction (π-π and electrostatic) of a copper(II) metallocyclophane 
with GMP.[156] Therefore the NMR data suggests that 19, like 20, can bind to quadruplex DNA 
through π-π interactions (with its bases) and electrostatic or covalent interactions (with its 
phosphate backbone) (see Figure 3-13). 
 
Figure 3-12: (a) The
1
H NMR spectra of GMP upon increasing amounts of 19 (top to bottom; 0-30 µM). (b) The 
31
P NMR 
spectra of GMP upon increasing amounts of 19 (top to bottom; 0-30 µM). 
 
 
 
Figure 3-13: Proposed binding mode of the bi-nuclear complexes 20, to GMP 
 
 
(a) (b) 
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3.6 Long term NMR Studies – Guanosine 
In order to study the interaction of the complexes with quadruplex DNA after long exposure times, 
1H NMR studies were carried with guanosine over 24 h.The NMR experiments were carried out in 
DMSO-d6.  A representative selection of complexes was chosen for this study (10, 13, 15 and 20). 
NMR spectra were recorded for guanosine, each of the compounds and 1:1 mixtures after 24 h 
incubation at 37oC (see Figure 3-14). For 10, clear changes in resonance were observed.  The 
guanosine H8 signal was observed to shift downfield (∆δ = ca. 0.1 ppm), indicative of coordination to 
the N7 atom.[157] Furthermore proton signals associated to the sugar unit were observed to 
broaden and shift downfield, suggestive of additional electrostatic interactions with the sugar 
moiety. In contrast, 13 and 20 produced no changes to the proton spectrum. Therefore these 
complexes are likely to bind via non-covalent interactions only. Upon addition of 15, the furanose 
ring signals were observed to broaden and shift downfield, however the guanine signals were 
unaffected. This suggests that like 13 and 20, 15 interacts solely by non-covalent interactions. 
 
Figure 3-14: (a) Chemical structure of 10. (b) Chemical structure of guanosine. (c; bottom) 
1
H NMR spectra obtained for 
guanosine (c; middle) 10 and (c; top) guanosine + 10 after 24 h incubation at 37
o
C. The H8 signal shifts downfield and the 
proton signals associated to the sugar moiety broaden significantly. 
 
A number of conclusions can be drawn from the NMR data. It is clear that after long exposure times 
(24 h), poly-pyridyl platinum(II) chloride complexes (like 10) platinate guanosine via displacement of 
the chloride. Therefore platinum(II) complexes with chloride on the fourth position can be expected 
to platinate DNA over time. The thiol substituted complexes (like 13 and 15) on the other hand do 
(a) 
(b) 
(c) 
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not platinate guanosine and can be expected to bind to DNA via non-covalent interactions only. 
Surprisingly the di-nuclear platinum(II)complex, 20 behaves in a similar manner to the thiol 
substituted complexes.  
3.8 Fluorescence Studies 
There are now a number of biological studies that show the existence of quadruplexes in vivo. 
Optical probes allow the possibility of imaging quadruplex structures and thereby show further 
evidence for their existence. Therefore the use of optical probes to selectively detect quadruplex 
DNA was explored. Potential probes must have the capacity to bind strongly to quadruplex DNA and 
at the same time give measureable changes to their photophysical properties upon binding.  
 
The cyclometallated platinum(II) phenyl-phenanthroline complex, 28 was previously reported to 
display interesting photophysical properties upon binding to duplex and quadruplex DNA.[158] 
Therefore it was of interest to explore the optical properties of 29. The absorption spectrum of 29 in 
dichloromethane displayed four distinctive absorption bands, [λ/nm (εmax/dm
3 mol-1 cm-1)]: 261 
(14650), 321 (8300), 390 (3700), 438sh (2158). The two higher energy bands were assigned to the 
intra-ligand π-π* and metal perturbed intra-ligand π-π* transitions respectively. The lower energy 
bands were assigned to MLCT. Similar spectra were obtained in acetonitrile and water, however the 
absorption intensities were comparatively lower. Excitation of a dichloromethane solution of 29 at 
430 nm resulted in two broad unstructured emission bands at 569 and 613nm. These emissions 
were assigned to the 3MLCT i.e. from the central platinum to the π* orbitals on L15, [Ptπ*(L15)]. 
Assignment was based on other structurally similar compounds reported in literature. Upon 
increasing the polarity of the solvent (dichloromethane < acetonitrile < water), emission was 
observed to decrease and was completely quenched in aqueous solution. Quenching is probably a 
result of non-radiative decay of the excited state through complex–polar solvent interactions. 29 is 
weakly emissive in Tris-HCl (10 mM, pH 7.4)/KCl (100 mM) buffer (the aqueous medium used for 
DNA binding experiments). Upon addition of small aliquots of c-myc quadruplex DNA the emission 
was observed to increase, reaching saturation at [c-myc DNA:29] = 50. At this point, emission was 
recorded to increase by 36-fold (see Figure 3-15). Enhancement is likely to result from end-stacking 
between two quadruplex structures. This can be envisaged to shield the complex from the aqueous 
buffer environment and thereby enhance the 3MLCT emission band. Similar experiments were 
carried out using Htelo and calf thymus DNA. With Htelo DNA the emission was observed to increase 
by a factor of 10 when [Htelo DNA: 29] = 50, four-fold lower than c-myc DNA. This is probably due to 
weaker end-stacking interactions. For ct-DNA even smaller enhancements in emission were 
recorded (increase by a factor of 3). This is surprising considering the fact that the un-functionalised 
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platinum complex 28 was reported to intercalate between base pairs of doubly-stranded DNA and 
displayed considerable emission enhancements. Therefore the lack of photo-luminescence upon 
addition of ct-DNA can be attributed to the compound not binding by intercalation to duplex DNA 
which in turn is likely to be due to the presence of the ethyl-piperidine side arm. The emission data 
suggests that 29 can potentially be used as a selective optical probe for c-myc quadruplex DNA.  
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Figure 3-15: The fluorescence spectrum of 29 (in Tris- KCl buffer) upon increasing concentration of c-myc DNA, λex = 430 
nm. At the point of saturation, [DNA/Pt] = 50, there is a 36-fold enhancement in emission. 
 
Other biomolecules such as amino acids and proteins (abundant in cells, predominantly in the 
cytoplasm) could also interact with 29 and induce optical changes (e.g. emission). Therefore the 
photophysical properties of 29 were studied in the presence of cysteine, glutathione and bovine 
serum albumin (BSA) – an adequate substitute for human serum albumin (HSA). Upon addition of 
excess amounts, [biomolecule: 29] > 50, of the respective biomolecules, limited enhancements in 
emission were observed (1-2.5 fold increase), indicative of weak binding. Therefore 29 was deemed 
optically selective for DNA (particularly c-myc DNA, see Figure 3-16) and hence suitable for 
fluorescence microscopy studies with live cells.  
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Figure 3-16: Bar chart depicting the enhancement in 29 emission (in Tris- KCl buffer) upon addition of 50 equivalents of 
various biomolecules. A clear optical selectivity for c-myc DNA is shown. 
 
Fluorescence microscopy studies were carried in collaboration with Dr. Marina Kuimova and Mr. Yilei 
Wu.  
 
Fluorescence microscopy is widely used to monitor the distribution of intrinsically fluorescent dyes 
within biological samples. In this case, it was used to determine if 29 can selectively stain quadruplex 
DNA. U2OS cells (at 50% confluency) were incubated with 29 at various non-toxic concentrations 
(10, 20 and 50 µM) and imaged at different time points (30 min, 16 and 24 h). No emission resulting 
from 29 was detected inside the cells, even with very high laser excitation power. Instead 
autofluorescence was noticed in all samples and its spectral features are clearly different from that 
of 29. The only emission detected for 29 was from crystalline material present on the outer surface 
of the cells. Therefore the data shows that 29 is not taken up by the U2OS cells but instead 
accumulates on the cell membrane. This means 29 cannot be used as an optical probe in biological 
samples.   
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Figure 3-17: Fluorescence microscopy image of U2OS cells after incubation with 29 (20 µM for 16 h). The platinum(II) 
complex (green patches) was not taken up by the cells, instead it formed crystals around the cell membrane.   
 
3.9 Interaction of the Platinum(II) Complexes with Glutathione 
Many of the platinum(II) complexes (8, 10, 16, 24, 26, 28 and 29) are susceptible to nucleophilic 
attack by bio-molecules once inside the cell, whereby the chlorine ligand on the fourth position is 
replaced. Glutathione (a tripepetide present in cell at high concentrations, ca. 5 mM) can react with 
the platinum(II) compounds (in a similar fashion to how it interacts with cis-platin) to form stable 
platinum(II)- biomolecule complexes.[157, 159] Stability arises from the formation of a 
thermodynamically favourable “soft-soft” Pt-S bond (an example of this reaction is given in Figure 3-
18). 
 
 
Figure 3-18: Possible intra-cellular reaction between 10 and glutathione. The adductis stable due to the formation of 
thermodynamically favourable Pt-S bond. 
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To investigate the propensity of the platinum(II) complexes to undergo reaction with glutathione, 1H 
NMR spectroscopy and ESI mass spectrometry studies were conducted. Stoichiometric amounts of 
10 and glutathione were added together in DMSO-d6 (at 37
oC) and monitored by 1H NMR 
spectroscopy over 24 h. Full conversion to the 1:1, 10-glutathione adduct was observed after 24 h 
(see Figure 3-19). Formation of this complex was elucidated by a downfield shift in the aromatic 
proton signals associated to 10. The disappearance of the -S-H1 proton signal (at 2.34 ppm) was 
indicative of interaction via the thiol moiety. The large downfield shift observed for the Ha 
terpyridine peak (0.4 ppm downfield) is likely to result from the magnetic anisotropy of the newly 
formed platinum-sulphur bond. Formation of the 10-glutathione adduct was confirmed using ESI 
mass spectrometry. The mass spectrum displayed the expected molecular ion peak with the correct 
isotopic pattern (see Figure 3-19). 
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Figure 3-19: (a)Chemical structure of 10. (b; bottom) 
1
H NMR spectra obtained for glutathione (b; middle) 10 and (b; top) 
glutathione + 10 after 24 h incubation at 37
o
C. The Ha signal shifts downfield and the proton signals associated to the 
thiol, H1 disappears. (c)The experimental ESI signal for the [10-glutathione adduct]
+
 molecular ion. (d) The theoretical 
signal for the [10-glutathione adduct]
+
 molecular ion,generated using http://fluorine.ch.man.ac.uk/research/mstool.ph 
php. The isotopic pattern obtained was the same as that predicted. 
 
The resultant 10-glutathione adduct is structurally non-planar. This was clearly demonstrated using 
DFT calculations (see Figure 3-20). 
The DFT calculations were performed by Dr. Oscar Mendoza Pomar 
The glutathione component is positioned in a manner that disrupts the planarity of the complex. 
Therefore the adduct is expected to bind weakly with quadruplex DNA (it has no accessible planar 
surface to π-π atop quadruplex DNA). This notion was proved using the FID assay. The data 
confirmed that the 10-glutathione adduct was unable to interact with quadruplex DNA (no DC50 
(d) (c) 
(a) 
(b) 
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values could be obtained for c-myc or Htelo DNA, the FID binding curves are reported in Figure 3-
20). 
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Figure 3-20: (a) DFT calculated structure for the 10-glutathione adduct, it displays a non-planar geometry. (b) FID 
displacement curves obtained for the 10-glutathione adduct and 10 with Htelo and c-myc DNA. Comparison of the data 
show how planarity affects quadruplex DNA binding. Upon addition of 40 eq. of the 10-glutathione adduct, 50% 
displacement of TO was not achieved, therefore no DC50 values were obtained. 
 
Overall the data suggests that once inside the cell, platinum(II)chloro complexes can undergo 
reaction with glutathione and other thiol containing biomolecules, yielding non-planar adducts 
which are unable to interact with quadruplex DNA.  Therefore intra-cellular modifications to the 
platinum(II) complexes can compromise their anti-cancer potential (prevent telomerase inhibition or 
c-myc down-regulation). 
 
(a) 
(b) 
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3.10 Conclusion 
3.10.1 Binding Modes 
Using the data obtained from the FID, UV-Vis, CD and NMR experiments, binding modes for the 
complexes with quadruplex DNA after short (<2 h) and long (24 h) exposure times can be proposed.  
The mono-functionalised platinum(II)-terpyridine complexes, 8-10 and 13 were found to effectively 
displace thiazole orange bound to quadruplex DNA (low DC50 values were obtained for both Htelo 
and c-myc DNA). Given the fact that TO binds to quadruplex DNA via end-stacking, the FID data 
suggests that the complexes also bind via a similar mode. The UV-Vis titration studies support this 
notion. Upon addition of quadruplex DNA to solutions of the respective complexes the absorption 
bands of the complexes displayed red shift and hypochromicity, indicative of end-stacking. The NMR 
studies further emphasised this point. The imino proton signals associated with quadruplex DNA 
were observed to shift upfield on addition of 8, a trait consistent with π-π stacking interactions. 
Therefore the biophysical evidence suggests that 8-10 and 13 interact with quadruplex DNA via an 
end-stacking mode after short exposure times. 
Similar results were obtained for the di-functionalised platinum(II)-terpyridine complexes, 14-16. 
The FID and UV-Vis results were both indicative of end-stacking. In comparison to the mono-
functionalised complexes, the absorption bands were observed to red shift less. Therefore the extra 
side arm reduces the ability of the complexes to π-π stack with quadruplex DNA but possibly 
provides a means for further interactions with the loop and grooves of DNA. This was reinforced by 
the NMR titration data. The imino proton signals shifted upfield upon the addition of 15 but the 
changes in chemical shifts were relatively small compared to the mono-functionalised derivative, 8. 
Overall the biophysical studies suggest that 14-16 interact with quadruplex via a slightly hindered 
end-stacking mode after short exposure times. 
Interesting biophysical results were obtained for the platinum(II) pyridyl- and phenyl-phenanthroline 
series, 24, 26, 27, 28 and 29. The FID data was suggestive of strong end-stacking interactions (G4DC50 
values > 0.5 µM) however the UV-Vis titration data was contradictory (no red shift in the absorption 
bands). Fluorescence studies conducted with 29 and quadruplex DNA (both Htelo and c-myc) are 
suggestive of end-stacking.  Therefore binding to quadruplex DNA after short exposure remains 
inconclusive but can be proposed to occur via end-stacking as well as other interactions (possibly to 
the DNA loops or grooves). 
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The mode of interaction for the di-metallic complexes was established using a combination of 
quadruplex DNA and single nucleotide (guanosine mono-phosphate) studies. The di-nuclear 
platinum and copper complexes gave lower DC50 values indicative of end-stacking. This was in 
agreement with the NMR titration results which showed the imino proton signals to shift upfield 
upon addition of 20. However UV-Vis titrations displayed no red shift, suggestive of additional 
interactions. Binding to the phosphate backbone was elucidated through NMR studies with 
guanosine mono-phosphate. The phosphate ion signal was observed to shift downfield upon 
addition of 20 and broaden upon addition of paramagnetic 19. Therefore after short exposure times, 
the complexes can be proposed to bind via π-π stacking interactions to the external tetrad (possibly 
with the metal-terpyridine part) and electrostatic or coordinative interactions to the phosphate 
backbone (possibly with the metal-DPA component). 
The 1H NMR data suggests that poly-pyridyl platinum(II) complexes with chloride ligands (such as 8-
10, 16, 24, 26, 28 and 29) bind covalently with DNA (platination) after longer exposure times. 
Therefore such complexes are expected to initially bind non-covalently (by end-stacking with the 
guanine tetrad or via electrostatic interactions with the loops, grooves or phosphate backbone of 
DNA, as discussed earlier in this section) and then over time form covalent bonds. The formation of 
covalent bonds can lead to the de-stabilisation of quadruplex DNA which means in the long term 
such complexes are not ideal for gene regulation or telomerase inhibition.[112, 160] The thiol 
substituted (13, 14, 15 and 27) and di-nuclear (20) complexes are not expected to form covalent 
bonds with DNA (even after long exposure times). Therefore there are expected to bind via non-
covalent interactions only. This makes them suitable for gene regulation or telomerase inhibition.  
3.10.2 Non-Covalent Interactions 
The mono, bi and tri-nuclear platinum(II), copper(II) and zinc(II)-terpyridine and platinum(II) pyridyl- 
and phenyl-phenanthroline complexes were shown to interact non-covalently with quadruplex (both 
Htelo and c-myc DNA) and duplex DNA after short exposure times (<2 h). 
The mono-functionalised platinum(II)-terpyridine complexes, 8-10 and 13 were found to interact 
strongly with quadruplex DNA (especially to c-myc DNA;c-mycDC50> 0.5 µM and 
c-mycKa = 10
6-107 M-1). 
8-10 also display reasonable selectivity over duplex DNA (the selectivity for 13 was very poor).The 
non-planar copper(II) (4 and 6 have square based pyramidal geometry) and zinc(II) (3 and 5 have 
trigonal bi-pyramidal) complexes displayed weak binding to quadruplex DNA (DC50 values were 
generally > 10 µM). The differing affinities can be explained by the planarity of the respective metal 
complexes. Planar platinum(II) complexes are able to effectively π-π stack atop quadruplex DNA 
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whereas the non-planar complexes are less able to do so. This point was further emphasised using 
VTCD: the planar platinum(II)  complexes (8-10 and 13) were found to stabilise c-myc DNA (∆Tm = 8 
to 18 oC) whereas the copper(II) and zinc(II) derivatives displayed little stabilisation. CD titration 
studies showed 8-10 and 13 to bind preferentially to the anti-parallel conformation of Htelo DNA in 
the presence of K+ ions. However in the absence of K+ ions, the complexes were unable to template 
the formation of Htelo quadruplex DNA (from singly stranded DNA).   
The di-functionalised platinum(II)-terpyridine complexes, 14-16 were found to interact very strongly 
with quadruplex DNA by FID, UV-Vis and VTCD studies (G4DC50 > 0.5 µM, 
G4Ka = 10
7 M-1 and ∆Tm = 9 -
21 oC).The values were in fact better than those obtained for the mono-functionalised platinum(II) 
complexes. The increased affinity can be attributed to the extra side arm which affords stronger 
interactions with the loop, grooves and phosphate backbone of quadruplex DNA. In terms of 
selectivity, differing results were obtained from the FID and UV-Vis assays. The FID results suggest 
indiscriminate binding to both quadruplex and duplex DNA (except for 16), however the UV-Vis data 
proposes good selectivity (the Ka values obtained for quadruplex DNA were 1-2 orders of magnitude 
higher than those obtained for ct-DNA). The increased selectivity obtained from the UV-Vis studies 
can be credited to the extra side arm which can be envisaged to sterically hinder intercalation 
between base pairs in duplex DNA. 
The FID assay measures the ability of the complexes to displace TO from quadruplex and duplex 
DNA. TO binds to quadruplex DNA via end-stacking and to duplex DNA via intercalation between 
base pairs. Therefore the FID assay probes π-π interactions only i.e. end-stacking for quadruplex 
DNA and intercalation for duplex DNA. In contrast the UV-Vis method considers all interactions. 
Electrostatic interactions such as those to the loops, grooves and phosphate backbone are 
unaccounted in the FID assay but are detected using the UV-Vis assay. Therefore selectivity data 
obtained from the FID assay merely compares end-stacking (to quadruplex DNA) with intercalation 
(to duplex DNA) and other interactions are overlooked. Hence the UV-Vis data should be taken with 
higher regard. Furthermore the FID assay is carried out using 17-mer and 26-mer duplex sequences 
whereas the UV-Vis studies are conducted with ct-DNA. ct-DNA is a long random coil of DNA which is 
widely used to represents genomic DNA. Therefore the data obtained from the UV-Vis studies can be 
considered as more biologically relevant and therefore can be taken with higher importance. 
FID, UV-Vis and VTCD studies found theplatinum(II) pyridyl- and phenyl-phenanthroline complexes, 
24 and 27-29, to bind very strongly to quadruplex DNA (G4DC50> 0.5 µM, 
G4Ka = 10
6-107 M-1 and ∆Tm = 
8 to 17 oC). Comparing the values to those obtained for the terpyridine family it is clearly evident 
that by increasing the aromatic π-surface, higher quadruplex DNA binding is achieved. This is not 
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surprising as larger π-surfaces yield more effective π-π stacking interactions with quadruplex DNA. 
The FID data indicates reasonable selectivity for quadruplex DNA (ds26DC50 /
cmycDC50 = 3-7) whereas 
the UV-Vis data suggests good selectivity (1-2 orders of magnitude). The improved selectivity values, 
compared to the mono-functionalised terpyridine complexes (8-10 and 13), can be attributed to the 
larger π-surface which prevents intercalation between base pair in duplex DNA. Additionally the 
platinum(II)-pyridyl-phenanthroline complexes, 24 and 26, were found to stabilise the anti-parallel 
conformation of Htelo DNA in the presence of K+ ions. Remarkably the same complexes were also 
able to template the formation of quadruplex DNA in the absence of K+ ions. Furthermore the 
cyclometalled platinum(II) complex, 29 displayed a 36-fold increase in its photoluminescence upon 
binding to c-myc DNA (end-stacking), which was 3 and 12 times larger than upon binding to Htelo 
and ctDNA respectively. Therefore 29 was put forward as a selective binder and luminescent probe 
for c-myc quadruplex DNA. 
Out of all the families evaluated by FID, UV-Vis and VTCD studies, the di- and tri-nuclear platinum(II), 
copper(II) and zinc(II) -terpyridine-DPA complexes, 19-22 (except 18), displayed the highest affinity 
and selectivity for quadruplex DNA (G4DC50> 0.5 µM, 
G4Ka = 10
7 M-1 and ∆Tm = 11 -17 
oC). The results 
can be largely attributed to the metal-DPA component, which can be envisaged to promote 
quadruplex DNA binding through direct coordination or electrostatic interactions with the 
phosphate backbone and provide selectivity by sterically hindering duplex DNA intercalation. 
Furthermore the bi-nuclear platinum(II), copper(II) and zinc(II) complexes, like the platinum(II) 
pyridyl-phenanthroline complexes, were shown to stabilise the anti-parallel topology of Htelo DNA 
in the presence of K+ ions. 18-20 were also able to template the formation of an anti-parallel Htelo 
structure in absence of K+ ions. 
From the biophysical studies conducted it is evident that the vast majority of metal complexes 
synthesised have high affinity and good selectivity for c-myc quadruplex DNA. As the complexes also 
display a degree of selectivity over Htelo quadruplex DNA, it is logical to study the biological activity 
of these complexes in terms of intra-cellular binding to c-myc DNA. Therefore studies were 
conducted to probe cellular binding of the complexes to c-myc DNA and thereby determine their 
ability to regulated c-myc (oncogene) expression. This enabled the anti-cancer potential of the 
complexes to be established (see Cellular Studies, Chapter 4). 
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CELLULAR STUDIES 
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4.1 Overview 
In order to determine biological activity of the prepared metal complexes, a number of cellular 
studies were conducted. The aim of these studies was to establish whether the complexes are able 
to target quadruplex DNA (the c-myc DNA sequence in particular) in a cellular environment and 
thereby exhibit anti-cancer properties. The MTS assay was used to determine the toxicity (IC50 
values) of the complexes towards cancer (U2OS and 293T) and normal (GMO5757) cell lines. Data 
corresponding to the U2OS cell line was of particular interest as it expresses high levels of c-Myc 
protein. Establishing the IC50 values is important for two reasons; (a) it allows identification of 
compounds that show selective toxicity for a particular cell line and (b) it determines the 
concentrations at which other cellular assays can be conducted without cell death occurring, in other 
words it identifies a “working” concentration for the compounds. In general, most of the compounds 
were observed to have higher toxicity towards the U20S cell line. Cellular uptake studies were 
carried out to determine the cell permeability of the complexes. As the complexes were designed to 
target quadruplex DNA, their ability to localise within the nucleus was also determined. Once the 
cytotoxicity and cellular uptake profiles had been established, the effect of the most promising 
candidates (and a few complexes used as negative controls) on the cellular production of c-myc RNA 
was investigated. This would provide an indication of the ability of a given compound to regulate c-
myc gene expression). Thus, real time q-PCR studies were carried out (in collaboration with Mr. 
George Stephen). In addition, to gain a better understanding of the effects of complexes on the cell 
cycle, flow cytometric studies (using the U2OS cell line) were performed (in collaboration with Miss 
Alexandra Alves Duarte). It is worth pointing out that non-lethal concentrations of the compounds 
were administered to the cells for these assays. This was done to investigate the propensity of the 
complexes to act as oncogence regulators rather than toxins.  
 
4.2 Cytotoxicity Studies: MTS Assay 
In order to determine the cellular toxicity of the complexes towards cancer and normal cell lines, the 
CellTiter 96® AQueous Assay (from Promega) was used.[161] This assay uses the tetrazolium 
compound, (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt; MTS) and the electron coupling reagent, phenazinemethosulfate (PMS). MTS 
is chemically reduced by dehydrogenase (an enzyme found in the mitochondria of metabolically 
active cells) to formazan, which strongly absorbs at 490 nm. Production of formazan is directly 
proportional to the viability of the cells, therefore the intensity of absorption at 490 nm gives a good 
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indication on the amount of living cells. By measuring the optical absorption of the cells after 
treatment (with various concentrations, 0.2-500 µM, of the compounds) and incubation (24 h in this 
case), the IC50 values were determined (the concentration that leads to 50% cell death) using the 
Conventional Method (see Section 4.2). Two cancer (U2OS and 293T) and one normal (GM05757) 
cell lines were used in this study. U2OS is a human osteosarcoma cell line that expresses high levels 
of c-Myc protein, therefore it was ideal for testing the anti-cancer properties of the synthesised 
quadruplex binders.[162, 163] 293T is a cancerous cell line derived from human embryonic kidney 
cells whereas GM05757 is a primary human fibroblast cell line used as a control.  
The IC50 values were obtained for a selection of compounds as well as cis-platin (a potent, clinically 
used anti-cancer drug). The results are summarised in Figures 4-1 and 4-2. In general, the 
compounds were observed to have higher toxicity towards the U20S cell line compared to the 293T 
and GM05757 cell lines. This is probably a result of its high c-myc expression, to which the test 
compounds have been shown to bind very strongly (see Chapter 3).  
Under the conditions used, platinum(II) complexes with chlorine bound to the fourth position (8, 10, 
16, 24, 26, 28 and 29) gave IC50 values ranging between 30 and 80 µM for the U2OS cell line, which 
are comparable to cis-platin (IC50 = 48 µM). 16 and 29 were found to have particularly promising 
toxicity profiles, in these cases the IC50 values for the U2OS cell line were lower or similar to that of 
cis-platin. At the same time they displayed little or no cytotoxicity towards the GM05757 normal 
human fibroblast cell line (130 and >500 µM respectively). Furthermore 16 and 29 exhibit some 
selectivity within the cancer cell lines (selectivity for U20S vs. 293T was around 3). On the other 
hand, platinum(II) complexes with thiol substituents (13-15 and 27) were found to be non-toxic (up 
to a concentration of 500 µM) for all three cell lines. Therefore the data suggests toxicity may result 
from platination (the formation of covalent bonds between the test complex and DNA bases). This is 
plausible considering the binding mode of 10 to guanosine after long exposure times (see Section 3.7 
in Chapter 3). Moreover platinum(II)-terpyridine chloride complexes have been previously reported 
to platinate both duplex and quadruplex DNA sequences.[112] Under physiological conditions 
platinum(II)-terpyridine chloride complexes undergo aquation, whereby the labile chloride is 
replaced by a water molecule. The resultant complex reacts with nucleophilic sites (particularly the 
N7 and N3 atoms on guanine and adenine) on DNA bases to form Pt-DNA covalent bonds. The 
formation of such bonds disrupts DNA structure (bending and unwinding) and consequently 
prevents the binding of transcription factors.[164, 165] This has a detrimental effect on the cell cycle 
and leads to cell death. Platinum(II)-thiol complexes, on the other hand, are resistant to aquation 
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because of their strong Pt-S “soft-soft” bond and therefore do not platinate DNA sequences.[166] 
This probably explains their lack of toxicity against the cell lines tested.  
 
Figure 4-1: IC50 values obtained for the mono-nuclear platinum(II)-terpyridine, pyridyl- and phenyl-phenanthroline 
complexes against U2OS (cancerous), 293T (cancerous) and GMO5757 (normal) cell lines. The values are an average of 
three independent measurements. The associated error for each value is represented in form of capped error bars. The 
plot shows values up to 500µM. 
 
A range of IC50 values were obtained for the bi- and tri-metallic complexes. The di-zinc(II) complex, 
18 was shown to be non-toxic (up to a concentration of 500 μM) whereas the other bi-metallic 
complexes exhibited reasonable toxicity. Interestingly, the copper(II) complex 19 was found to be 
more toxic that cis-platin for the U2OS cell line. 19 exhibited reasonable selectivity for the U20S cell 
line, around 7 and 3 times more potent (lower IC50) than 293T and GM05757 respectively. The tri-
metallic complexes were found to be very potent against all three cell lines. In fact the IC50 values of 
21 and 22 were comparable to that of cis-platin in all cases.  
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Figure 4-2: IC50 values obtained for the bi- and tri-nuclear copper(II) and zinc(II)-terpyridine-DPA complexes against U2OS 
(cancerous), 293T (cancerous) and GMO5757 (normal) cell lines. The values are an average of three independent 
measurements. The associated error for each value is represented in form of capped error bars.The plot shows values up 
to 500µM. 
 
 
4.3 Cellular Uptake Studies 
Cellular uptake studies were carried out to determine the cell permeability of the complexes.[167, 
168] As the complexes were designed to target quadruplex DNA it was of importance to know if the 
complexes were able to enter the nucleus. Therefore studies to determine the intra-cellular 
distribution of the complexes (i.e. whether it localises in the cytoplasm or nucleus) were also carried 
out.  
 The cellular uptake of a selection of complexes was studied using inductively coupled plasma mass 
spectrometry (ICP-MS). ICP-MS is a highly sensitive technique which allows very low amounts (in the 
ppm range) of metal to be detected.[169] Thus, U20S cells were incubated for 24 h at 37oC with sub-
lethal concentrations (10 μM) of the complexes. After this time the cells were extracted, thoroughly 
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washed and suspended in MilliQ water. At this stage the solution was split into two, one part was 
used to determine the metal content for the whole cell, the other part was used for cytoplasmic and 
nucleus analysis. From each of the fractions, aliquots were removed for protein determination using 
the Bradford Assay. The remaining cell suspensions were mineralized with concentrated nitric acid 
and then completely dried. The solid extracts were re-dissolved in 2% nitric acid and analysed using 
ICP-MS. Cellular metal levels were expressed as ng of metal/mg of protein. The results reported are 
a mean of 7 determinations for each data point (summarised in Figure 4-3 and 4-4).  
 
Figure 4-3: The cellular uptake data for selection of platinum(II) poly-pyridyl complexes. The amount of platinum (ng) 
per protein (mg) is expressed for the whole cell, cytoplasm and nucleus.  
 
The platinum(II)-terpyridine complexes (8, 15 and 16) were found to penetrate the U2OS cell 
membrane (between  5 and 15% of the administered complexes at 10 µM). Importantly the 
complexes were also found to enter the nucleus (> 0.5 ng of Pt/mg of protein corresponding to 2-8% 
of the added complexes, was found in the nuclear fractions). The cellular uptake values are 
comparable to those obtained for other platinum(II) terpyridine-like complexes that have been 
reported to be taken up by cells in large quantities.[170, 171] Studying the platinum(II) terpyridine 
series further it is clear that the complexes are taken up regardless of the number or position of side 
arms present. The platinum(II) pyridyl-phenanthroline complex, 24 and the bi-metallic complex, 20 
were also taken up by the cells (4 and 7% of the administered amount respectively). Interestingly, 
for 20, a higher platinum concentration was found in the cytoplasm relative to the nucleus, possibly 
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as a result of cytoplasmic protein interactions.[172-174] The thiol functionalised platinum(II) pyridyl-
phenanthroline complex 27 and the cyclometallated complex 29, were not taken up by the cells. This 
is in agreement with the fluorescence microscopy data obtained for 29 (see Section 3.8 in Chapter 
3). 
Cellular uptake studies were also carried out for the zinc(II) and copper(II) complexes (18, 19, 21 and 
22), the results are summarised in Figure 4-4. The bi-metallic zinc(II) complex, 18 was not taken up 
by the cells. Zinc(II)-DPA complexes (similar to 18) are known to interact strongly with phosphate 
moieties such as those found within the cell membrane (phospholipid bi-layer).[175, 176] Therefore 
it is likely that 18 binds tightly to the cell membrane rather than passing through it. In contrast, the 
copper analogue was readily taken up. Around 23% of the administered complex (10 µM) was found 
to penetrate the cell membrane. In comparison to the platinum(II) complexes discussed above, a 
significantly higher amount of 19 (three times more) was taken up. Copper(II) complexes are 
generally taken up via a passive mechanism, which is dependent on the lipophilicity and charge of 
the compound.[177, 178] The lipophilicity and neutrality of 19 (it has a large organic framework), 
make it ideal for transport across the cell membrane. Copper(II) complexes such as copper(II) 
bis(thiosemicarbazonato) have also been reported to internalised through protein carrier mediated 
pathways (active mechanisms).[179] Therefore the accumulation of 19 could in some part result 
from the presence of specific copper uptake proteins on the U2OS cell surface. The copper-transport 
1 (Ctr1) protein has been identified to facilitate the uptake of cis-platin and other platinum based 
compounds.[180, 181] Therefore this protein could also have a role in the cellular accumulation of 
19.  
The tri-metallic complexes 21 and 22 were found to enter the cells in large quantities (14 and 44% of 
the administered complexes respectively). In fact the values obtained for the whole cell fractions 
were the highest of any of the complexes tested. It was interesting to note that the tri-nuclear zinc 
complex, 21 displayed significantly better cell permeability properties relative to the bi-nuclear 
derivative, 18 (however it did not penetrate the nucleus). The tri-metallic copper complex, 22 was 
found to penetrate the nucleus, although a larger proportion was detected in the cytoplasm. This is 
not surprising considering the high affinity of structurally similar copper(II) complexes to cytoplasmic 
proteins.[182] 
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Figure 4-4:The cellular uptake data for the bi- and tri-nuclear copper(II) and zinc(II)-terpyridine-DPA complexes. The 
amount of zinc or copper (ng) per protein (mg) is expressed for the whole cell, cytoplasm and nucleus. 
 
4.4 Cytotoxicity vs. Cellular Uptake 
In general, the IC50 values of the complexes correlate with the cellular uptake data (for the U2OS cell 
line) (see Figure 4-5). The toxicity of the complexes was observed to increase (IC50 values decrease) 
with cell permeability. This trend was also noted for toxicity and uptake into the nucleus. Therefore 
DNA interactions could be a possible cause of cytotoxicity. Some complexes did not fit with these 
trends. The bi-functionalised platinum(II)-terpyridine complex 15 was found to enter the cell and 
nucleus but proved to be non-toxic over 24 hr incubation. Its impotency can be explained by its 
inability to covalently interact with DNA (once inside the nucleus), see Section 3.7. Similar results 
were also obtained for the di-metallic platinum(II) complex, 20 (although it did display higher toxicity 
relative to 15). On the other hand, compound 29 was not taken up by the cells but proved to be 
highly toxic (similar IC50 value to cis-platin was obtained).Therefore the compound can be proposed 
to induce cell death by cell membrane interactions. 29 can be proposed to form adducts with thiol 
moieties on membrane proteins, whereby the chlorine ligand on the fourth position is placed. This 
could lead to cell membrane degradation and disruption in membrane functions such as calcium 
transport.[183] Fluctuations in intra-cellular CaII levels could then result in apoptosis or cell death by 
necrosis.[184, 185] 21 displayed a very low IC50 value but was not taken up by the nucleus (although 
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uptake into the cytoplasm was observed). This implies that 21 induces cell death through 
interactions within the cytoplasmic region rather than the nuclear part.  
 
 
Figure 4-5: (a) A graphical representation of the relationship between cytotoxicity (IC50 values) and uptake of the 
complexes into the cell as a whole. (b) A graphical representation of the relationship between cytotoxicity (IC50 values) 
and uptake of the complexes into the nucleus. The blue points represent complexes that follow the trend discussed 
above and the red points represent the anomalous data.  
 
4.5 c-myc Gene Expression: RT qPCR Analysis 
This assay was carried out by Mr. George Stephen and supervised by Dr. David Mann (Division of Cell 
and Molecular Biology, Imperial College London) as part of our ongoing collaboration with this 
group. 
Many of the metal complexes reported in this thesis have been established to bind c-myc DNA with 
high affinity and selectivity over duplex DNA (see Chapter 3). It was therefore of interest to establish 
whether those complexes would also lead to a down regulation of this gene in the cell. For this, real 
time qPCR analysis was used to determine the amount of c-myc mRNA produced by the cell in the 
presence of the different compounds.[186, 187] The U2OS cell line was chosen for this assay as it 
expresses high levels of c-myc (the gene of interest). U2OS cells (approximately 2 million) were 
incubated with a selection of complexes (at a concentration of 10 µM, chosen because it was shown 
from the cytotoxicity studies – see above – to be a non-lethal dose) for 24 h at 37oC. After this 
period, cellular mRNA was extracted and converted to complementary DNA (cDNA) using reverse 
transcriptase. Singly stranded cDNA gives a direct representation of cellular mRNA, therefore cDNA 
can be analysed to determine c-myc mRNA levels (which is directly related to c-myc transcription 
and thus expression). cDNA was harvested with primers and probes for c-myc and  β-actin (a 
constitutively expressed control gene) and analysed by RT-qPCR. This yielded data relating to the 
(a) (b) 
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expression of c-myc DNA. The expression values for c-myc were normalised with respective to the 
control gene (β-actin). The normalised c-myc expression data for untreated and treated cells were 
compared to determine the effect of the metal complexes.The results are summarised in Figure 4-6. 
 
 
Figure 4-6: Graphical representation of the expression of c-myc in U20S cells after treatment with a selection of metal 
complexes (10 µM). The expression values are normalised relative to the control gene, β-actin.The values are an average 
of three independent measurements. The associated error for each value is represented in form of capped error bars. 
 
RT-qPCR analysis showed that the di-functionalised platinum(II)-terpyridine complex, 15 and the di-
copper metal complex, 19 were able to significantly down-regulate c-myc expression (c-myc mRNA 
levels were reduced by  40 and 70 % respectively). In fact the data obtained for 15 and 19 were 
superior to that obtained for TmPyP4 (a porphyrin previously reported by a luciferase assay to down 
regulate c-myc expression levels by 30% - hence we used it as the positive control).[149]  As 
discussed in Chapter 3, compounds 15 and 19 have been shown to interact with c-myc quadruplex 
DNA with high affinity and selectivity ; furthermore these complexes have been shown to localise in 
the nucleus(see Section 4.3). Therefore the data obtained (i.e. the inhibition of c-myc transcriptional 
activity by the complexes) can be proposed to result from the stabilisation of c-myc quadruplex DNA 
(by 15 and 19). 
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The di-platinum(II) complex, 20 reduced c-myc mRNA levels by 18%. However the mono-platinum(II)  
complexes, 8 and 24 were unable to down-regulate c-myc expression (in fact 24 up-regulates c-myc 
expression). This was surprising considering their ability to interact with c-myc DNA and penetrate 
the nucleus. These results can be rationalised taking into account, structural changes that may occur 
once the complexes have entered the cells (see Section 3.9 ). Once inside the cell, 8 and 24 are 
susceptible to undergo nucleophilic substitution with glutathione (a tripeptide with an intra-cellular 
concentration of 5 nM). During this intra-cellular reaction, glutathione attaches to the metal centre 
via the thiol moiety (the chlorine ligand bound to the fourth position is replaced). This results in a 
non-planar adduct which is unable to interact with c-myc quadruplex DNA and therefore unable to 
down-regulate c-myc expression. So intra-cellular modifications to 8 and 24 can prevent interaction 
with c-myc DNA and hence weaken their function as gene regulators.  
The thiol substitued platinum(II)-terpyridine complex, 13 displayed a 21 % reduction in c-myc mRNA 
levels (comparable to TmPyP4), which is consistent with its nuclear permeability and affinity for c-
myc DNA. In comparison to 15 and 19, complex 13 is less effective. This can be explained by its lack 
of selectivity for c-myc DNA (binds indiscriminately to quadruplex and duplex DNA, see Chapter 3).  
The di-nuclear zinc complex 18 and the thiol substitued platinum(II)-pyridyl-phenanthroline complex 
27 were unable to down-regulate c-myc expression (both complexes up-regulate c-myc expression). 
This was expected considering their inability to penerate the cell membrane. 
 
4.6 Flow Cytometry Studies  
This assay was carried out in collaboration with Miss AlexandraAlves Duarte supervised by Dr. David 
Mann (Division of Cell and Molecular Biology, Imperial College London) as part of our ongoing 
collaboration with this group. 
In order to monitor the effect of the complexes on the cell cycle, DNA-flow cytometric studies were 
carried out using the U2OS cell line. The effect of a compound on the different phases of the cell 
cycle can be analysed using this type of study.[188, 189] This was achieved by fluorescently labelling 
(using propidium iodide) the nuclei and analysing the fluorescence properties of each cell in a 
population. This technique is based on the principle that cells in the G0/G1 phase of the cell cycle 
have one copy of DNA and therefore display half the fluorescence intensity compared to cells in the 
G2/M phase. Cells in the S phase are in the process of synthesising DNA and therefore will have 
fluorescence between those expressed by cells in the G0/G1 and G2/M phases. During the flow 
cytometry experiment, each cell is categorised in terms of size and texture. This is displayed as a dot-
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plot where each cell in a population is repesented by one dot. From the dot-plot, a selection of cells 
are chosen for analysis using pre-determined selection citeria (according to the FlowJo and Diva 6.2 
programmes). The fluoresecence intensity of the selected cells was then used to draw histograms, 
which represent the population of cells found in each phase of the cell cycle. Histograms resulting 
from untreated and treated cell populations were compared to determine the effect of the metal 
complexes on cell cycle and the results are summarised in Figures 4-7 and 4-8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 4-7: Histograms resulting from flow cytometric analysis after 24 h of: (a) untreated U2OS cells; (b) U2OS cells treated with 10 µM of 16; (c) U2OS cells treated with 10 µM of 19; (d) U2OS cells 
treated with 10 µM of cis-platin; (e) U2OS cells treated with 10 µM of 22; (f) U2OS cells treated with 10 µM of 21. 
 
(a) (b) (c) 
(d) (e) (f) 
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Figure 4-8: Histograms resulting from flow cytometric analysis after 48 h of: (a) untreated U2OS cells; (b) U2OS cells treated with 10 µM of 10; (c) U2OS cells treated with 10 µM of 19; (d) U2OS cells 
treated with 10 µM of cis-platin; (e) U2OS cells treated with 10 µM of 22; (f) U2OS cells treated with 10 µM of 21. 
(a) (b) (c) 
(d) (e) (f) 
After 24 h the majority of untreated U2OS cells were found to be in the G1 phase (ca. 75%) with a 
significantly reduced number in the S and G2/M phases (15% and 10% respectively). After 48 h the 
statistics remained largely unchanged (only a ± 1% change was observed for the different phases). At 
the concentration administered (10 µM), many of the complexes had little or no effect on the cell 
cycle (after 24 and 48 h). The mono-nuclear platinum(II)-terpyridine complexes (8, 10, 13 and 15) did 
not affect the cell cycle after 24 h. However there was a noticeable increase in the proportion of 
dead cells after 48 h (for 8 and 10, 5-7 % relative to untreated cells).  
The bi-functionalised platinum(II)-terpyridine complex 16 had a significant effect on the cell cycle. 
Upon addition of 16, the U2OS cells were observed to undergo G0/G1 phase cell cycle arrest. After 
24 h, the percentage of cells displaying G0/G1 phase characteristics increased by 8% and those 
displaying S and G2/M phase characteristics decreased by 4 and 8% respectively. This would be 
consistent with down-regulation of c-myc which is known to prevent the expression of cyclin 
proteins, D1, D2 and D3.[190] As the cyclin proteins form complexes with and function as regulatory 
subunits of cyclin dependent kinases (enzymes involved in the regulation of the cell cycle), reduced 
levels of cyclin proteins have a direct affect on the cell cycle. The cyclin proteins associated to the c-
Myc protein, control CDK4 and CDK6, which are required for G1 to S phase transition.[162, 191] 
Therefore binding of 16 to c-myc DNA can be proposed to have a negative downstream effect on 
CDK4 and CDK6 and as a result lead to G0/G1 phase cell cycle arrest.  
Similar DNA-flow cytometric data was obtained for the bi-nuclear copper(II) complex 19. In this case, 
G0/G1 phase cell cycle arrest was accompanied by an increase in dead cells, as reflected by the sub-
duploid peak (see Figure 4-7; sub-G1 phase proportions were 10.29 % (24 h) and 11.34 % (48 h) 
versus 2.61 (24 h) and 3.72 % (48 h) in the untreated control samples). This suggests that 19 is able 
to disrupt G1 to S phase transition (probably through interaction with c-myc DNA, as shown in the 
DNA binding and RT-qPCR sections) and at the same time induce cell death.  
The tri-nuclear copper(II) and zinc(II) complexes (21 and 22) exhibited similar DNA-flow cytometric 
data to cis-platin. The data is indicative of S/G2 phase cell cycle arrest. Upon 24 h incubation, the 
proportion of cells at G0/G1 decreased by 10-12 % and those at S and G2 increased considerably (13 
and 4 % for 21 and 3 and 11 % for 22). More pronounced changes were observed for cis-platin 
(G0/G1: -29%, S: +20% and G2: +17%). Cis-platin is known to cause DNA damage by forming 1,2-
intrastrand crosslinks and thereby activate ATR and ATM (ataxia-telangiectasia mutated, a protein 
kinase enzyme).[192] ATM phosphorylates several proteins that activate DNA damage checkpoint 
kinases (CHK1 and CHK2), which lead to cell cycle arrest.[193] For cis-platin, activation of CHK1 and 
CHK2 leads to enhancement of CDC25C (a phosphatase that de-phospholayes and hence activates 
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cyclin dependent kinase 1, an enzyme involved in cell cycle regulation) phosphorylation which leads 
to G2 phase cell arrest (i.e. cells do not enter mitosis).[194, 195] As the flow cytometric profile of 21 
and 22 are similar to cis-platin, one could propose that their interaction with DNA could also result in 
a similar cellular cascade, leading to G2 arrest.  Interestingly after 48 h the cells treated with 21 and 
22 were unable to recover. Cis-platin, 21 and 22 treated cells remained in the G2 arrested state.  
 
4.7 Conclusion 
In order to determine the anti-cancer potential of the prepared metal complexes, a series of cellular 
studies were carried out. The MTS cytotoxicity assay showed that a number of metal complexes 
displayed IC50 values against two cancer cell lines comparable to cis-platin. In general, most of the 
complexes displayed selective toxicity for the U2OS cell line (over the cancerous 293T and somatic 
GM05757 cell lines), probably due to its high c-myc expression, to which the test compounds have 
been shown to bind very strongly. This suggests that interaction with c-myc DNA is a potential 
mechanism for the observed cytotoxicity. The toxicity profiles obtained for 16, 19 and 29 are 
particularly promising, in these cases the IC50 values for the U2OS cell line are lower or similar to that 
of cis-platin. At the same time they displayed little or no toxicity towards the GM05757 cell line.  
Cellular uptake studies showed that a selection of complexes were able to penetrate the U2OS cell 
membrane. A larger amount of the copper(II) and zinc(II) complexes (19, 21 and 22) were 
internalised in comparison to the platinum(II) complexes. This was attributed to an enhanced uptake 
mechanism for the copper(II) and zinc(II) complexes (passive and membrane protein facilitated 
pathways). Furthermore a clear correlation was established between toxicity (IC50 values) and 
nuclear localisation (although there were a few anomalies). This trend proposes that, DNA 
interactions could be a possible cause of cytotoxicity.  
The uptake values obtained from the ICP-MS studies represent the amount of metal internalised, 
and therefore provides an indication on the amount of metal complex taken up. There are a number 
of possible pathways for metal accumulation; (a) the metal complex is taken up and does not 
undergo any structural modifications, (b) the metal complex is taken up, but once inside the cells it 
undergoes a structural modification whereby the metal cation is released from the ligand and (c) the 
metal is taken up as the cation rather than the complex. The ICP-MS method is unable to distinguish 
between the different metal accumulation pathways. Therefore the interpretation of the cell 
penetration results has to been taken with caution. 
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Real time q-PCR analysis was carried out to determine the effect of the complexes on the cellular 
production of c-myc RNA and thereby determine their ability to regulate c-myc expression. The qPCR 
data showed that a selection of complexes (13, 15, 19 and 20) were able to down-regulate c-myc 
expression (comparable to TmPyP4). Taking into account their nuclear permeabilty and high affinity 
for c-myc DNA (elucidated by cellular uptake and DNA binding studies), the inhibition of c-myc 
transcriptional activity (c-myc down-regulation) can be proposed to result from the stabilisation of c-
myc quadruplex DNA. 
The effect of the complexes on the cell cycle was investigated using DNA-flow cytometric studies. 16 
and 19 were found to induce G0/G1 phase cell cycle arrest, which was proposed to result from 
down-regulation of c-myc DNA. For 19, G0/G1 arrest was accompanied by cell death. This result in 
combination with the RT q-PCR data suggests that interaction with c-myc DNA and concomitant 
down-regulation could lead to a cascade of cellular events that ultimately causes cell death.  
Overall the cellular studies suggest that some of the complexes are able to regulate the expression 
of c-myc oncogene and therefore induce (in some case) cell death in human osteosarcoma cells 
(U2OS). The data clearly highlights the anti-cancer potential of the synthesised metal complexes.  
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CHAPTER 5 
 
 
CONCLUSION 
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This thesis provides further evidence that metal complexes can be used as excellent quadruplex DNA 
stabilisers and therefore oncogene regulators. A series of mono-, bi- and tri-nuclear metal(II)-
terpyridine and platinum(II)-pyridyl- and phenyl-phenanthroline complexes functionalised with cyclic 
amine (piperidine, pyrrolidine and morpholine) or metal(II)-dipicolyl side arms have been designed 
and synthesised. The complexes displayed planar cores to π-π stack atop quadruplex DNA and side 
arms to interact electrostatically with the loops, grooves and phosphate backbone of DNA.  
The platinum(II) complexes were shown to π -π stack in solid and solution state using X-ray 
crystallography and 1H NMR and/or UV-vis spectroscopy respectively. This demonstrated their 
propensity to interact with quadruplex DNA via π-π interactions. Non-covalent interactions with 
quadruplex DNA (both Htelo and c-myc) were probed using fluorescence intercalator displacement 
assays, UV-vis, fluorescence, 1H NMR and circular dichroism spectroscopicstudies. Several of the 
complexes were found to bind with high affinity and selectivity for quadruplex DNA (especially c-myc 
DNA). The planarity of the complexes was critical for binding to quadruplex DNA, those complexes 
with at least one accessible face (platinum(II) and copper(II) complexes) were found to bind with 
high affinity. Those with non-planar geometries displayed weak binding. Structural modifications to 
the mono-nuclear platinum(II)-terpyridine family, through; (a) incorporation of additional cyclic 
amine side arms, (b) incorporation of metal(II)-dipicolyl side arms and (c) increasing the π-surface 
yielded complexes with higher affinity and selectivity for quadruplex DNA. 
 The biophysical studies were also used to elucidate the binding mode of the complexes. Most of the 
complexes were proposed to π -π stackatop quadruplex DNA and in some cases display additional 
interactions with the loops, grooves (those with cyclic amine side arms) and phosphate backbone 
(those with metal-dipicolyl side arms). Long term 1H NMR spectroscopic experiments with guanosine 
showed that some platinum(II) complexes (those with a chlorine ligand on the fourth position) have 
the potential to form covalent bonds with DNA. Therefore such complexes are expected to initially 
bind non-covalently and then over time form covalent bonds. The thiol substituted platinum(II) are 
resistant to platination and therefore are expected to bind via non-covalent interactions only. 
The biological activity and anti-cancer potential of the most promising compounds were investigated 
using a number of cellular studies. The MTS cytotoxicity assay showed that some of the complexes 
displayed selective toxicity for the cancerous U2OS cell line (with IC50 values comparable to cis-platin, 
a clinically approved anti-caner drug) over the 293T and GM07575 cell lines. This was attributed to 
the high c-myc expression in U2OS cells, to which the test compounds have been shown to bind very 
strongly. The toxicity profiles obtained for the di-functionalised platinum(II) complex, 16, the di-
copper(II) complex 19 and the mono-functioanlised pyridyl-phenanthroline complex, 29 were 
150 
 
particularly promising, in these cases the IC50 values for the U2OS cell line were comparable to that 
of cis-platin. At the same time they displayed little or no toxicity towards the somatic GM05757 cell 
line. Cellular uptake studies showed that a selection of complexes were able to penetrate the U2OS 
cell membrane and enter the nucleus.The study found a larger amount of the copper(II) and zinc(II) 
complexes (19, 21 and 22) to be taken up by the cells in comparison to the platinum(II) complexes. 
This was attributed to an enhanced uptake mechanism for the copper(II) and zinc(II) complexes 
(passive and membrane protein facilitated pathways). Additionally a correlation between cellular/ 
nuclear penetration and cytotoxicity was established, suggesting that toxicity may be related to DNA 
interactions.   
Real time q-PCR analysis showed that a selection of complexes (13, 15, 19 and 20) were able to 
down-regulate c-myc expression (comparable to TmPyP4, a well known c-myc regulator). These 
complexes also displayed nuclear permeabilty and high affinity for c-myc DNA, therefore c-myc 
down-regulation can be proposed to result from the stabisation of c-myc quadruplex DNA. DNA-flow 
cytometric studies found that 16 and 19 were able to induce G0/G1 phase cell cycle arrest, which 
was proposed to result from the down-regulation of c-myc DNA. 21 and 22, like cis-platin, resulted in 
G2 phase cell cycle arrest, which is proposed to result from DNA damge. Overall the cellular studies 
suggest that some of the complexes are able to regulate the expression of c-myc oncogene and 
therefore induce (in some cases) cell death in human osteosarcoma cells (U2OS). The data clearly 
highlights the anti-cancer potential of the synthesised metal complexes.  
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CHAPTER 6 
 
 
EXPERIMENTAL DETAILS 
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6.1 General Procedures 
1H NMR, 13C NMR and 31P NMR spectra were recorded on a BrukerAvance 400 MHz Ultrashield NMR 
spectrometer. Electron spray ionisation massspectra were recorded on a BrukerDaltronics Esquire 
3000 spectrometer by Mr. J. Barton (Imperial College London). Elemental Analysis of the compounds 
prepared was performed by Mr. Alan Dickerson (University of Cambridge). The X-ray crystal 
structures where resolved by Dr. A. J. P. White (Imperial College London) using a OD Xcalibur PX 
Ultra Diffractometer (1.54184 Å). 
 
L1 and L17 were purchased from Sigma-Aldrich Chemical Company, the purities of these ligands were 
verified by 1H NMR spectroscopy. L2-4 and 8-10 were prepared during my MSci project and the 
method for preparation has been published since then. Metal complexes, 1, 2, 7, 31, 32 and ligands, 
L8, L13, L14 and L18 were prepared by small modifications of reported procedures. 
 
6.2 Synthesis of the Ligands 
 
 
Synthesis of L7: 6,6’’-Dibromo-2,2’:6’,2’’-terpyridine (50 mg, 0.12 mmol) and 1-(2-
hydroxyethyl)piperidine (73 mg, 0.28 mmol) were slowly added to a stirred suspension of powered 
KOH (36 mg, 0.64 mmol) in DMSO (5 ml). The solution was stirred under nitrogen at 60oC for 24 h. 
The reaction mixture was extracted with DCM (50 ml × 3), washed thoroughly with water (30 ml × 3) 
and dried over sodium sulphate. The solvent was removed under reduced pressure to yield the 
product as a brown solid (32 mg, 52%); 1H NMR (400MHz, CDCl3): δH 8.41 (d, 2H, 
3JHH = 8.0, tpy’3-H 
and 5-H), 8.45 (d, 2H, 3JHH = 8.0, tpy 5-H), 7.93 (t, 1H, 
3JHH = 8.0, tpy’ 4-H), 7.76 (t, 2H,
 3JHH = 8.0, tpy 4-
H), 6.83 (d, 2H,3JHH = 8.0,tpy 3-H), 4.69 (t, 4H,
 3JHH = 6.0, ethyl 1-H), 2.95 (t, 4H,
 3JHH = 6.0, ethyl 2-H), 
2.67 (m, 8H, pip 1-H), 1.72 (m, 8H, pip 2-H), 1.53 (m, 4H, pip 3-H); 13C NMR (400MHz, DMSO-d6): δC 
163.1, 155.2, 153.6, 139.3, 137.5, 120.7, 113.8, 111.4, 63.3, 57.9, 55.1, 25.9, 24.2; ESI-MS Calcd. for 
C29H37N5O [M]
+: 487.3 a.m.u. Found [M+H]+: 488.0 a.m.u.; Anal. Calcd. for C29H37N5O∙1.5HCl: C 64.91, 
H 7.57, N 12.74; Found: C 64.23, H 7.13, N 12.97. 
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Synthesis of L8: To a solution of 2-aminoethanol (2  g, 33 mmol) in 1,2- dichloroethane (20 ml), 
pyridine-2-carbaldehyde (7.36 g, 69 mmol) was added. The mixture was stirred at room temperature 
for 30 min under a nitrogen atmosphere.  Upon cooling the solution to 0oC, sodium triacetoxy-
borohydride (16.08 g, 76 mmol) was added in small fractions. The resultant slurry was allowed to 
warm to room temperature and stirred for a further 2 h. After which the reaction was quenched 
with 2% sodium bicarbonate solution (30 ml) and extracted with DCM (40 ml × 3). The organic layer 
was dried over sodium sulphate, concentrated to ca. 3 ml, and purified by silica-gel based column 
chromatography (MeOH/DCM 5:95). The product was isolated as a pale yellow oil (5.51 g, 69%); 1H 
NMR (400MHz, CDCl3): δH 8.57 (dd, 2H, 
3JHH = 8.0, 
4JHH = 2.0,py 2-H), 7.64 (dt, 2H, 
3JHH = 8.0, 8.0 
4JHH = 
2.0, py 4-H), 7.36 (d, 2H, 3JHH = 8.0, py 5-H), 7.19 (ddd, 2H, 
3JHH = 8.0, 8.0, py 3-H), 3.95 (s, 4H, py 6-H), 
3.70 (t,2H, 3JHH = 6.0, ethyl 1-H),  2.89 (t, 2H, 
3JHH = 6.0, ethyl 2-H). 
 
 
 
Synthesis of L9: L8 (250 mg, 1.0 mmol) and 4’-chloro-2,2’:6’2’’-terpyridine (250 mg, 0.9 mmol) were 
slowly added to a stirred suspension of powered KOH (262 mg, 5.0 mmol) in DMSO (5 ml). The 
solution was stirred under nitrogen at 60oC for 4 h. The reaction mixture was extracted with DCM 
(40 ml × 3), washed thoroughly with water (30 ml × 3) and dried over sodium sulphate. The solvent 
was removed under reduced pressure to yield the product as a brown oily solid (256 mg, 58%); 1H 
NMR (400MHz, DMSO-d6): δH 8.73 (d, 2H, 
3JHH = 4.0,tpy 2-H), 8.61 (d, 2H, 
3JHH = 8.0, tpy 5-H), 8.48 (dd, 
2H, 3JHH = 8.0, 
4JHH = 2.0, py 2-H), 8.01 (dt, 2H, 
3JHH = 8.0, 8.0, 
4JHH = 2.0, tpy 4-H), 7.94 (s, 2H, tpy’ 3-H 
and 5-H), 7.73 (dt, 2H, 3JHH = 8.0, 8.0 
4JHH = 2.0, py 4-H), 7.60 (d, 2H, 
3JHH = 8.0, py 5-H), 7.51 (ddd, 2H, 
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3JHH = 8.0, 8.0, tpy 3-H), 7.22 (ddd, 2H, 
3JHH = 8.0, 8.0, py 3-H), 4.40 (t, 2H, 
3JHH= 6.0, ethyl 1-H), 3.92 (s, 
4H, py 6-H), 3.02 (t, 2H, 3JHH = 6.0, ethyl 2-H); 
13C NMR (400MHz, DMSO-d6): δC 167.02, 159.78, 
157.10, 155.33, 149.71, 149.21, 137.83, 136.94, 124.97, 123.07, 122.57, 121.36, 107.27, 66.70, 
60.54, 52.69; ESI-MS Calcd. for C24H26N6O [M]
+: 474.2 a.m.u. Found [M+H]+: 475.0 a.m.u.; Anal. Calcd. 
for C24H26N6O∙1.6H2O: C 69.16, H 5.85, N 16.70; Found: C 69.74, H 5.62, N 15.96.
 
 
 
 
Synthesis of L10: 6,6’’-Dibromo-2,2’:6’,2’’-terpyridine (100 mg, 0.25 mmol) and L8 (137 mg, 0.56 
mmol) were slowly added to a stirred suspension of powered KOH (100 mg, 1.79 mmol) in DMSO (5 
ml). The solution was stirred under nitrogen at 85oC for 24 h. The reaction mixture was extracted 
with DCM (50 ml × 3), washed thoroughly with water (30 ml × 3) and dried over sodium sulphate. 
The solvent was removed under reduced pressure to yield the product as a brown oily solid (102 mg, 
56%); 1H NMR (400MHz, DMSO-d6): δH 8.52 (d, 4H, 
3JHH = 4.0, py 2-H), 8.23 (d, 2H, 
3JHH = 8.0, tpy’ 3-H 
and 5-H), 8.20 (d, 2H, 3JHH= 8.0, tpy 3-H), 7.82 (t, 1H, 
3JHH = 8.0, tpy’ 4-H), 7.74 (t, 2H, 
3JHH = 8.0, tpy 4-
H), 7.63 (d, 4H, 3JHH = 4.0, py 5-H), 7.60 (t, 4H, 
3JHH = 4.0, 4.0, py 4-H), 7.12 (t, 4H, 
3JHH = 4.0, 4.0, py 3-
H), 6.79 (d, 2H, 3JHH = 8.0, tpy 5-H), 4.64 (t, 4H, 
3JHH = 6.0, ethyl 1-H), 4.02 (s, 8H, py 6-H), 3.13 (t, 4H, 
3JHH = 6.0, ethyl 2-H); 
13C NMR (400MHz, DMSO-d6): δC 163.02, 159.82, 155.00, 153.54, 148.97, 
139.33, 137.45, 136.39, 125.53, 122.84, 121.92, 120.59, 111.30, 67.99, 61.00, 53.26; ESI-MS Calcd. 
for C43H41N9O2[M]
+:  715.8 a.m.u. Found [M+H]+: 716.9 a.m.u. [M+Na]+: 738.0 a.m.u. 
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Synthesis of L11: 5-chloro-1,10-phenanthroline (200 mg, 0.94 mmol) and 1-(2-
hydroxyethyl)piperidine (146 mg, 0.94 mmol) were slowly added to a stirred suspension of powered 
KOH (264 mg, 5.0 mmol) in DMSO (5 ml). The solution was stirred under nitrogen at 60oC for 4 h. The 
reaction mixture was extracted with DCM (50 ml × 3), washed thoroughly with water (30 ml × 3) and 
dried over sodium sulphate. The solvent was removed under reduced pressure to yield the product 
as a brown solid (212 mg, 73%); 1H NMR (400MHz, CDCl3): δH 9.23 (dd, 1H,
3JHH = 6.0, 2.0, phen 2-H), 
9.05 (dd, 1H,3JHH = 6.0, 2.0, phen’ 2-H), 8.71 (dd, 1H, 
3JHH = 8.0, 2.0, phen 4-H), 8.14 (dd, 1H, 
3JHH = 8.0, 
2.0, phen’ 4-H), 7.68 (dd, 1H, 3JHH = 8.0, 4.0, phen 3-H), 7.59 (dd, 1H,
3JHH = 8.0, 4.0, phen’ 3-H), 7.00 (s, 
1H, phen 5-H), 4.44 (t, 2H, 3JHH = 6.0, ethyl 1-H), 3.03 (t, 2H, 
3JHH = 6.0, ethyl 2-H), 2.65 (m, 4H, pip 1-
H), 1.67 (m, 4H, pip 2-H), 1.51 (m, 2H, pip 3-H); 13C NMR (400MHz, DMSO-d6): δC 152.1, 150.6, 147.9, 
134.6, 130.9, 129.2, 123.7, 123.2, 122.6, 101.7, 66.9, 57.8, 55.2, 26.0, 24.1; ESI-MS Calcd. for 
C19H21N3O [M]
+: 307.2 a.m.u. Found [M+H]+: 308.0 a.m.u.; Anal. Calcd. for C19H21N3O∙1.45H2O: C 
68.42, H 7.22, N 12.60; Found: C 68.86, H 6.76, N 12.58. 
 
 
Synthesis of L12: nbutyl-lithium (2 M solution in cyclohexane, 0.81 ml, 1.63 mmol) was added 
dropwise to a solution of 2-bromopyridine (0.16 ml, 1.63 mmol) in dry THF (7 ml) under nitrogen at -
78oC. The resultant deep red solution was stirred for 15 min. A solution of L11 (100 mg, 0.33 mmol) in 
dry THF (5 ml) was then added via a cannula to the lithiated reaction mixture. The reaction was 
allowed to proceed for 2.5 h. After this period, water (30 ml) was added to quench the reaction and 
the organic material was extracted with DCM (50 ml × 3). The reaction products were re-oxidised by 
incubating the DCM solution with MnO4 (3 g) for 2 h. MnO4 was filtered and then dried using NaSO4. 
The solvent was then removed under reduced pressure to give the crude product as a brown oil. The 
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crude product was purified by alumina column chromatography using a THF:hexane:Et3N  (5:1:0.02) 
solvent system to give L12 as an off-white oily-solid (0.21 g, 21%); 1H NMR (400MHz, CDCl3): δH 9.09 
(dd, 1H, 3JHH = 4.0, 2.0, phen 2-H), 9.02 (dd, 1H,
3JHH = 8.0, pyridyl 2-H), 8.83 (s, 1H, phen 6-H), 8.82 (d, 
1H, 3JHH = 4.0, phen 9-H), 8.78 (dd, 1H, 
3JHH = 4.0, 2.0, phen 4-H), 8.15 (dd, 1H, 
3JHH = 4.0, 2.0, phen 10-
H), 7.94 (td, 1H, 3JHH = 4.0, 2.0, pyridyl 4-H), 7.60 (dd, 1H, 
3JHH = 4.0, 2.0, pyridyl 3-H), 7.40 (dd, 1H, 
3JHH = 4.0, 2.0, phen 3-H), 7.28 (m, 1H, pyridyl 5-H), 4.46 (t, 2H, 
3JHH = 6.0, ethyl 1-H), 3.06 (t, 2H, 
3JHH = 
6.0, ethyl 2-H), 2.66 (m, 4H, pip 1-H), 1.68 (m, 4H, pip 2-H), 1.51 (m, 2H, pip 3-H); ESI-MS Calcd. for 
C24H24N4O [M]
+: 384.2 a.m.u. Found [M+Na]+: 407.0 a.m.u. 
 
 
 
 
Synthesis of L13: nbutyl-lithium (2 M solution in cyclohexane, 1.38 ml, 2.77 mmol) was added 
dropwise to a solution of 2-bromopyridine (0.27 ml, 2.77 mmol) in dry THF (7 ml) under nitrogen at -
78oC. The resultant deep red solution was stirred for 15 min. A solution of 1,10-phenanthroline (100 
mg, 0.55 mmol) in dry THF ( 5 ml) was then added via a cannula to the lithiated reaction mixture. The 
reaction was allowed to proceed for 2.5 h. After this period, water (30 ml) was added to quench the 
reaction and the organic material was extracted with DCM (50 ml × 3). The reaction products were 
re-oxidised by incubating the DCM solution with MnO4 (3 g) for 2 h. MnO4 was filtered and then 
dried using NaSO4. The solvent was then removed under reduced pressure to give the crude product 
as a brown oil. The crude product was purified by alumina column chromatography using a 
THF:hexane:Et3N  (5:1:0.02) solvent system to give L
13 as an off-white solid (0.57 g, 40%); 1H NMR 
(400MHz, CDCl3): δH 9.29 (dd, 1H, 
3JHH = 4.0, 2.0, phen 2-H), 9.03 (dt, 1H,
 3JHH = 4.0, 2.0, pyridyl 2-H), 
8.86 (dd, 1H, 3JHH = 8.0, phen 9-H), 8.78 (dt, 1H, 
3JHH = 4.0, 2.0, phen 4-H), 8.43 (d, 1H, 
3JHH = 8.0, phen 
10-H), 8.32 (dd, 1H, 3JHH = 4.0, 2.0, pyridyl 5-H), 7.96 (td, 1H, 
3JHH = 4.0, 2.0, phen 3-H), 7.88 (d, 2H, 
3JHH = 8.0, phen 6-H and 7-H), 7.70 (dd, 1H, 
3JHH = 4.0, 2.0, pyridyl 3-H), 7.41 (ddd, 1H, 
3JHH = 4.0, 2.0, 
pyridyl 4-H); ESI-MS Calcd. for C17H11N3[M]
+: 251.7 a.m.u. Found [M+H]+: 253.0 a.m.u. 
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Synthesis of L14: nbutyl-lithium (2M solution in cyclohexane, 0.81 ml, 1.63 mmol) was added 
dropwise to a solution of 2-bromobenzene (0.16 ml, 1.63 mmol) in dry THF (7 ml) under nitrogen at -
78oC. The resultant deep red solution was stirred for 15 min. A solution of 1,10-phenanthroline (100 
mg, 0.33 mmol) in dry THF (5 ml) was then added via a cannula to the lithiated reaction mixture. The 
reaction was allowed to proceed for 2.5 h. After this period, water (30 ml) was added to quench the 
reaction and the organic material was extracted with DCM (50 ml × 3). The reaction products were 
then re-oxidised by incubating the DCM extracts with MnO4 (3 g) for 2h. MnO4 was filtered from the 
DCM solution and this was then dried using NaSO4. The solvent was then removed under reduced 
pressure to give the crude product as a brown oil. The crude product was purified by alumina 
column chromatography using a THF:hexane:Et3N  (5:1:0.02) solvent system to give L
14 as a brown 
oily-solid (0.74 mg, 52%); 1H NMR (400MHz, CDCl3, ppm): δH 9.27 (dd, 1H,
 3JHH = 4.0, phen 2-H), 8.36 
(m, 3H, phen 4-H, 3-H and 9-H), 8.29 (dd, 2H, 3JHH = 4.0, 2.0, phenyl 2-H), 8.14 (d, 1H,
 3JHH = 8.0, phen 
10-H), 7.83 (dd, 2H, phen 6-H and 7-H), 7.66 (dd, 1H, 3JHH = 8.0, 4.0, phenyl 4-H), 7.57 (m, 1H, phenyl 
3-H and 6-H), 7.49 (m, 1H, phenyl 5-H); ESI-MS Calcd. for C18H12N2 [M]
+: 256.1 a.m.u. Found [M+H]+: 
257.0 a.m.u. 
 
 
Synthesis of L15: nbutyl-lithium (2M solution in cyclohexane, 0.81 ml, 1.63 mmol) was added 
dropwise to a solution of 2-bromobenzene (0.16ml, 1.63mmol) in dry THF (7ml) under nitrogen at -
78oC. The resultant deep red solution was stirred for 15 min. A solution of L11 (100mg, 0.33mmol) in 
dry THF (5 ml) was then added via a cannula to the lithiated reaction mixture. The reaction was 
allowed to proceed for 2.5 h. After this period, water (30 ml) was added to quench the reaction and 
the organic material was extracted with DCM (50 ml × 3). The reaction products were then re-
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oxidised by incubating the DCM extracts with MnO4 (3 g) for 2 h. MnO4 was filtered from the DCM 
solution and this was then dried using NaSO4. The solvent was then removed under reduced 
pressure to give the crude product as a brown oil. The crude product was purified by alumina 
column chromatography using a THF:hexane:Et3N  (5:1:0.02) solvent system to give L
15 as an off-
white oily-solid (0.12 mg, 8%); 1H NMR (400MHz, CDCl3, ppm): δH 9.09 (d, 1H,
 3JHH = 4.0, phen 2-H), 
8.76 (d, 1H, 3JHH = 8.0, phen 4-H), 8.37 (d, 1H,
 3JHH = 8.0, 4.0, phen 3-H), 8.36 (d, 1H,
 3JHH = 8.0, 4.0, 
phen 9-H), 8.14 (m, 2H, phen 10-H and phenyl 2-H), 8.57 (m, 3H, phenyl 3-H, 4-H and 5-H), 7.50 (d, 
1H, 3JHH = 8.0, phenyl 6-H), 7.69 (s, 1H,
 3JHH = 8.0, phen 7-H), 4.45 (br s, ethyl 1-H), 3.04 (br s, 2H, ethyl 
2-H), 2.66 (br s, 4H, pip 1-H), 1.68 (br s, 1H, pip N+-H), 1.60 (br s, 4H, pip 2-H), 1.52 (br s, 2H, pip 3-H); 
ESI-MS Calcd. for C25H25N3O [M]
+: 383.2 a.m.u. Found [M+H]+: 384.0 a.m.u. 
 
 
Synthesis of L16: nbutyl-lithium (2 M solution in cyclohexane, 0.81 ml, 1.63 mmol) was added 
dropwise to  a solution of L19 (93 mg, 0.33 mmol) in dry THF (7 ml) under nitrogen at -78oC. The 
resultant deep red solution was stirred for 15 min. A solution of L11 (100 mg, 0.33 mmol) in dry THF 
(5 ml) was then added via a cannula to the lithiated reaction mixture. The reaction was allowed to 
proceed for 2.5 h. After this period, water (30ml) was added to quench the reaction and the organic 
material was extracted with DCM (50 ml × 3). The reaction products were then re-oxidised by 
incubating the DCM extracts with MnO4 (3 g) for 2h.MnO4 was filtered from the DCM solution and 
this was then dried using NaSO4. The solvent was then removed under reduced pressure to give the 
crude product as a brown oil. The crude product was purified by alumina column chromatography 
using a THF:hexane:Et3N  (5:1:0.02) solvent system to give L
16 as a brown oily-solid (0.16 mg, 10%); 
1H NMR (400MHz, CDCl3, ppm): δH 8.48 (dd, 1H,
 3JHH= 4.0, 2.0, phen 2-H), 7.85 (dd, 1H, 
3JHH = 4.0 2.0, 
phen  3-H), 7.29 (m, 2H, phen 4-H and 9-H), 7.03 (m, 2H, phen 10-H and phenyl 4-H), 6.85 (m, 2H, 
phenyl 3-H and 5-H), 6.30 (s, 1H, phen 7-H), 6.27 (m, 1H, phenyl 6-H),  4.24 (t, 2H, 3JHH = 4.0, ethyl 1-
H), 4.09 (t, 2H, 3JHH = 4.0, ethyl’ 1-H), 2.90 (t, 2H,
 3JHH = 4.0, ethyl 2-H), 2.75 (t, 2H,
 3JHH = 4.0, ethyl’ 2-
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H), 2.59 (m, 4H, pip 1-H), 2.49 (m, 4H, pip’ 1-H), 1.63 (m, 8H, pip 2-H and pip’ 2-H), 1.48 (m, 4H, pip 
3-H and pip’ 3-H); ESI-MS Calcd. for C32H38N4O2 [M]
+: 510.3 a.m.u. Found [M+H]+: 511.0 a.m.u. 
 
Synthesis of L18: Piperidine (2.0 g, 23.8 mmol) was added to dry benzene (5 ml) and the mixture was 
flushed with nitrogen. Etylenesulfide (1.42 ml, 47.6 mmol) was added dropwise and the resulting 
solution was stirred at 65oC for 48 h. The solution was then filtered to remove any polymeric 
material. The solvent was then removed and the resulting yellow oil was re-dissolved in 
dichloromethane (50 ml). Then solution was filtered through a plug of silica to remove any remnant 
polymeric impurities. The filtrate was then removed to yield the product as a yellow oil (2.54 g, 
75%); 1H NMR (400MHz, CDCl3): δH 2.86 (t, 2H,
 3JHH = 6.0, ethyl 1-H), 2.53 (t, 2H,
 3JHH = 6.0, ethyl 2-H), 
2.35 (m, 4H, pip 1-H), 1.49 (m, 4H, pip 2-H), 1.38 (m, 2H, pip 3-H). 
 
 
 
Synthesis of L19: 2-Bromophenol (6.0 g, 34.7 mmol) and potassium carbonate (15.8 g, 114.4 mmol) 
were placed in acetone (100 ml) and heated until reflux. A solution of 1-(2-chloroethyl) piperidine 
hydrochloride (6.4 g, 34.7 mol) in acetone (100 ml) was then added dropwise to the refluxing 
mixture. After which the mixture was heated under reflux for a further 12 h. Once cooled the 
potassium carbonate was filtered off and water was added to the filtrate. The product was extracted 
twice into diethyl ether and the combined organic extracts were washed with water, 5% sodium 
hydroxide and dried over MgSO4. The solvent was removed to yield a pale yellow oil (6.58 g, 67%); 
1H 
NMR (400MHz, CDCl3): δH 7.15 (m, 1H, phenyl 3-H), 7.09 (m, 2H, phenyl 4-H and 5-H), 6.85 (m, 1H, 
phenyl 6-H), 4.10 (t, 2H, 3JHH = 6.0, ethyl 1-H), 2.77 (t, 2H, 
3JHH = 6.0, ethyl 2-H), 2.51 (m, 4H, pip 1-H), 
1.61 (m, 4H, pip 2-H), 1.46 (m, 2H, pip 3-H); 13C NMR (400MHz, DMSO-d6): δC 130.5, 123.8, 122.8, 
117.9, 113.6, 66.3, 57.8, 55.1, 26.0, 24.2; ESI-MS Calcd. for C13H18BrNO [M]
+: 283.1 a.m.u. Found 
[M+H]+: 284.0 a.m.u. 
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6.3 Synthesis of the Metal Complexes 
 
 
 
Synthesis of 1: L1 (94 mg, 0.4 mmol) and ZnCl2 (55 mg, 0.4 mmol) were dissolved separately in MeOH 
(2.5 ml each). The methanolic solutions were combined slowly and stirred at room temperature for 
24 h. The resultant white precipitate was filtered and washed with warm MeOH and diethyl ether. 
The zinc complex was isolated as white crystals (104 mg, 70%); 1H NMR (400MHz, DMSO-d6): δH 8.85 
(br s, 2H, tpy 2-H), 8.84 (br d, 2H, 3JHH = 8.0, tpy 5-H), 8.75 (br d, 2H,
 3JHH = 8.0, tpy’ 3-H and 5-H), 8.61 
(br t, 1H, 3JHH = 8.0, tpy’ 4-H), 8.34 (br t, 2H, 
3JHH = 8.0, tpy 4-H), 7.90 (br t, 2H, 
3JHH = 8.0, tpy 3-H); ESI-
MS Calcd. for C15H11Cl2N3Zn [M]
+: 369.0 a.m.u. Found [M-Cl]+: 332.0 a.m.u.;  Anal. Calcd. for 
C15H11Cl2N3Zn·H2O: C 46.48, H 3.38, N 10.84; Found: C 46.51, H 2.90, N 10.56. 
 
 
 
Synthesis of 2: L1 (94 mg, 0.4 mmol) and CuCl2·2H2O (69 mg, 0.4 mmol) were dissolved separately in 
MeOH (2.5 ml each). The methanolic solutions were combined slowly and stirred at room 
temperature for 24 h. The resultant green precipitate was filtered and washed with warm MeOH and 
diethyl ether. The product was purified by slow diffusion of acetone into a concentrated aqueous 
solution. The copper complex was isolated as green crystals (102 mg, 69%); ESI-MS Calcd. for 
C15H11Cl2CuN3 [M]
+: 368.0 a.m.u. Found [M-Cl]+: 331.0 a.m.u.; Anal. Calcd. for C15H11Cl2CuN3: C 48.99, 
H 3.02, N 11.43; Found: C 48.53, H 3.03, N 11.04. 
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Synthesis of 3: L2 (176 mg, 0.49 mmol) and ZnCl2 (67 mg, 0.49 mmol) were dissolved separately in 
MeOH (2.5 ml each). The methanolic solutions were combined slowly and stirred at room 
temperature for 24 h. The resultant white precipitate was filtered and washed with warm MeOH and 
diethyl ether. The zinc complex was isolated as white crystals (185 mg, 77%); 1H NMR (400MHz, 
DMSO-d6): δH 8.81 (br d, 2H, 
3JHH = 4.0, tpy 2-H), 8.79 (br d, 2H, 
3JHH = 8.0, tpy 5-H), 8.39 (br s, 2H, tpy’ 
3-H and 5-H), 8.32 (br t, 2H, 3JHH = 6.0, tpy 4-H), 7.86 (br t, 2H, 
3JHH = 6.0,tpy 3-H), 4.56 (t, 
3JHH = 6.0, 
2H, ethyl 1-H), 2.81 (t, 2H,3JHH = 6.0, ethyl 2-H), 2.51 (m, 4H, pip 1-H), 1.52 (m, 4H, pip 2-H), 1.43 (m, 
4H, pip 3-H); ESI-MS Calcd. for C22H24Cl2N4OZn [M]
+: 496.0 a.m.u. Found [M-Cl]+: 459.0 a.m.u.; Anal. 
Calcd. for C22H24Cl2N4OZn∙1.7H2O: C 50.10, H 5.24, N 10.62; Found: C 49.78, H 4.75, N 10.50. 
 
 
 
Synthesis of 4: L2 (199 mg, 0.55 mmol) and CuCl2·2H2O (94 mg, 0.55 mmol) were dissolved separately 
in MeOH (2.5 ml each). The methanolic solutions were combined slowly and stirred at room 
temperature for 24 h. The resultant green precipitate was filtered and washed with warm MeOH and 
diethyl ether. The product was purified by slow diffusion of acetone into a concentrated aqueous 
solution. The copper complex was isolated as blue crystals (180 mg, 66%); ESI-MS Calcd. for 
C22H24Cl2CuN4O [M]
+: 495.0 a.m.u. Found [M-Cl]+: 458.0 a.m.u.; Anal. Calcd. for 
C22H24Cl2CuN4O∙3H2O∙HCl: C 45.14, H 5.34, N 9.57; Found: C 44.92, H 4.78, N 9.24. 
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Synthesis of 5: L4 (90 mg, 0.3 mmol) and ZnCl2 (34 mg, 0.3 mmol) were dissolved separately in MeOH 
(2.5 ml each). The methanolic solutions were combined slowly and stirred at room temperature for 
24 h. The resultant white precipitate was filtered and washed with warm MeOH and diethyl ether. 
The zinc complex was isolated as white crystals (120 mg, 84%); 1H NMR (400MHz, DMSO-d6): δH 8.82 
(br d, 2H, 3JHH = 4.0, tpy 2-H), 8.78 (br d, 2H, 
3JHH = 8.0, tpy 5-H), 8.39 (br s, 2H, tpy’ 3-H and 5-H), 8.31 
(br t, 2H, 3JHH = 8.0, tpy 4-H), 7.86 (br t, 2H, 
3JHH = 8.0, tpy 3-H), 4.58 (t, 
3JHH = 6.0, 2H, ethyl 1-H), 3.62 
(m, 4H, mor 1-H), 2.85 (t, 2H, 3JHH = 6.0, ethyl 2-H), 2.51 (m, 4H, mor 2-H); ESI-MS Calcd. for 
C21H22N4O2Cl2Zn [M]
+: 498.7 a.m.u. Found [M-Cl]+: 463.0 a.m.u.; Anal. Calcd. for C21H22N4O2Cl2Zn: C 
50.57, H 4.45, N 11.23; Found: C 50.20, H 4.40, N 10.83. 
 
 
 
 
Synthesis of 6: L4 (73 mg, 0.2 mmol) and CuCl2·2H2O (34 mg, 0.2 mmol) were dissolved separately in 
MeOH (2.5 ml each). The methanolic solutions were combined slowly and stirred at room 
temperature for 24 h. The resultant green precipitate was filtered and washed with warm MeOH and 
diethyl ether. The product was purified by slow diffusion of acetone into a concentrated aqueous 
solution. The copper complex was isolated as blue crystals (92 mg, 88%); ESI-MS Calcd. for 
C21H22N4O2Cl2Cu [M]
+: 496.9 a.m.u. Found [M-Cl]+: 460.0 a.m.u.; Anal. Calcd. for C21H22N4O2Cl2Cu∙ 
H2O: C 48.99, H 4.70, N 10.88; Found: C 48.84, H 4.60, N 10.68. 
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Synthesis of 7: L1 (54 mg, 0.23 mmol) and K2PtCl4 (96 mg, 0.23 mmol) were dissolved separately in 
DMSO (2.5 ml each). The solutions were combined slowly and stirred at room temperature for 24 h. 
The resultant deep red solution was added to acetone (20 ml) and a red solid precipitated. The 
product was filtered and washed with acetone and diethyl ether. The platinum complex was isolated 
as a red powder (75 mg, 65%); 1H NMR (400MHz, DMSO-d6): δH 8.95 (br d, 2H,
 3JHH = 8.0, tpy 2-H), 
8.69 (m, 5H, tpy 5-H, tpy’ 3-H, 5-H and 4-H), 8.54 (dt, 2H, 3JHH = 6.0, 4.0, tpy 4-H), 7.98 (dt, 2H, 
3JHH = 
6.0, 4.0, tpy 3-H); ESI-MS Calcd. for C15H11Cl2N3Pt [M]
+: 498.0 a.m.u. Found [M+Na]+: 520.0 a.m.u. 
 
 
 
 
Synthesis of 11: L2 (102 mg, 0.28 mmol) and KAuCl4 (107 mg, 0.28 mmol) were stirred in water (10 
ml) at room temperature, 1M HCl(aq)was then used to adjust the pH to 3. After which the reaction 
was allowed to stir at 50oC for 2 h. The mixture was heated to 85oC for a further 2 h. During this time 
the solution turned red. Upon cooling the solution a saturated aqueous solution of NaPF6 was added 
to give the product as a pink solid. The solid was filtered and washed thoroughly with water (10 ml) 
and diethyl ether (10 ml). The protonated mono-arm complex was isolated as a pale pink powder (85 
mg, 28 %); 1H NMR (400MHz, DMSO-d6): δH 9.21 (dd, 2H, 
3JHH = 6.0 
4JHH = 2.0, tpy 2-H), 8.74 (td, 2H, 
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3JHH = 6.0, 6.0 
4JHH = 2.0, tpy 4-H), 8.58 (dd, 2H, 
3JHH = 6.0 
4JHH = 2.0, tpy 5-H), 8.15 (td, 2H, 
3JHH = 6.0,  
6.0 4JHH= 2.0, tpy 3-H), 8.07 (s, 2H, tpy’ 3-H and 5-H), 4.84 (t, 2H,
3JHH = 4.0, ethyl 1-H), 3.69 (m, 3H, 
ethyl 2-H and pip N+-H), 3.12 (m, 4H, pip 1-H), 1.87 (m, 4H, pip 2-H), 1.58 (m, 2H, pip 3-H); 31P NMR 
(400MHz, DMSO-d6): δP -144.67 (sept, 3P, 
1JPF = 1756, PF6); Anal. Calcd. for C22H25AuClF18N4OP3.2H2O: 
C 24.82, H 2.75, N 5.26; Found: C 24.58, H 2.45, N 5.30. 
 
 
 
Synthesis of 12: L3 (104 mg, 0.30 mmol) and KAuCl4 (114 mg, 0.30 mmol) were stirred in water (10 
ml) at room temperature, 1M HCl(aq)was then used to adjust the pH to 3. After which the reaction 
was allowed to stir at 50oC for 2 h. The mixture was heated to 85oC for a further 2 h. During this time 
the solution turned red. Upon cooling the solution a saturated aqueous solution of NaPF6 was added 
to give the product as a pink solid. The solid was filtered and washed thoroughly with water (10 ml) 
and diethyl ether (10 ml). The protonated mono-arm complex was isolated as a pale pink powder 
(112 mg, 36 %); 1H NMR (400MHz, DMSO-d6): δH 9.21 (dd, 2H, 
3JHH = 6.0 
4JHH = 2.0, tpy 2-H), 8.74 (td, 
2H, 3JHH = 6.0, 6.0 
4JHH = 2.0, tpy 4-H), 8.58 (dd, 2H, 
3JHH = 6.0 
4JHH = 2.0, tpy 5-H), 8.15 (td, 2H, 
3JHH = 
6.0, 6.0 4JHH = 2.0, tpy 3-H), 8.06 (s, 2H, tpy’ 3-H and 5-H), 4.81 (t, 2H, 
3JHH = 4.0, ethyl 1-H), 3.84 (m, 
1H, pip N+-H), 3.82 (t, 2H, 3JHH = 4.0, ethyl 2-H), 3.26 (m, 4H, pyr 1-H), 2.10 (m, 4H, pyr 2-H);
 31P NMR 
(400MHz, DMSO-d6): δP -144.67 (sept, 3P, 
1JPF = 1756, PF6); Anal. Calcd. for C21H23AuClF18N4OP3.H2O: C 
24.42, H 2.44, N 5.42; Found: C 23.93, H 2.27, N 5.07. 
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Synthesis of 13: 7 (100 mg, 0.19 mmol) and L18 (108 mg, 0.76 mmol) were stirred in water (10 ml) at 
room temperature for 48 h to afford a deep purple solution. After removing excess thiol by 
extraction with diethyl ether (10 ml × 3) the aqueous layer was removed under reduced pressure. 
The resultant solid was washed thoroughly with diethyl ether (20 ml). The desired complex was 
isolated as dark red crystals (80 mg, 71%); 1H NMR (400MHz, D2O): δH 8.93 (d, 2H,
 3JHH = 6.0, tpy 2-H), 
8.29 (t, 1H, 3JHH = 8.0, tpy’ 4-H), 8.24 (td, 2H, 
3JHH = 8.0, 4.0, tpy 4-H), 8.11 (d, 2H, 
3JHH = 8.0, tpy 5-H), 
8.07 (d, 2H, 3JHH = 8.0, tpy’3-H and 5-H), 7.68 (td, 2H, 
3JHH = 6.0, 4.0, tpy 3-H), 3.18 (m, 3H, ethyl 1-H 
and pip N+-H), 2.99 (br s, 4H, pip 1-H), 2.63 (t, 2H, 3JHH = 8.0, ethyl 2-H), 1.62 (br s, 4H, pip 2-H), 1.45 
(br s, 2H, pip 3-H); 13C NMR (400MHz, D2O): δC 158.78, 153.40, 152.19, 142.70, 129.53, 129.12, 
126.02, 124.45, 59.59, 52.52, 23.68, 22.86, 21.43; ESI-MS Calcd. for C22H26Cl2N4PtS [M]
+: 643.2 a.m.u. 
Found [M-2Cl]+: 572.0 a.m.u.; Anal. Calcd. for C22H26Cl2N4PtS∙3H2O:C 37.83, H 4.62, N 8.02; Found: C 
37.83, H 4.22, N 7.82. 
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Synthesis of 14: 8 (100 mg, 0.16 mmol) and L18 (139 mg, 0.96 mmol) were stirred in water (15 ml) at 
40oC for 48 h to afford an orange solution. After removing excess thiol by extraction with diethyl 
ether (20 ml × 3) the aqueous layer was removed under reduced pressure. The resultant solid was 
purified by alumina column chromatography using 100% DCM to give the product as a chloride salt. 
In order to form the PF6 salt the solid was dissolved in the minimum amount of DMSO, to which 
excess NaPF6 (as an aqueous solution) was added dropwise. This yielded a red precipitate which was 
isolated by filtration and washed repeatedly diethyl ether. The di-arm complex was isolated as an 
orange powder (15 mg, 13%);1H NMR (400MHz, DMSO-d6): δH 9.40 (d, 2H,
 3JHH = 4.0, tpy 2-H), 8.73 (d, 
2H, 3JHH = 6.0, tpy 5-H), 8.59 (t, 2H, 
3JHH = 6.0, tpy 4-H), 8.42 (s, 2H, tpy 3’-H and 5’-H), 8.03 (t, 2H, 
3JHH 
= 6.0, tpy 4-H), 4.77 (t, 2H, 3JHH = 4.0, O-ethyl 1-H), 3.70 (t, 2H, 
3JHH = 4.0, O-ethyl 2-H), 3.60 (br s, 4H, 
O-pip 1-H), 3.12 (m, 2H, S-ethyl 1-H), 2.82 (m, 2H, S-ethyl 2-H), 1.90 (m, 4H, S-pip 1-H), 1.74 (m, 10H, 
S-pip 2-H, O-pip 2-H and pip N+-H), 1.55 (m, 4H, S-pip 3-H, O-pip 3-H); 31P NMR (400MHz, DMSO-d6): 
δP -144.19 (sept, 3P, 
1JPF = 1760, PF6); ESI-MS Calcd. C29H40F18N5OP3PtS [M]
+: 1135.2 a.m.u. Found [M-
PF6]
+: 991.0 a.m.u., [M-2PF6]
+: 846.0 a.m.u., [M-3PF6]
+: 699.2 a.m.u.; Anal. Calcd. for 
C29H40F18N5OP3PtS∙H2O: C 30.16, H 3.67, N 6.07; Found: C 29.71, H 3.63, N 5.71. 
 
 
 
Synthesis of 15: 10 (100 mg, 0.16 mmol) and L18 (139 mg, 0.96 mmol) were stirred in water (15 ml) at 
40oC for 48 h to afford an orange solution. After removing excess thiol by extraction with diethyl 
ether (20 ml × 3) the aqueous layer was removed under reduced pressure. The resultant solid was 
dissolved in the minimum amount of DMSO, to which excess NaPF6 (as an aqueous solution) was 
added dropwise. This yielded a red precipitate which was isolated by filtration and washed 
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repeatedly diethyl ether. The di-arm complex was isolated as an orange powder (23 mg, 21%); 1H 
NMR (400MHz, DMSO-d6): δH 9.39 (d, 2H,
 3JHH = 4.0, tpy 2-H), 8.70 (d, 2H, 
3JHH = 6.0, tpy 5-H), 8.57 (t, 
2H, 3JHH = 6.0, tpy 4-H), 8.41 (s, 2H, tpy’ 3-H and 5-H), 8.01 (t, 2H, 
3JHH = 6.0, tpy 3-H), 4.70 (br s, 2H, O-
ethyl 1-H), 4.07 (br s, 2H, O-ethyl 2-H), 3.76 (br s, 4H, O-mor, 1-H), 3.60 (br s, 4H, O-mor, 2-H), 3.09 
(t, 2H, 3JHH = 8.0, S-ethyl 1-H),  2.95 (t, 2H,
 3JHH = 8.0, S-ethyl 2-H), 2.82 (m, 4H, S-pip 1-H), 1.78 (m, 4H,  
S-pip, 2-H),  1.61 (m, 2H, pip N+-H and mor N+-H), 1.33 (m, 2H, S-pip 3-H); 31P NMR (400MHz, DMSO-
d6): δP -144.20 (sept, 3P,
1JPF = 1752, PF6); ESI-MS Calcd. C28H38F18N5O2P3PtS [M]
+: 1136.1 a.m.u. Found 
[M-PF6]
+: 993.2 a.m.u., [M-2PF6]
+: 847.2 a.m.u., [M-3PF6]
+: 701.2 a.m.u.; Anal. Calcd. for 
C28H38F18N5O2P3PtS∙3H2O: C 28.20, H 3.72, N 5.87; Found: C 28.02, H 3.44, N 5.50. 
 
 
 
Synthesis of 16: K2PtCl4 (0.23 mg, 0.055 mmol) was added to DMSO (3 ml) at 50
oC. To this, a solution 
of L7 (0.24 mg, 0.05 mmol) in DMSO (3 ml) was added dropwise and the resulting mixture was stirred 
for 15 h to yield a deep orange solution. The solution was then added dropwise to acetone (ca. 100 
ml) and a yellow solid precipitated. The product was isolated by filtration and repeatedly washed 
with acetone. This solid was dissolved in the minimum amount of DMSO, to which an excess of 
NaPF6 (as an aqueous solution) was added dropwise. The resultant yellow precipitate was isolated by 
filtration and washed repeatedly with water, methanol and diethyl ether. The yellow solid was dried 
under reduced pressure to yield the platinum complex (23 mg, 55%); 1H NMR (400MHz, DMSO-d6): 
δH 8.43 (d, 2H, 
3JHH = 8.0, tpy’ 3-H and 5-H), 8.28 (d, 2H, 
3JHH = 8.0, tpy 5-H), 8.14 (t, 1H, 
3JHH = 8.0, tpy’ 
4-H), 7.99 (t, 2H, 3JHH = 8.0, tpy 4-H), 7.02 (d, 2H, 
3JHH = 8.0, tpy 3-H), 4.81 (t, 4H,
 3JHH = 4.0, ethyl 1-H), 
3.60 (t, 4H, 3JHH = 6.0, ethyl 2-H), 1.86 (m, 8H, pip 1-H), 1.71 (m, 8H, pip 2-H), 1.42 (m, 4H, pip 3-H); 
31P NMR (400MHz, DMSO-d6): δP -144.21 (sept, 1P, 
1JPF = 1756, PF6); ESI-MS Calcd. for 
C29H37ClF6N5O2PPt [M]
+: 862.2 a.m.u. Found [M-PF6+ K+ Na]
+: 780.0 a.m.u.;  Anal. Calcd. for 
C29H37ClF6N6O2PPt∙1.3DMSO: C 39.94, H 4.75, N 7.37; Found: C 40.34, H 4.32, N 7.00. 
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Synthesis of 17: L7 (100 mg, 0.20 mmol) and KAuCl4 (77 mg, 0.20 mmol) were stirred in water (10 ml) 
at room temperature, 1M HCl(aq)was then used to adjust the pH to 3. After which the reaction was 
allowed to stir at 50oC for 2 h. The mixture was heated to 85oC for a further 2 h. During this time the 
solution turned red. Upon cooling the solution a saturated aqueous solution of NaPF6 was added to 
give the product as a yellow solid. The solid was filtered and washed thoroughly with water (10 ml) 
and diethyl ether (10 ml). The gold complex was isolated as a yellow powder (42 mg, 20%); 1H NMR 
(400MHz, DMSO-d6): δH 8.44 (d, 2H, 
3JHH = 8.0, tpy’ 3-H and 5-H), 8.29 (d, 2H, 
3JHH = 8.0, tpy 5-H), 8.15 
(t, 1H, 3JHH = 8.0, tpy’ 4-H), 8.00 (t, 2H,
 3JHH = 8.0, tpy 4-H), 7.03 (d, 2H,
 3JHH = 8.0, tpy 3-H), 4.80 (t, 4H,
 
3JHH = 4.0, ethyl 1-H), 3.61 (t, 4H,
 3JHH = 6.0, ethyl 2-H), 3.07 (m, 2H, pip N
+-H), 1.85 (m, 8H, pip 1-H), 
1.71 (m, 8H, pip 2-H), 1.41 (m, 4H, pip 3-H); 31P NMR (400MHz, DMSO-d6): δP -144.55 (sept, 3P, 
1JPF = 
1752, PF6); ESI-MS Calcd. for C29H37AuClF12N5O2P2 (M
+): 1010.0 a.m.u. Found (M-PF6+ K+ Na
+): 781.0 
a.m.u.; Anal. Calcd. for C29H37AuClF12N5O2P2: C 36.49, H 3.69, N 6.93; Found: C 36.42, H 3.69, N 7.13. 
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Synthesis of 18: L9 (100 mg, 0.2 mmol) and ZnCl2 (63 mg, 0.5 mmol) were dissolved separately in 
MeOH (2.5 ml each). The methanolic solutions were combined slowly and stirred at room 
temperature for 24 h. The resultant white precipitate was filtered and washed with warm MeOH and 
diethyl ether. The di-zinc complex was isolated as a white powder (131 mg, 81%); 1H NMR (400MHz, 
DMSO-d6): δH 8.93 (br s, 2H, py 2-H), 8.83 (d, 2H, 
3JHH = 4.0,tpy 2-H), 8.70 (d, 2H, 
3JHH = 8.0, tpy 5-H), 
8.34 (t, 2H, 3JHH = 8.0, tpy 4-H), 8.26 (s, 2H, tpy’ 3-H and 5-H), 8.07 (br s, 2H, py 4-H),7.88 (ddd, 2H, 
3JHH = 8.0, 8.0, tpy 3-H), 7.60 (d, 2H, 
3JHH = 4.0, py 5-H), 7.59 (br s, 2H, py 3-H), 4.54 (br s, 2H, ethyl 1-
H), 4.37 (br s, 4H, py 6-H), 3.12 (br s, 2H, ethyl 2-H); 13C NMR (400MHz, DMSO-d6): ESI-MS Calcd. 
C29H26Cl4N6OZn2 [M]
+: 745.9 a.m.u. Found [M-2Cl]+: 673.0 a.m.u.; Anal. Calcd. for 
C29H26Cl4N6OZn2∙2H2O: C 44.47, H 3.86, N 10.73; Found: C 44.59, H 3.43, N 10.23. 
 
 
 
Synthesis of 19: L9 (100 mg, 0.2 mmol) and CuCl2·2H2O (80 mg, 0.5 mmol) were dissolved separately 
in MeOH (2.5 ml each). The methanolic solutions were combined slowly and stirred at room 
temperature for 24 h. The resultant green precipitate was filtered and washed with warm MeOH and 
diethyl ether. The product was purified by slow diffusion of acetone into a concentrated aqueous 
solution. The di-copper complex was isolated as blue crystals (120 mg, 70%); ESI-MS Calcd. 
C29H26Cl4Cu2N6O [M]
+: 741.9 a.m.u. Found [M-2Cl]+: 672.0 a.m.u.; Anal. Calcd. for C29H26Cl4Cu2N6O∙ 
4H2O: C 42.71, H 4.20, N 10.31; Found: C 42.64, H 3.76, N 9.97. 
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Synthesis of 20: L9 (100 mg, 0.2 mmol) and K2PtCl4 (63 mg, 0.5 mmol) were dissolved separately in 
DMSO (3 ml each). The solutions were combined slowly and stirred at room temperature for 24 h. 
The resultant orange solution was added to acetone (20 ml) and a yellow solid precipitated. This was 
filtered and washed with acetone and diethyl ether. The solid was dissolved in the minimum amount 
of DMSO, to which excess NaPF6 (as an aqueous solution) was added dropwise. The resultant orange 
precipitate was isolated by filtration and washed repeatedly with methanol and diethyl ether.The di-
platinum complex was isolated as an orange powder (131 mg, 81%); 1H NMR (400MHz, DMSO-d6): 
8.98 (d, 2H, 3JHH = 4.0,tpy 2-H), 8.74 (d, 2H, 
3JHH = 4.0, tpy 5-H), 8.61 (d, 2H, 
3JHH = 4.0, py 2-H), 8.55 (dt, 
2H, 3JHH = 4.0, 4.0 
4JHH = 1.0, tpy 4-H), 8.18 (dt, 2H, 
3JHH = 4.0, 4.0 
4JHH = 1.0, py 4-H), 8.06 (s, 2H, tpy’ 3-
H and 5-H), 7.99 (ddd, 2H, 3JHH = 4.0, 2.0, tpy 3-H), 7.89 (d, 2H, 
3JHH = 8.0, py 5-H), 7.53 (br t, 2H, 
3JHH = 
8.0, py 3-H), 5.49 (d, 2H, 2JHH = 16.0, py 6-H), 4.96 (d, 2H, 
2JHH = 16.0, py 6’-H), 4.73 (br s, 2H, ethyl 1-
H), 3.75 (br s, 2H, ethyl 2-H); 31P NMR (400MHz, DMSO-d6): δP -144.20 (sept, 2P, 
1JPF = 1756, PF6); ESI-
MS Calcd. for C29H26Cl2F12N6OP2Pt2 [M]
+: 1225.0 a.m.u Found [M-2PF2+2Na]
+: 980.0 a.m.u.; Anal. 
Calcd. for C29H26Cl2F12N6OP2Pt2: C 28.42, H 2.14, N 6.89; Found: C 28.43, H 2.12, N 6.73. 
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Synthesis of 21: L10 (50 mg, 0.06 mmol) and ZnCl2 (3.2 mg, 0.23 mmol) were dissolved separately in 
MeOH (2.5 ml each). The methanolic solutions were mixedslowly and stirred at room temperature 
for 24 h. The resultant white precipitate was filtered and washed with warm MeOH and diethyl 
ether. The tri-metallic complex was isolated as a white powder (26 mg, 33%); 1H NMR (400MHz, 
DMSO-d6): δH 8.88 (d, 4H, 
3JHH = 4.0, py 2-H), 8.14 (m, 2H, tpy’ 3-H and 5-H), 8.10 (m, 4H, py 4-H), 
8.07 (m, 1H, tpy’ 4-H), 8.06 (m, 2H, tpy 3-H), 7.87 (m, 2H, tpy 4-H), 7.62 (d, 4H, 3JHH = 8.0, py 5-H), 
7.60 (t, 4H, 3JHH = 8.0, py 3-H), 6.96 (d, 2H, 
3JHH = 4.0, tpy 5-H), 4.42 (t, 4H, 
3JHH = 4.0, ethyl 1-H), 4.35 
(br s, 8H, py 6-H), 3.18 (t, 4H, 3JHH = 4.0, ethyl 2-H); ESI-MS Calcd. C43H41Cl6N9O2Zn3 [M]
+: 1124.9 
a.m.u. Found [M-3Cl]+: 1016.0 a.m.u.; Anal. Calcd. for C43H41Cl6N9O2Zn3·H2O: C 45.19, H 3.79, N 
11.03; Found: C 44.72, H 3.39, N 10.59. 
 
 
Synthesis of 22: L10 (50 mg, 0.06 mmol) and CuCl2·2H2O (3.9 mg, 0.23 mmol) were dissolved 
separately in MeOH (2.5 ml each). The methanolic solutions were combined slowly and stirred at 
room temperature for 24 h. The resultant white precipitate was filtered and washed with warm 
MeOH and diethyl ether. The tri-metallic complex was isolated as a white powder (18 mg, 33%); ESI-
MS Calcd. C43H41Cl6Cu3N9O2 [M]
+: 1119.9 a.m.u. Found [M-3Cl]+: 1011.0 a.m.u.; Anal. Calcd. for 
C43H41Cl6Cu3N9O2·H2O: C 45.19, H 3.79, N 11.03; Found: C 44.72, H 3.39, N 10.59. 
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Synthesis of 23: L10 (50 mg, 0.06 mmol) and K2PtCl4 (10 mg, 0.23 mmol) were dissolved separately in 
DMSO (3 ml each). The solutions were combined slowly and stirred at room temperature for 24 h. 
The resultant orange solution was added to acetone (20 ml) giving a yellow precipitate. This was 
filtered and washed with acetone and diethyl ether. The solid was dissolved in the minimum amount 
of DMSO, to which excess NaPF6 (as an aqueous solution) was added dropwise. The resultant orange 
precipitate was isolated by filtration and washed repeatedly with methanol and diethyl ether. The 
tri-metallic complex was isolated as an orange powder (37 mg, 29%);1H NMR (400MHz, DMSO-d6): δH 
8.71 (d, 4H, 3JHH = 4.0, py 2-H), 8.16 (m, 2H, tpy’ 3-H and 5-H), 8.14 (m, 4H, py 4-H), 8.10 (m, 1H, tpy’ 
4-H), 8.09 (m, 2H, tpy 3-H), 7.87 (m, 2H, 3JHH = 4.0, tpy 4-H), 7.81 (d, 4H, 
3JHH = 8.0, py 5-H), 7.49 (t, 4H, 
3JHH = 8.0, py 3-H), 6.82 (d, 2H, 
3JHH = 4.0, tpy 5-H), 5.42 (d, 4H, 
3JHH = 16.0, py 6-H), 4.97 (d, 4H, 
3JHH = 
16.0, py 6’-H), 4.70 (t, 4H, 3JHH = 6.0, ethyl 1-H), 3.45 (t, 4H, 
3JHH = 6.0, ethyl 2-H); 
31P NMR (400MHz, 
DMSO-d6): δP -144.20 (sept, 3P, 
1JPF = 1758, PF6); ESI-MS Calcd. for C43H41Cl3F18N9O2P3Pt3 (M
+): 1872.0 
a.m.u. Found (M-3PF6 - 3Cl + Na
+): 1323.0 a.m.u. 
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Synthesis of 24: L12 (50 mg, 0.13 mmol) and Pt(COD)Cl2 (49 mg, 0.13 mmol) were placed in water (7 
ml) and stirred at 75oC for 3 h. During this time the reactants completely dissolved giving a yellow 
solution. Upon cooling the reaction mixture a saturated aqueous solution of NaPF6 was added to 
give the product as an orange solid. The solid was filtered and washed thoroughly with water (10 ml) 
and diethyl ether (10 ml). The mono-arm complex was isolated as a orange powder (15 mg, 13%); 1H 
NMR (400MHz, DMSO-d6): δH 9.18 (d, 1H, 
3JHH = 8.0, phen 2-H), 8.76 (m, 4H, pyridyl 2-H, phen 4-H, 9-
H and 10-H), 8.70 (d, 1H, 3JHH = 8.0, pyridyl 5-H), 8.56 (t, 1H, 
3JHH = 8.0, phen 3-H), 8.04 (t, 1H, 
3JHH = 
8.0, pyridyl 3-H), 7.98 (t, 1H, 3JHH = 8.0, pyridyl 4-H), 7.70 (s, 1H, phen 6-H), 4.73 (br s, 3H, ethyl 1-H 
and pip N+-H), 3.71 (br s, 2H, ethyl 2-H), 3.31 (m, 4H, pip 1-H), 1.81 (m, 4H, pip 2-H), 1.58 (m, 2H, pip 
3-H); 31P NMR (400MHz, DMSO-d6): δP -144.2 (sept, 2P, 
1JP-F = 1756, PF6); ESI-MS Calcd. 
C24H25ClF12N4OP2Pt [M]
+: 905.0 a.m.u. Found [M-PF6]
+: 759.0 a.m.u., [M-2PF6]
+: 615.0 a.m.u.; Anal. 
Calcd. for C24H25ClF12N4OP2Pt: C 31.82, H 2.78, N 6.18; Found: C 31.24, H 2.97, N 5.32. 
 
 
 
 
Synthesis of 26: L13 (50 mg, 0.19 mmol) and Pt(COD)Cl2 (73 mg, 0.19 mmol) were placed in water (7 
ml) and stirred at 75oC for 3 h. During this time the reactants completely dissolved giving a deep 
orange solution. Upon cooling the solution, the solvent was removed to give a red solid. The solid 
was then washed thoroughly with water (10 ml) and diethyl ether (10 ml). The platinum(II) complex 
was isolated as a red powder (49 mg, 49%); 1H NMR (400MHz, DMSO-d6): δH 9.12 (dd, 1H, 
3JHH = 4.0, 
2.0, phen 2-H), 9.01 (dt, 1H, 3JHH = 4.0, 2.0, pyridyl 2-H), 8.78 (m, 2H, phen 9-H and 4-H), 8.71 (m, 2H, 
phen 10-H and pyridyl 5-H), 8.53 (td, 1H, 3JHH = 4.0, 2.0, phen 3-H), 8.23 (d, 2H, 
3JHH = 8.0, phen 6-H 
and 7-H), 8.12 (dd, 1H, 3JHH = 4.0, 2.0, pyridyl 3-H), 7.95 (ddd, 1H, 
3JHH = 4.0, 2.0, pyridyl 4-H). 
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Synthesis of 27: 26 (25 mg, 0.048 mmol) and L18 (35 mg, 0.240 mmol) were stirred in water (5 ml) at 
40oC for 48 h to afford an orange solution. After removing excess thiol by extraction with diethyl 
ether (10 ml × 3) the aqueous layer was removed under reduced pressure. The resultant solid was 
dissolved in the minimum amount of DMSO, to which excess NaPF6 (as an aqueous solution) was 
added dropwise. This yielded apurple precipitate which was isolated by filtration and washed 
repeatedly with water and diethyl ether. The mono-arm complex was isolated as an purple powder 
(28 mg, 66%); 1H NMR (400MHz, DMSO-d6): δH 9.39 (d, 1H, 
3JHH = 8.0, phen 2-H), 9.35 (d, 1H, 
3JHH = 
4.0, pyridyl 2-H), 9.22 (d, 1H, 3JHH = 8.0, phen 9-H), 9.10 (d, 1H, 
3JHH = 8.0, phen 4-H), 8.94 (d, 1H, 
3JHH = 
8.0, phen 10-H), 8.80 (d, 1H, 3JHH = 4.0, pyridyl 5-H), 8.59 (t, 1H, 
3JHH = 8.0, phen 3-H), 8.38 (dd, 2H, 
3JHH = 8.0, phen 6-H and 7-H), 8.27 (dd, 1H, 
3JHH = 8.0, 4.0, pyridyl 3-H), 8.05 (t, 1H, 
3JHH = 8.0, pyridyl 4-
H), 2.92 (m, 2H, ethyl 1-H), 2.81 (m, 2H, ethyl 2-H), 2.67 (m, 1H, pip N+-H), 1.74 (m, H, pip 1-H), 1.59 
(m, 6H, pip 2-H and 3-H); 31P NMR (400MHz, DMSO-d6): δP -144.8 (sept, 2P, 
1JP-F = 1756, PF6); ESI-MS 
Calcd. for C24H25F12N4P2PtS [M]
+: 886.6 a.m.u. Found [M+3H+-2PF6]
+: 623.0a.m.u.; Anal. Calcd. for 
C24H25F12N4P2PtS∙2HCl: C 30.04, H 2.84, N5.84; Found: C 29.52, H 2.83, N 5.21. 
 
 
Synthesis of 28: L14 (50 mg, 0.20 mmol) and sodium acetate (16 mg, 0.20 mmol) were stirred in 
acetonitrile (10 ml) for 10 min. K2PtCl4 (81 mg, 0.20 mmol) and DMSO (0.5 mL) were then added. The 
reaction mixture was warmed to 65oC and stirred for 3 days. After which the volume of the solution 
was reduced to ca. 5 ml under vacuum. The resultant precipitate was filtered, washed with water, 
chilled methanol and diethyl ether, and dried at room temperature. A red/brown solid was obtained 
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(45 mg, 48%); 1H NMR (400MHz, DMSO-d6, ppm): δH 9.06 (dd, 1H,
 3JHH = 4.0, 2.0, phen 2-H), 8.90 (dd, 
1H, 3JHH = 4.0, 2.0, phen 3-H), 8.72 (dd, 1H,
 3JHH = 4.0, 2.0, phen 9-H), 8.26 (d, 1H,
 3JHH = 8.0, phen 10-
H), 8.15 (dd, 3H, 3JHH = 4.0, 2.0, phen 4-H, 6-H and 7-H), 7.76 (dd, 1H, 
3JHH = 4.0, 2.0, phenyl 2-H), 7.56 
(dd, 1H, 3JHH = 4.0, 2.0, phenyl 4-H), 7.21 (td, 1H, 
3JHH = 4.0, 2.0, phenyl 3-H), 7.14 (td, 1H, 
3JHH = 4.0, 
2.0, phenyl 5-H); ESI-MS Calcd. for C18H12ClN2Pt [M]
+: 486.6 a.m.u. Found [M-Cl+H]+: 452.0 a.m.u. 
 
 
Synthesis of 29: L15 (50 mg, 0.13 mmol) and sodium acetate (11 mg, 0.13 mmol) were stirred in 
acetonitrile (10 ml) for 10 min. K2PtCl4 (54 mg, 0.13 mmol) and DMSO (0.5 ml) were then added. The 
reaction mixture was warmed to 65oC and stirred for 3 days. After which the volume of the solution 
was reduced to ca. 5 ml under vacuum. The resultant precipitate was filtered, washed with water, 
chilled methanol and diethyl ether, and dried at room temperature. Upon re-crystallisation with 
DCM, the platinum complex was obtained as a yellow-brown solid. (17 mg, 21%); 1H NMR (400MHz, 
DMSO-d6, ppm): δH 8.84 (d, 1H,
 3JHH = 4.0, phen 2-H), 8.65 (d, 1H,
 3JHH = 8.0, phen 4-H), 8.61 (d, 1H,
 3JHH 
= 8.0, phenyl 3-H), 8.20 (d, 1H, 3JHH = 8.0, phenyl 2-H), 8.03 (dd, 1H,
 3JHH = 4.0, 4.0, phen 3-H), 7.73  (d, 
1H, 3JHH = 8.0, phenyl 4-H), 7.56 (d, 1H,
 3JHH = 8.0, phen 9-H), 7.51 (s, 1H, phen 7-H), 7.22 (d, 1H,
 3JHH =  
8.0, 8.0, phen 10-H), 7.14 (d, 1H, 3JHH = 8.0, 8.0, phenyl 5-H), 4.90 (t, 2H,
 3JHH = 4.0, ethyl 1-H), 2.90 (t, 
2H, 3JHH = 4.0, ethyl 2-H), 1.55 (m, 4H, pip 2-H), 1.43 (m, 2H, pip 3-H); ESI-MS Calcd. for C25H24ClN3OPt 
[M]+: 612.1 a.m.u. Found [M-Cl+2H]+: 578.0 a.m.u.; Anal. Calcd. for C25H24ClN3OPt·H2O: C 47.58, H 
4.15, N 6.66; Found: C 47.10, H 3.68, N 5.97. 
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Synthesis of 30: L16 (50 mg, 0.10 mmol) and sodium acetate (8 mg, 0.10 mmol) were stirred in 
acetonitrile (10 ml) for 10 min. K2PtCl4 (41 mg, 0.10 mmol) and DMSO (0.5 ml) were then added. The 
reaction mixture was warmed to 65oC and stirred for 3 days. After which the volume of the solution 
was reduced to ca. 5 ml under vacuum. The resultant precipitate was filtered, washed with water, 
chilled methanol and diethyl ether, and dried at room temperature. A brown solid was obtained (23  
mg, 32%); 1H NMR (400MHz, DMSO-d6, ppm): δH 8.82 (d, 1H,
 3JHH = 4.0, phen 2-H), 8.64 (d, 1H,
 3JHH = 
8.0, phen 3-H), 8.58 (d, 1H, 3JHH = 8.0, phen 9-H), 8.23 (d, 1H,
 3JHH = 8.0, phen 10-H), 8.01 (d, 1H,
 3JHH = 
4.0, phen 4-H), 7.49 (s, 1H, phen 7-H), 7.56 (m, 1H, phenyl 4-H), 7.29 (m, 1H, phenyl 3-H), 7.23 (m, 
1H, phenyl 5-H), 4.42 (t, 2H, 3JHH = 4.0, ethyl 1-H), 4.14 (t, 2H,
 3JHH = 4.0, ethyl’ 1-H), 2.93 (m, 2H, ethyl 
2-H), 2.74 (m, 2H, ethyl’ 2-H), 2.54 (m, 8H, pip 1-H and pip’ 1-H), 1.55 (m, 8H, pip 2-H and pip’ 2-H), 
1.43 (m, 4H, pip 3-H and pip’ 3-H); ESI-MS Calcd. for C32H38ClN4O2Pt [M]
+: 740.2 a.m.u. Found [M-
Cl+H]+: 706.0 a.m.u. 
 
 
Synthesis of 31: L17 (100 mg, 0.37 mmol) and K2PtCl4 (155 mg, 0.37 mmol) were dissolved separately 
in DMSO (2.5 ml each). The solutions were combined slowly and stirred at room temperature for 24 
h. The resultant yellow solution was added to acetone (20 ml) and a yellow precipitated. The 
product was filtered and washed with acetone and diethyl ether. The platinum complex was isolated 
as a yellow powder (152 mg, 76%); 1H NMR (400MHz, DMSO-d6): δH 9.02 (s, 2H, tpy’ 3-H and 5-H), 
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9.01 (d, 2H, 3JHH = 4.0, tpy 2-H), 8.77 (d, 2H, 
3JHH = 6.0, tpy 5-H), 8.58 (t, 2H, 
3JHH = 6.0, tpy 4-H), 8.03 (t, 
2H, 3JHH = 6.0, tpy 3-H). 
 
 
 
Synthesis of 31: L8 (500 mg, 2.1 mmol) and Zn(NO2)2.6H2O (611 mg, 2.1 mmol) were dissolved 
separately in MeOH (5 ml each). The methanolic solutions were combined slowly and stirred at room 
temperature for 2 h. The resultant white precipitate was filtered and washed with warm MeOH. The 
zinc complex was isolated as an off-white powder (489 mg, 54%); 1H NMR (400MHz, DMSO-d6): δH 
8.64 (dd, 2H, 3JHH = 8.0 
4JHH = 2.0, py 2-H), 8.15 (dt, 2H, 
3JHH = 8.0, 8.0 
4JHH = 2.0, py 4-H), 7.68 (ddd, 2H, 
3JHH = 8.0, 8.0, py 3-H),  7.65 (d, 2H, 
3JHH = 8.0, py 5-H), 4.41 (d, 2H, 
2JHH = 14.0, py 6-H), 4.30 (d, 2H, 
2JHH 
= 16.0, py 6’-H),  4.12 (br s, 2H, ethyl 1-H), 3.07 (br s, 2H, ethyl 2-H). 
 
6.4 Attempted Synthesis 
6.4.1 Attempted Synthesis of the Hetero-Nuclear Platinum(II)-Zinc(II) 
Complex 
 Method 1: 31 (60 mg, 0.11 mmol) and 32 (45 mg, 0.11 mmol) were slowly added to a stirred 
suspension of powered KOH (31 mg, 0.56 mmol) in DMSO (5 ml). The solution was stirred under 
nitrogen at 60oC for 4 h. After the period, KOH was filtered and acetone (20 ml) was added to the 
filtrate to yield a brown precipitate. The solid was filtered and washed thoroughly with acetone (10 
ml) and di-ethyl ether (10 ml). 1H NMR analysis showed that a mixture of the starting materials (31 
and 32) had been obtained, therefore the reaction did not proceed. 
Method 2: 31 (60 mg, 0.11 mmol) and L8 (27 mg, 0.11 mmol) were slowly added to a stirred 
suspension of powered KOH (31 mg, 0.56 mmol) in DMSO (5 ml). The solution was stirred under 
nitrogen at 60oC for 4 h. After this period, KOH was filtered and acetone (20 ml) was added to the 
filtrate to yield a brown precipitate. The solid was filtered and washed thoroughly with acetone (10 
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ml) and di-ethyl ether (10 ml). 1H NMR analysis showed that a mixture of the starting materials had 
been isolated (31 and L8), therefore the reaction did not proceed. 
Method 3a: 32 (50 mg, 0.13 mmol) and L17 (33 mg, 0.13 mmol) were slowly added to a stirred 
suspension of powered KOH (35 mg, 0.63 mmol) in DMSO (5 ml). The solution was stirred under 
nitrogen at 60oC for 4 h. The reaction mixture was extracted with DCM (40 ml × 3), washed 
thoroughly with water (30 ml × 3) and dried over sodium sulphate. The solvent was removed under 
reduced pressure to yield the product as a brown oily solid. 1H NMR analysis showed that L9 had 
been isolated. Although the terpyridine and DPA component had been attached, the zinc metal had 
de-coordinated from 32 during the reaction. 
Method 3b: 32 (50 mg, 0.13 mmol) and L17 (33 mg, 0.13 mmol) were slowly added to a stirred 
suspension of powered KOtBu (70 mg, 0.63 mmol) in DMSO (5 ml). The solution was stirred under 
nitrogen at 60oC for 4 h. The reaction mixture was extracted with DCM (40 ml × 3), washed 
thoroughly with water (30 ml × 3) and dried over sodium sulphate. The solvent was removed under 
reduced pressure to yield the product as a brown oily solid. 1H NMR analysis showed that L9 had 
been isolated. Although the terpyridine and DPA component had been attached, the zinc metal had 
de-coordinated from 32 during the reaction. 
 
6.4.2 Attempted Synthesis of 25 
One step method: 24 (15 mg, 0.016 mmol) and L18 (14 mg, 0.016 mmol) were stirred in water (15 ml) 
at 60oC for 48 h to afford a purple solution. After removing excess thiol by extraction with diethyl 
ether (20 ml × 3) the aqueous layer was removed under reduced pressure. The resultant solid was 
dissolved in the minimum amount of DMSO, to which excess NaPF6 (as an aqueous solution) was 
added dropwise. This yielded a precipitate which was isolated by filtration and washed repeatedly 
diethyl ether. 1H NMR analysis showed that a mixture of the product (25) and side products had 
been isolated, therefore the reaction did not proceed to full conversion. 
Two step method: (a) L18 (50 mg, 0.35 mmol) was added slowly to 60% NaH (w/w) (72 mg, 1.72 
mmol) in THF (25 ml) and stirred at 0oC for 2 h under a nitrogen atmosphere. After which the 
solution was stirred at room temperature for a further 2 h. The solvent was then removed to yield 
the sodium thiolate salt corresponding to L18, as an off-white solid (42 mg, 72%).  
(b) The sodium thiolate salt (NaL18) (42 mg, 0.25 mmol) and 24 (23 mg, 0.25 mmol) were stirred in 
water (15 ml) at 60oC for 48 h to afford an orange solution. After removing excess thiol by extraction 
179 
 
with diethyl ether (20 ml × 3) the aqueous layer was removed under reduced pressure. The resultant 
solid was dissolved in the minimum amount of DMSO, to which excess NaPF6 (as an aqueous 
solution) was added dropwise. This yielded a precipitate which was isolated by filtration and washed 
repeatedly diethyl ether. 1H NMR analysis that a mixture of the starting materials had been isolated 
(L18 and 24), therefore the reaction did not proceed. 
  
6.5 Variable Temperature and Variable Concentration 1H NMR Spectroscopic 
Studies 
The 1H NMR spectroscopic studies were carried out in DMSO-d6.  For the variable concentration 
1H 
NMR studies, various concentrations were used (0.000625 - 0.02 M). Spectra were recorded on a 
BrukerAvance 400 MHz Ultrashield NMR spectrometer.The variable temperature 1H NMR studies 
were conducted on a BrukerAvance 500 MHz Ultrashield NMR spectrometer. The 1H NMR spectra 
were recorded at 293-433 K. The concentration used for the VT studies was 0.008 M. 
 
6.6 Variable Concentration UV-Vis Spectroscopic Studies 
The UV-Vis spectroscopic studies were carried out in DMSO. Seven different concentrations were 
tested: 0.00125 M, 0.0025 M, 0.005 M, 0.01 M, 0.02 M, 0.03 M, 0.035 M and 0.04 M.The UV-Vis 
spectra were recorded on a Perkin Elmer Lambda 25 spectrometer. 
 
6.7 Fluorescent Intercalator Displacement (FID) Assay 
Oligonucleotide Preparation for FID Assay: All the oligonucleotides used were purchased from 
Eurogentec S.A. (U.K.). The 22AG strand (5’-AGG-GTT-AGG-GTT-AGG-GTT-AGG-G-3’) and 20AG 
strand (5’-GG-GAG-GGT-GGG-GAG-GGT-GGG-3’) were used for the human telomeric and c-myc 
studies, respectively. For the duplex DNA studies, a 17 basepair complementary strand (5’-GGG-TTA-
CTA-CGA-ACT-GG-3’ with 5’-CCA-GTT-CGT-AGT-AAC-CC-3’) and a 26 base pair self-complimentary 
strand (5’-CAA-TCG-GAT-CGA-ATT-CGA-TCC-GAT-TG-3’) were used. The oligonucleotides were 
dissolved in Milli Q water to yield 20 μM stock solutions. This was then diluted using 10 mM 
potassium cacodylate (pH 7.4)/ 50 mM potassium chloride (60 mM K+) buffer to the appropriate 
concentrations. Prior to use in the FID assay, the DNA strands were annealed by heating to 95°C for 
5 min and then by cooling to room temperature overnight. 
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Sample Preparation: The test compounds and thiazole orange (TO) were dissolved in DMSO to give 1 
mM stock solutions. The corresponding solution was then diluted using 10 mM potassium 
cacodylate (pH 7.4)/50 mM potassium chloride (60 mM K+) buffer to the appropriate concentrations. 
FID Assay Procedure: The FID assay was carried out as previously reported. To a mixture of DNA 
sequence (0.25 μM) and TO (0.50 μM) in 10 mM potassium cacodylate (pH 7.4)/ 50 mM potassium 
chloride (60 mM K+) buffer an increasing amount of the corresponding molecule under study was 
added (0.0625 to 10 μM, which corresponds to 0.25 to 40 equiv). After an equilibration time of 3 min 
the emission spectrum was recorded between 510 and 750 nm with an excitation wavelength of 501 
nm. This was recorded using a Varian Cary Eclipse Spectrometer. The fluorescence area was 
calculated using the “trapezium rule” method. The area was converted into percentage TO 
displacement by the following formula: % TO displacement = 100 − [(fluorescence area of 
sample/fluorescence area of standard) × 100]. The standard fluorescence spectrum was obtained in 
the absence of any molecule. % TO displacement was then plotted against each of the compound 
concentrations to give the respective FID curves. 
 
6.8 UV-Vis Titration Studies 
The UV-Vis spectra were recorded on a Perkin Elmer Lambda 25 spectrometer. In order to determine 
the binding constants of the selected complexes with c-myc, Htelo and ct-DNA, the complexes (10-
20 µM) were titrated with concentrated solutions of DNA (c-myc: 1.14 mM, Htelo: 2.85 mM and ct-
DNA: 3.78 mM) in 50 mM Tris-HCl (pH 7.4)/100 mM KCl buffer. A 1cm path-length quartz cuvette 
was used to carry out the measurements.The binding constants were obtained by fitting the data to 
a reciprocal plot of D/∆εap versus D using the following equation:D / ∆εap = D / ∆ε+ 1 / (∆ε × K) where 
the concentration of DNA is expressed in terms of base pairs (determined by measuring the 
absorption at 260 nm and the appropriate extinction coefficients), the apparent molar extinction 
coefficient εa = Aobserved/ [Complex], ∆εap = [εa – εf] and ∆ε = [εb – εf]. εb is the extinction coefficient of 
the DNA bound complex and  εf is the extinction coefficient of the free complex. 
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6.9 Circular Dichroism (CD) Studies 
Oligonucleotide Preparation for CD Studies: All oligonucleotides used were purchased from 
Eurogentec S.A. (U.K.). The same Htelo and c-myc DNA sequence as those used in the FID assay were 
used. The oligonucleotides were dissolved in Milli Q water to yield a 100 μM stock solution. This was 
then diluted using 50 mM Tris-HCl (pH 7.4) or 50 mM Tris-HCl (pH 7.4)/150 mM KCl buffer to 20 μM. 
Prior to use in the CD assay, the DNA solution was annealed by heating to 95°C for 5 min and then by 
cooling to room temperature. 
Sample Preparation: The test compounds were dissolved in DMSO to yield a 1 mM stock solution. 
This was then diluted using Tris-HCl or Tris-HCl/KCl buffer to the appropriate concentrations. 
CD procedure: The CD spectra were recorded in a strainfree 10 mm × 2 mm rectangular cell path 
length cuvette. The data was obtained on an Applied Photophysics Ltd Chirascan spectrometer. The 
CD spectra were measured in the wavelength region of 700-180 nm with the following parameters: 
bandwidth, 1 nm; spectral range, 230-360 nm; step-size, 0.5 nm; time-pep-point, 1.5 s. The CD 
spectra were collected and analysed using the Chirascan and Chirascan Viewer softwares 
respectively. The following CD spectra were recorded: (1) CD spectra for the Htelo sequence (10 µM) 
with and without the presence of the test compounds (20 µM, 2eq.) in Tris-HCl buffer (2) CD spectra 
for the Htelo sequence (10 µM) with varying oligonucleotide/test compound ratios (0.5- 10) in Tris-
HCl/ KCl buffer (3) variable temperature CD studies were done for the c-myc sequence (5 µM) with 
and without the presence of the test compound (10 µM, 2eq.) in Tris-HCl buffer. 
 
6.10 1H NMR Titration Studies 
Oligonucleotide Preparation for NMR Studies: d(TTAGGG) was purchased from Eurogentec S.A. 
(U.K.). The sequence was dissolved in potassium phosphate buffer (50 mM, pH 7.0) containing 300 
mM KCl to give a quadruplex concentration of 1 mM. The concentration was verified 
spectrophotometrically using the absorption value at 260 nm (ε260 = 6.89 ×10
4 cm-1 M-1). The DNA 
solution was annealed by heating to 95°C for 5 min and then by cooling to room temperature. 
Sample Preparation: The test compounds were dissolved in DMSO-d6to yield a 20 mM stock solution. 
This was used directly in the NMR studies. 
 
NMR Procedure: The 1H NMR spectrum of a 1 mM solution of quadruplex d(TTAGGG) in potassium 
phosphate buffer (50 mM,pH 7.0) containing 300 mM KCl with 10% d6-DMSO was recorded. It was 
measured using a BrukerAvance500 MHz Ultrashield NMR spectrometer. The 1H NMR spectrum was 
182 
 
obtained with a 20 ppm spectral width, 32k data points, a 2 s relaxation delay, and 64 transients at 
25 °C. Water suppression was achieved bythe Watergate method and the signal:noise ratio of the 
spectrum was improved by apodization. The quadruplex d(TTAGGG) NMR mixture was then titrated 
with a 20 mM DMSO-d6 solution of the test compound and the spectrum was re-recorded after each 
aliquot addition. The spectrum for [test compound:DNA] ratios of 0.5, 1, 1.9, 3 and 5 were 
measured. 
 
 
6.11 1 NMR Studies with Guanosine 
The 1H NMR spectra were recorded on the BrukerAvance400 MHz Ultrashield NMR spectrometer. 
The NMR spectraofguanosine (2.5 mM) and the test compound (2.5 mM) were measured in DMSO-
d6. The test compound was then added to guanosine to give a [test compound:guanosine] ratio of 1. 
This mixture was incubated at 37oC for 24 h. The spectrum of this mixture was then measured.  
 
6. 12 1H and 31P NMR Studies with Guanosine monophosphate  
The 1H and 31P NMR spectra were recorded on the BrukerAvance400 MHz Ultrashield NMR 
spectrometer. The 1H and 31P NMR spectra of guanosine monophosphate (2.5 mM) and 20 (2.5 mM) 
were measured in a 1:1 mixture of D2O and DMSO-d6. 20 was then added to guanosine 
monophosphate to give a [test compound:guanosine monophosphate] ratio of 1. This mixture was 
incubated at 37oC for 2 h. The 1H and 31P  NMR spectra of this mixture were then measured. 
 
The 1H and 31P NMR spectra were recorded on the BrukerAvance400 MHz Ultrashield NMR 
spectrometer.The 1H and 31P NMR spectrum of guanosine monophosphate (2.5 mM) was measured 
in a 1:1 mixture of D2O and DMSO-d6. Aliquots of 19 were then added to the guanosine 
monophosphate solution to give final 19 concentrations ranging form 0-30 µM. The 1H and 31P NMR 
spectra for each of concentrations were measured. 
 
6.13 1H NMR and ESI Studies with Glutathione 
The 1H NMR spectra were recorded on the BrukerAvance400 MHz Ultrashield NMR spectrometer. 
The electron spray ionisation (ESI) mass spectra were recorded on BrukerDaltronics Esquire 3000 
spectrometer. The 1H NMR spectra of glutathione (2.5 mM) and 10 (2.5 mM) were measured in 
DMSO-d6. The test compound was then added to glutathione to give a [10:glutathione] ratio of 1. 
This mixture was incubated at 37oC for 24 h. The1H NMR and ESI spectra of this mixture were then 
measured.  
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6.14 DFT Calculations for the 10-Glutathione Adduct 
The 10-glutathione adduct was optimised using DFT with a BP86 level of theory. The 6-31g** base 
set was used for all the atom, except platinum, to which the 1an1 2D2 base set was applied. 
 
6.15 Fluorescence Titration Studies 
The emission spectra were recorded on a Varian Cary Eclipse Spectrometer. 29 (20 µM) was titrated 
with concentrated solutions of DNA (c-myc: 1.14 mM, Htelo: 2.85 mM and ct-DNA: 3.78 mM) and 
various biomolecules (S-cysteine: 10 mM, glutathione: 10 mM and BSA: 10 mM) in 10 mM Tris-HCl 
(pH 7.4)/100 mM KCl buffer. The emission spectra were recorded after each aliquot addition of the 
DNA or biomolecule solutions, until a saturation in fluorescencewas reached. A 1 cm path-length 
quartz cuvette was used to carry out the measurements. 
 
6.16 Cell Culture 
The U2OS human osteosarcoma, embryonic kidney cancer 293T and GM05757 normal human 
fibroblast cell lines were obtained from Dr David Mann (Division of Cell and Molecular Biology, 
Imperial College London). The cells were maintained in Dulbecco’s Modified Eagle’s Medium 
(DMEM- low glucose) media which was supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin. All cells weregrown at 310 K in a humidified atmosphere containing 5% CO2. 
 
6.17 Cytotoxicity Studies: MTS Assay 
Various numbers of cells (5 × 104 for U20S, 5 × 104 for 293T and 1 × 104 for GM05757) were seeded 
in each well of a 96-well plate. After 24 h the cells were exposed to various concentrations of the 
test compound (0.2-500 µM) for a further 24 h (total volume 100 µL). The test compounds were 
prepared as 10 mM solutions in DMSO and diluted further using DMSO. The final concentration of 
DMSO in each well was 4%. After the incubation period, 20 µL of the MTS solution (made up of 2 
mg/mL MTS reagent + 100 µL of PMS 0.96 mg/mL) was added to each well. The mixture was 
incubated for a further 1.5 h at 37 °C. After this time, an ELISA reader was used to record the 
absorption at 490 nm and the IC50 values were determined using the Conventional Method. This 
method involves determining the Abs IC50 value for each test. This was calculated from the following 
equation: Abs IC50 = (Abs IC0 + Abs IC100)/ 2; where IC0 is the mean absorption at 490 nm of the media 
only and IC100 is the mean absorption at 490 nm of the cells only. Then the X-axis intercept of the 
dose-response curve atAbs IC50 (determined by the above equation) was considered as IC50 value for 
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each test compound. The dose-response curve is plot of absorption at 490 nm (y-axis) and the 
concentration of test compound exposed to the cells (x-axis). Prior to plotting the curve the 
background absorption (due to the reaction of the test compound and MTS reagents) was 
subtracted from the absorption values obtained from the cells that had been incubated with the 
compounds.   
6. 18 Cellular Uptake Studies 
To measure the cellular uptake of the metal complexes, ca. 2 million U2OS cells were treated with 10 
µM of the complex at 37 °C for 24 h. Then the media was removed, the cell were washed with PBS 
solution (×3), harvested and centrifuged. The cellular pellet was suspended in an appropriate volume 
of MilliQ water to obtain a homogeneous cell suspension. The suspension was divided in two. One 
part was used to analyse the metal content in the whole cell and the other was used for the 
cytoplasmic and nucleus analysis. The Thermo Scientific NE-PER Nuclear and Cytoplasmic Extraction 
Kit was used to extract the separate cytoplasmic and nuclear protein fractions. From each of the 
fraction aliquots were removed for protein determination using the Bradford Assay (carried 
according to the instructions of the manufacturer (Sigma Aldrich, micro-well plate protocol). The 
remaining cell suspension was mineralized with 65% HNO3 and then completely dried at 120°C. The 
solid extracts were re-dissolved in 2% HNO3 and analysed using ICP-MS. Cellular metal levels were 
expressed as ng Pt/mg protein, results are presented as the mean of 7 determinations for each data 
point ± standard deviation obtained in three separate experiments. 
 
6.19 Flow Cytometry Studies 
In order to monitor the cell cycle, flow cytometry studies were carried out. First ca. 2 million U2OS 
cells were treated with 10µM of the complex at 37°C for 24 h. The cells were trypsinated, keeping 
the media to avoid loss of dead cells. Then the cells were centrifuged to give cellular pellets 
(containing dead and living cells). After washing the cellular pellets with PBS (1 ml), fixing buffer 
(70% EtOH/PBS) was added dropwise (up to 1 ml) while vortexing. The cells were again centrifuged 
and the fixing buffer was aspirated. Upon washing with further PBS, 10 uL RNAse was added and the 
mixture was thoroughly vortexed. Finally the cells were re-suspended in 0.5 ml propidium Iodide 
buffer (50 µg/ml PI, PBS) and the solution was filter through a porous film. The resulting solutions 
were then used to carry out the flow cytometry studies. The studies were conducted using the FACS 
Aria III cell sorter and the FACS Calibur analysers. The data was analysed using flow cytometry 
software, FlowJo and Diva 6.2. 
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A.1 1H COSY NMR Spectra
 
Figure A-1:
1
H COSY NMR of 18 taken in DMSO-d6 at 298K 
 
 
Figure A-2: 
1
H COSY NMR of 20 taken in DMSO-d6 at 298K 
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Figure A-3: 
1
H COSY NMR of 15 taken in DMSO-d6 at 298K 
 
 
 
Figure A-4: 
1
H COSY NMR of 16 taken in DMSO-d6 at 298K 
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 Figure A-5: 
1
H COSY NMR of 24 taken in DMSO-d6 at 298K 
 
 
 Figure A-6: 
1
H COSY NMR of 29 taken in DMSO-d6 at 298K 
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A.2 Nuclear Magnetic Resonance (NMR) Spectroscopic Studies  
 
Figure A-7: The NMR spectra of d(TTAGGG) in KCl, phosphate buffer (1 mM) upon increasing equivalents of 20. The G4-6 
imino signals are observed to shift upfield and undergo line broadening. 
 
Figure A-8: The NMR spectra of d(TTAGGG) in KCl, phosphate buffer (1 mM) upon increasing equivalents of 15. The G4-6 
imino signals are observed to shift upfield and undergo line broadening. 
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A.3 Fluorescence Displacement Assay (FID): TO Displacement Curves 
0 2 4 6 8 10
0
20
40
60
80
100
%
 T
O
 d
is
p
la
c
e
m
e
n
t
Metal complex conc/ uM
 Htelo
 c-myc
 ds 17
 ds 26
 
Figure A-9: Graphical representation of TO displacement from duplex 17-mer DNA, duplex 26-mer DNA, c-myc 
quadruplex DNA and Htelo quadruplex DNA upon increasing concentration of 4 from 0.25 to 10 μM. 
 
0 2 4 6 8 10
0
20
40
60
80
100
%
 T
O
 d
is
p
la
c
e
m
e
n
t
Metal complex conc/ uM
 ds 26
 
Figure A-10: Graphical representation of TO displacement from duplex 26-mer DNA upon increasing concentration of 8 
from 0.25 to 10 μM. Data for duplex 17-mer DNA, c-myc quadruplex DNA and Htelo quadruplex DNA were recorded 
during the MSci project and have been published. 
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Figure A-11: Graphical representation of TO displacement from duplex 26-mer DNA upon increasing concentration of 10 
from 0.25 to 10 μM. Data for duplex 17-mer DNA, c-myc quadruplex DNA and Htelo quadruplex DNA were recorded 
during the MSci project and have been published. 
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Figure A-12: Graphical representation of TO displacement from duplex 17-mer DNA, duplex 26-mer DNA, c-myc 
quadruplex DNA and Htelo quadruplex DNA upon increasing concentration of 13 from 0.125 to 5 μM. 
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Figure A-13: Graphical representation of TO displacement from duplex 17-mer DNA, duplex 26-mer DNA, c-myc 
quadruplex DNA and Htelo quadruplex DNA upon increasing concentration of 14 from 0.125 to 5 μM. 
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Figure A-14: Graphical representation of TO displacement from duplex 17-mer DNA, duplex 26-mer DNA, c-myc 
quadruplex DNA and Htelo quadruplex DNA upon increasing concentration of 15 from 0.0625 to 5 μM. 
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Figure A-15: Graphical representation of TO displacement from duplex 17-mer DNA, duplex 26-mer DNA, c-myc 
quadruplex DNA and Htelo quadruplex DNA upon increasing concentration of 16 from 0.5 to 10 μM. 
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Figure A-16: Graphical representation of TO displacement from duplex 17-mer DNA, duplex 26-mer DNA, c-myc 
quadruplex DNA and Htelo quadruplex DNA upon increasing concentration of 18 from 0.125 to 10 μM. 
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Figure A-17: Graphical representation of TO displacement from duplex 17-mer DNA, duplex 26-mer DNA, c-myc 
quadruplex DNA and Htelo quadruplex DNA upon increasing concentration of 19 from 0.125 to 5 μM. 
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Figure A-18: Graphical representation of TO displacement from duplex 17-mer DNA, duplex 26-mer DNA, c-myc 
quadruplex DNA and Htelo quadruplex DNA upon increasing concentration of 20 from 0.125 to 5 μM. 
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Figure A-19: Graphical representation of TO displacement from duplex 17-mer DNA, duplex 26-mer DNA, c-myc 
quadruplex DNA and Htelo quadruplex DNA upon increasing concentration of 21 from 1.25 to 10 μM. 
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Figure A-20: Graphical representation of TO displacement from duplex 17-mer DNA, duplex 26-mer DNA, c-myc 
quadruplex DNA and Htelo quadruplex DNA upon increasing concentration of 22 from 0.25 to 10 μM. 
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Figure A-21: Graphical representation of TO displacement from duplex 17-mer DNA, duplex 26-mer DNA, c-myc 
quadruplex DNA and Htelo quadruplex DNA upon increasing concentration of 24 from 0.0625 to 5 μM. 
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Figure A-22: Graphical representation of TO displacement from duplex 17-mer DNA, duplex 26-mer DNA, c-myc 
quadruplex DNA and Htelo quadruplex DNA upon increasing concentration of 26 from 0.125 to 5 μM. 
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Figure A-23: Graphical representation of TO displacement from duplex 17-mer DNA, duplex 26-mer DNA, c-myc 
quadruplex DNA and Htelo quadruplex DNA upon increasing concentration of 27 from 0.0625 to 2.5 μM. 
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Figure A-24: Graphical representation of TO displacement from duplex 17-mer DNA, duplex 26-mer DNA, c-myc 
quadruplex DNA and Htelo quadruplex DNA upon increasing concentration of 28 from 1.25 to 2.5 μM. 
 
198 
 
0 2 4 6 8 10
0
20
40
60
80
100
 Htelo
 c-myc
 ds 17
 ds 26
Metal complex conc/ uM
%
 T
O
 d
is
p
la
c
e
m
e
n
t
 
Figure A-25: Graphical representation of TO displacement from duplex 17-mer DNA, duplex 26-mer DNA, c-myc 
quadruplex DNA and Htelo quadruplex DNA upon increasing concentration of 29 from 0.5 to 2.5 μM. 
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A.4 UV-Vis: UV-Vis Titrations and Reciprocal Plots of D/∆εap vs. D 
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Figure A-26: UV-Vis titration and reciprocal plot of D/∆εap versus D for 8 (20µM) upon addition of Htelo DNA. 
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Figure A-27: UV-Vis titration and reciprocal plot of D/∆εap versus D for 8 (20µM) upon addition of ct-DNA. 
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Figure A-28: UV-Vis titration and reciprocal plot of D/∆εap versus D for 8 (20µM) upon addition of c-myc DNA. 
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Figure A-29: UV-Vis titration and reciprocal plot of D/∆εap versus D for 10 (20µM) upon addition of Htelo DNA. 
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Figure A-30: UV-Vis titration and reciprocal plot of D/∆εap versus D for 10 (20µM) upon addition of ct-DNA. 
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Figure A-31: UV-Vis titration and reciprocal plot of D/∆εap versus D for 10 (20µM) upon addition of c-myc DNA. 
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Figure A-32: UV-Vis titration and reciprocal plot of D/∆εap versus D for 13 (20µM) upon addition of Htelo DNA. 
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Figure A-33: UV-Vis titration and reciprocal plot of D/∆εap versus D for 13 (20µM) upon addition of ct-DNA. 
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Figure A-34: UV-Vis titration and reciprocal plot of D/∆εap versus D for 13 (20µM) upon addition of c-myc DNA. 
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Figure A-35: UV-Vis titration and reciprocal plot of D/∆εap versus D for 14 (20µM) upon addition of Htelo DNA. 
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Figure A-36: UV-Vis titration and reciprocal plot of D/∆εap versus D for 14 (20µM) upon addition of ct-DNA. 
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Figure A-37: UV-Vis titration and reciprocal plot of D/∆εap versus D for 14 (20µM) upon addition of c-myc DNA. 
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Figure A-38: UV-Vis titration and reciprocal plot of D/∆εap versus D for 15 (20µM) upon addition of Htelo DNA. 
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Figure A-39: UV-Vis titration and reciprocal plot of D/∆εap versus D for 15 (20µM) upon addition of ct-DNA. 
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Figure A-40: UV-Vis titration and reciprocal plot of D/∆εap versus D for 15 (20µM) upon addition of c-mycDNA. 
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Figure A-41: UV-Vis titration and reciprocal plot of D/∆εap versus D for 16 (20µM) upon addition of Htelo DNA. 
 
250 300 350 400 450 500 550 600
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
A
b
s
o
rp
ti
o
n
/ 
a
.u
.
Wavelength/ nm
 
Figure A-42: UV-Vis titration and reciprocal plot of D/∆εap versus D for 16 (20µM) upon addition of ct-DNA. 
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Figure A-43: UV-Vis titration and reciprocal plot of D/∆εap versus D for 16 (20µM) upon addition of c-myc DNA. 
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Figure A-44: UV-Vis titration and reciprocal plot of D/∆εap versus D for 26 (20µM) upon addition of Htelo DNA. 
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Figure A-45: UV-Vis titration and reciprocal plot of D/∆εap versus D for 26 (20µM) upon addition of ct-DNA. 
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Figure A-46: UV-Vis titration and reciprocal plot of D/∆εap versus D for 26 (20µM) upon addition of c-mycDNA. 
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Figure A-47: UV-Vis titration and reciprocal plot of D/∆εap versus D for 24 (20µM) upon addition of Htelo DNA. 
 
250 300 350 400 450 500 550 600
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
A
b
s
o
rp
io
n
/ 
a
.u
.
Wavelength/ nm
 
Figure A-48: UV-Vis titration and reciprocal plot of D/∆εap versus D for 24 (20µM) upon addition of ct-DNA. 
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Figure A-49: UV-Vis titration and reciprocal plot of D/∆εap versus D for 24 (20µM) upon addition of c-myc DNA. 
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Figure A-50: UV-Vis titration and reciprocal plot of D/∆εap versus D for 27 (20µM) upon addition of Htelo DNA. 
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Figure A-51: UV-Vis titration and reciprocal plot of D/∆εap versus D for 27 (20µM) upon addition of ct-DNA. 
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Figure A-52: UV-Vis titration and reciprocal plot of D/∆εap versus D for 27 (20µM) upon addition of c-myc DNA. 
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Figure A-53: UV-Vis titration and reciprocal plot of D/∆εap versus D for 28 (20µM) upon addition of Htelo DNA. 
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Figure A-54: UV-Vis titration and reciprocal plot of D/∆εap versus D for 28 (20µM) upon addition of c-myc DNA. 
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Figure A-55: UV-Vis titration and reciprocal plot of D/∆εap versus D for 29 (20µM) upon addition of Htelo DNA. 
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Figure A-56: UV-Vis titration and reciprocal plot of D/∆εap versus D for 29 (20µM) upon addition of ct-DNA. 
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Figure A-57: UV-Vis titration and reciprocal plot of D/∆εap versus D for 29 (20µM) upon addition of c-myc DNA. 
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Figure A-58: UV-Vis titration and reciprocal plot of D/∆εap versus D for 19 (20µM) upon addition of Htelo DNA. 
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Figure A-59: UV-Vis titration and reciprocal plot of D/∆εap versus D for 19 (20µM) upon addition of ct-DNA. 
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Figure A-60: UV-Vis titration and reciprocal plot of D/∆εap versus D for 19 (20µM) upon addition of c-myc DNA. 
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Figure A-61: UV-Vis titration and reciprocal plot of D/∆εap versus D for 20 (20µM) upon addition of Htelo DNA. 
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Figure A-62: UV-Vis titration and reciprocal plot of D/∆εap versus D for 20 (20µM) upon addition of ct-DNA. 
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Figure A-63: UV-Vis titration and reciprocal plot of D/∆εap versus D for 20 (20µM) upon addition of c-myc DNA. 
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Figure A-64: The CD spectra of Htelo DNA (10 µM) in the presence of potassium ions, upon addition of increasing 
amounts of 8. 
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Figure A-65: The CD spectra of Htelo DNA (10 µM) in the presence of potassium ions, upon addition of increasing 
amounts of 15. 
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Figure A-66: The CD spectra of Htelo DNA (10 µM) in the presence of potassium ions, upon addition of increasing 
amounts of 18 
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Figure A-67: The CD spectra of Htelo DNA (10 µM) in the presence of potassium ions, upon addition of increasing 
amounts of 19. 
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Figure A-68: The CD spectra of Htelo DNA (10 µM) in the presence of potassium ions, upon addition of increasing 
amounts of 20. 
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Figure A-69: The CD spectra of Htelo DNA (10 µM) in the presence of potassium ions, upon addition of increasing 
amounts of L
9
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Figure A-70: The CD spectra of Htelo DNA (10 µM) in the presence of potassium ions, upon addition of increasing 
amounts of 26. 
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Figure A-71: The CD spectra of Htelo DNA (10 µM) in the presence of potassium ions, upon addition of increasing 
amounts of 24. 
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Figure A-72: The CD spectra of Htelo DNA (10 µM) in the presence of potassium ions, upon addition of increasing 
amounts of 27. 
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Figure A-73: The CD spectra of Htelo DNA (10 µM) in the presence of potassium ions, upon addition of increasing 
amounts of L
13
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A.5.2 Htelo DNA CD Titrations (in the absence of K+ ions) 
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Figure A-74: The CD spectra of Htelo DNA (10 µM) in the absence of salts, with and without the addition of two 
equivalents of 8, 10 and 15. 
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Figure A-75: The CD spectra of Htelo DNA (10 µM) in the absence of salts, with and without the addition of two 
equivalents of 18, 19, 20 and L
9
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A.5.3 c-myc DNA VTCD (in the absence of K+ ions) Melting Curves  
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Figure A-76: CD melting curves for c-myc DNA (5 µM) with and without the presence of 3 and 4 (2eq., 10 µM).  
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Figure A-77: CD melting curves for c-myc DNA (5 µM) with and without the presence of L
4
, 10, 13, 14 and 15 (2eq., 10 
µM).
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Figure A-78: CD melting curves for c-myc DNA (5 µM) with and without the presence of 24, 26 and 27 (2eq., 10 µM).
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Figure A-79: CD melting curves for c-myc DNA (5 µM) with and without the presence of 21 and 22 (2eq., 10 µM).
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Figure A-80: CD melting curves for c-myc DNA (5 µM) with and without the presence of TmPyP4 (2eq., 10 µM).
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A.6 1H NMR Spectra with Guanosine 
 
 
 
Figure A-81: (a) Chemical structure of 20. (b) Chemical structure of guanosine. (c; bottom) 
1
H NMR spectra obtained for 
guanosine (c; middle) 20 and (c; top) guanosine + 20 after 24 h incubation at 37
o
C.  
 
 
Figure A-82: (a) Chemical structure of 15. (b) Chemical structure of guanosine. (c; bottom) 
1
H NMR spectra obtained for 
guanosine (c; middle) 15 and (c; top) guanosine + 15 after 24 h incubation at 37
o
C.  
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Figure A-83: (a) Chemical structure of 13. (b) Chemical structure of guanosine. (c; bottom) 
1
H NMR spectra obtained for 
guanosine (c; middle) 13 and (c; top) guanosine + 13 after 24 h incubation at 37
o
C.  
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A.7 X-ray Crystallography Data 
Data for 13 
Empirical formula [C22 H26 N4 Pt S](Cl)2 . 2MeOH 
Formula weight 708.60 
Temperature 173(2) K 
Diffractometer, wavelength OD Xcalibur PX Ultra, 1.54184 Å 
Crystal system, space group Triclinic, P-1 
Unit cell dimensions a = 7.46100(15) Å 
 b = 13.0861(3) Å 
 c = 14.1346(3) Å 
Volume, Z 1348.07(5) Å3, 2 
Density (calculated) 1.746 Mg/m3 
Absorption coefficient 12.511 mm-1 
F(000) 700 
Crystal colour / morphology Red needles 
Crystal size 0.19 x 0.07 x 0.04 mm3 
θ range for data collection 3.17 to 72.47° 
Index ranges -9<=h<=9, -16<=k<=16, -17<=l<=17 
Reflns collected / unique 18509 / 5329 [R(int) = 0.0306] 
Reflns observed [F>4ϭ(F)] 4924 
Absorption correction Analytical 
Max. and min. transmission 0.632 and 0.203 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5329 / 21 / 337 
Goodness-of-fit on F2 1.054 
Final R indices [F>4ϭ(F)] R1 = 0.0295, wR2 = 0.0729 
R indices (all data) R1 = 0.0340, wR2 = 0.0748 
Largest diff. peak, hole 1.375, -1.310 eÅ-3 
Mean and maximum shift/error 0.000 and 0.001 
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Bond lengths [Å] and angles [°] for 13 
Pt-N(1) 1.972(3) 
Pt-N(8) 2.026(4) 
Pt-N(14) 2.044(4) 
Pt-S(19) 2.3131(10) 
N(1)-C(2) 1.339(6) 
N(1)-C(6) 1.344(6) 
C(2)-C(3) 1.396(6) 
C(2)-C(7) 1.478(6) 
C(3)-C(4) 1.397(6) 
C(4)-C(5) 1.384(7) 
C(5)-C(6) 1.381(6) 
C(6)-C(13) 1.476(6) 
C(7)-N(8) 1.370(6) 
C(7)-C(12) 1.378(6) 
N(8)-C(9) 1.341(6) 
C(9)-C(10) 1.376(7) 
C(10)-C(11) 1.375(8) 
C(11)-C(12) 1.393(7) 
C(13)-N(14) 1.373(6) 
C(13)-C(18) 1.380(7) 
N(14)-C(15) 1.326(6) 
C(15)-C(16) 1.383(8) 
C(16)-C(17) 1.387(9) 
C(17)-C(18) 1.382(8) 
S(19)-C(20) 1.814(5) 
C(20)-C(21) 1.509(7) 
C(21)-N(22) 1.493(6) 
N(22)-C(27) 1.494(6) 
N(22)-C(23) 1.501(6) 
N(22)-Cl(1) 3.063(4) 
C(23)-C(24) 1.508(8) 
C(24)-C(25) 1.507(10) 
C(25)-C(26) 1.522(8) 
C(26)-C(27) 1.508(7) 
O(30)-C(31) 1.389(17) 
O(30')-C(31') 1.40(2) 
O(40)-C(41) 1.372(14) 
O(40')-C(41') 1.38(2) 
 
N(1)-Pt-N(8) 80.69(14) 
N(1)-Pt-N(14) 80.60(15) 
N(8)-Pt-N(14) 161.29(15) 
N(1)-Pt-S(19) 178.78(10) 
N(8)-Pt-S(19) 98.57(11) 
N(14)-Pt-S(19) 100.13(11) 
C(2)-N(1)-C(6) 124.7(4) 
C(2)-N(1)-Pt 117.5(3) 
C(6)-N(1)-Pt 117.9(3) 
N(1)-C(2)-C(3) 118.9(4) 
N(1)-C(2)-C(7) 113.3(4) 
C(3)-C(2)-C(7) 127.7(4) 
C(2)-C(3)-C(4) 117.7(4) 
C(5)-C(4)-C(3) 121.2(4) 
C(6)-C(5)-C(4) 119.2(4) 
N(1)-C(6)-C(5) 118.3(4) 
N(1)-C(6)-C(13) 113.0(4) 
C(5)-C(6)-C(13) 128.7(4) 
N(8)-C(7)-C(12) 121.6(4) 
N(8)-C(7)-C(2) 115.1(4) 
C(12)-C(7)-C(2) 123.3(4) 
C(9)-N(8)-C(7) 118.8(4) 
C(9)-N(8)-Pt 127.7(3) 
C(7)-N(8)-Pt 113.4(3) 
N(8)-C(9)-C(10) 122.0(5) 
C(11)-C(10)-C(9) 119.4(4) 
C(10)-C(11)-C(12) 119.6(5) 
C(7)-C(12)-C(11) 118.5(4) 
N(14)-C(13)-C(18) 120.5(4) 
N(14)-C(13)-C(6) 115.8(4) 
C(18)-C(13)-C(6) 123.8(4) 
C(15)-N(14)-C(13) 120.3(4) 
C(15)-N(14)-Pt 126.9(3) 
C(13)-N(14)-Pt 112.7(3) 
N(14)-C(15)-C(16) 121.2(5) 
C(15)-C(16)-C(17) 119.4(5) 
C(18)-C(17)-C(16) 119.3(5) 
C(13)-C(18)-C(17) 119.2(5) 
C(20)-S(19)-Pt 103.57(15) 
C(21)-C(20)-S(19) 110.9(3) 
N(22)-C(21)-C(20) 113.5(4) 
C(21)-N(22)-C(27) 113.3(4) 
C(21)-N(22)-C(23) 110.6(4) 
C(27)-N(22)-C(23) 110.9(4) 
N(22)-C(23)-C(24) 110.8(4) 
C(25)-C(24)-C(23) 112.4(5) 
C(24)-C(25)-C(26) 110.1(5) 
C(27)-C(26)-C(25) 111.1(5) 
N(22)-C(27)-C(26) 111.2(4) 
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Data for 5 
Empirical formula C21 H22 Cl2 N4 O2 Zn 
Formula weight 498.70 
Temperature 173(2) K 
Diffractometer, wavelength OD Xcalibur PX Ultra, 1.54184 Å 
Crystal system, space group Triclinic, P-1 
Unit cell dimensions a = 9.7525(3) Å 
 b = 10.3473(4) Å 
 c = 11.4850(4) Å 
Volume, Z 1097.53(7) Å3, 2 
Density (calculated) 1.509 Mg/m3 
Absorption coefficient 4.004 mm-1 
F(000) 512 
Crystal colour / morphology Colourless blocky needles 
Crystal size 0.24 x 0.20 x 0.11 mm3 
θ range for data collection 4.06 to 72.56° 
Index ranges -9<=h<=12, -12<=k<=12, -14<=l<=14 
Reflns collected / unique 13269 / 4322 [R(int) = 0.0217] 
Reflns observed [F>4ϭ(F)] 3920 
Absorption correction Analytical 
Max. and min. transmission 0.700 and 0.502 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4322 / 0 / 272 
Goodness-of-fit on F2 1.053 
Final R indices [F>4ϭ(F)] R1 = 0.0294, wR2 = 0.0759 
R indices (all data) R1 = 0.0330, wR2 = 0.0777 
Extinction coefficient 0.0022(3) 
Largest diff. peak, hole 0.300, -0.326 eÅ-3 
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Bond lengths [Å] and angles [°] for 5 
Zn-N(1) 2.1049(14) 
Zn-N(8) 2.1953(14) 
Zn-N(14) 2.2017(15) 
Zn-Cl(2) 2.2556(5) 
Zn-Cl(1) 2.2824(5) 
N(1)-C(2) 1.332(2) 
N(1)-C(6) 1.346(2) 
C(2)-C(3) 1.389(2) 
C(2)-C(7) 1.492(2) 
C(3)-C(4) 1.398(2) 
C(4)-O(19) 1.346(2) 
C(4)-C(5) 1.400(2) 
C(5)-C(6) 1.382(2) 
C(6)-C(13) 1.487(2) 
C(7)-N(8) 1.345(2) 
C(7)-C(12) 1.389(2) 
N(8)-C(9) 1.338(2) 
C(9)-C(10) 1.385(3) 
C(10)-C(11) 1.378(3) 
C(11)-C(12) 1.387(3) 
C(13)-N(14) 1.344(2) 
C(13)-C(18) 1.391(3) 
N(14)-C(15) 1.334(2) 
C(15)-C(16) 1.382(3) 
C(16)-C(17) 1.384(3) 
C(17)-C(18) 1.389(3) 
O(19)-C(20) 1.455(2) 
C(20)-C(21) 1.508(2) 
C(21)-N(22) 1.467(2) 
N(22)-C(27) 1.458(2) 
N(22)-C(23) 1.460(2) 
C(23)-C(24) 1.510(3) 
C(24)-O(25) 1.429(3) 
O(25)-C(26) 1.428(2) 
C(26)-C(27) 1.512(3) 
N(1)-Zn-N(8) 74.45(5) 
N(1)-Zn-N(14) 74.28(5) 
N(8)-Zn-N(14) 147.22(6) 
N(1)-Zn-Cl(2) 135.14(4) 
N(8)-Zn-Cl(2) 96.83(4) 
N(14)-Zn-Cl(2) 98.36(4) 
N(1)-Zn-Cl(1) 105.61(4) 
N(8)-Zn-Cl(1) 99.81(4) 
N(14)-Zn-Cl(1) 97.78(4) 
Cl(2)-Zn-Cl(1) 119.25(2) 
C(2)-N(1)-C(6) 120.08(15) 
C(2)-N(1)-Zn 120.15(11) 
C(6)-N(1)-Zn 119.62(11) 
N(1)-C(2)-C(3) 122.34(15) 
N(1)-C(2)-C(7) 114.14(14) 
C(3)-C(2)-C(7) 123.51(15) 
C(2)-C(3)-C(4) 117.85(16) 
O(19)-C(4)-C(3) 124.47(16) 
O(19)-C(4)-C(5) 115.92(15) 
C(3)-C(4)-C(5) 119.60(16) 
C(6)-C(5)-C(4) 118.50(16) 
N(1)-C(6)-C(5) 121.62(16) 
N(1)-C(6)-C(13) 114.02(15) 
C(5)-C(6)-C(13) 124.35(15) 
N(8)-C(7)-C(12) 121.98(16) 
N(8)-C(7)-C(2) 114.86(14) 
C(12)-C(7)-C(2) 123.16(15) 
C(9)-N(8)-C(7) 119.26(15) 
C(9)-N(8)-Zn 124.63(12) 
C(7)-N(8)-Zn 116.06(11) 
N(8)-C(9)-C(10) 122.19(17) 
C(11)-C(10)-C(9) 118.26(17) 
C(10)-C(11)-C(12) 120.38(17) 
C(11)-C(12)-C(7) 117.88(17) 
N(14)-C(13)-C(18) 121.79(16) 
N(14)-C(13)-C(6) 114.79(15) 
C(18)-C(13)-C(6) 123.41(16) 
C(15)-N(14)-C(13) 119.34(16) 
C(15)-N(14)-Zn 124.71(13) 
C(13)-N(14)-Zn 115.37(11) 
N(14)-C(15)-C(16) 121.94(18) 
C(15)-C(16)-C(17) 119.27(18) 
C(16)-C(17)-C(18) 118.95(18) 
C(17)-C(18)-C(13) 118.57(18) 
C(4)-O(19)-C(20) 117.41(13) 
O(19)-C(20)-C(21) 109.37(14) 
N(22)-C(21)-C(20) 112.51(14) 
C(27)-N(22)-C(23) 108.85(15) 
C(27)-N(22)-C(21) 112.51(15) 
C(23)-N(22)-C(21) 111.42(14) 
N(22)-C(23)-C(24) 109.15(16) 
O(25)-C(24)-C(23) 111.49(17) 
C(26)-O(25)-C(24) 109.79(15) 
O(25)-C(26)-C(27) 111.01(16) 
N(22)-C(27)-C(26) 109.74(16) 
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Data for 6 
Empirical formula [C21 H22 Cl2 Cu N4 O2] . H2O 
Formula weight 514.88 
Temperature 173(2) K 
Diffractometer, wavelength OD Xcalibur PX Ultra, 1.54184 Å 
Crystal system, space group Monoclinic, P2(1)/c 
Unit cell dimensions a = 16.01719(19) Å 
 b = 14.02884(14) Å 
 c = 9.97472(12) Å 
Volume, Z 2183.41(4) Å3, 4 
Density (calculated) 1.566 Mg/m3 
Absorption coefficient 3.931 mm-1 
F(000) 1060 
Crystal colour / morphology Blue thin plates 
Crystal size 0.31 x 0.28 x 0.03 mm3 
θ range for data collection 2.83 to 72.49° 
Index ranges -19<=h<=13, -15<=k<=17, -10<=l<=12 
Reflns collected / unique 8103 / 4194 [R(int) = 0.0207] 
Reflns observed [F>4ϭ(F)] 3314 
Absorption correction Analytical 
Max. and min. transmission 0.894 and 0.432 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4194 / 2 / 288 
Goodness-of-fit on F2 1.044 
Final R indices [F>4ϭ(F)] R1 = 0.0354, wR2 = 0.0982 
R indices (all data) R1 = 0.0474, wR2 = 0.1045 
Largest diff. peak, hole 0.476, -0.309 eÅ-3 
Mean and maximum shift/error 0.000 and 0.001 
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Bond lengths [Å] and angles [°] for 6 
Cu-N(1) 1.9525(18) 
Cu-N(14) 2.0418(18) 
Cu-N(8) 2.0526(17) 
Cu-Cl(2) 2.2393(5) 
Cu-Cl(1) 2.5237(6) 
N(1)-C(6) 1.331(3) 
N(1)-C(2) 1.337(3) 
C(2)-C(3) 1.383(3) 
C(2)-C(7) 1.479(3) 
C(3)-C(4) 1.405(3) 
C(4)-O(19) 1.344(3) 
C(4)-C(5) 1.399(3) 
C(5)-C(6) 1.394(3) 
C(6)-C(13) 1.479(3) 
C(7)-N(8) 1.355(3) 
C(7)-C(12) 1.382(3) 
N(8)-C(9) 1.334(3) 
C(9)-C(10) 1.395(3) 
C(10)-C(11) 1.387(3) 
C(11)-C(12) 1.390(3) 
C(13)-N(14) 1.358(3) 
C(13)-C(18) 1.384(3) 
N(14)-C(15) 1.331(3) 
C(15)-C(16) 1.393(3) 
C(16)-C(17) 1.385(3) 
C(17)-C(18) 1.383(3) 
O(19)-C(20) 1.440(2) 
C(20)-C(21) 1.514(3) 
C(21)-N(22) 1.463(3) 
N(22)-C(23) 1.466(3) 
N(22)-C(27) 1.470(3) 
C(23)-C(24) 1.512(3) 
C(24)-O(25) 1.425(3) 
O(25)-C(26) 1.428(3) 
C(26)-C(27) 1.520(3) 
N(1)-Cu-N(14) 79.27(7) 
N(1)-Cu-N(8) 79.47(6) 
N(14)-Cu-N(8) 157.30(7) 
N(1)-Cu-Cl(2) 163.60(6) 
N(14)-Cu-Cl(2) 98.77(5) 
N(8)-Cu-Cl(2) 99.36(5) 
N(1)-Cu-Cl(1) 94.98(6) 
N(14)-Cu-Cl(1) 92.59(5) 
N(8)-Cu-Cl(1) 97.10(5) 
Cl(2)-Cu-Cl(1) 101.39(2) 
C(6)-N(1)-C(2) 121.94(18) 
C(6)-N(1)-Cu 119.23(13) 
C(2)-N(1)-Cu 118.83(13) 
N(1)-C(2)-C(3) 120.65(18) 
N(1)-C(2)-C(7) 113.26(17) 
C(3)-C(2)-C(7) 126.09(18) 
C(2)-C(3)-C(4) 118.27(18) 
O(19)-C(4)-C(5) 125.25(18) 
O(19)-C(4)-C(3) 114.35(17) 
C(5)-C(4)-C(3) 120.39(19) 
C(6)-C(5)-C(4) 117.19(19) 
N(1)-C(6)-C(5) 121.50(19) 
N(1)-C(6)-C(13) 112.86(17) 
C(5)-C(6)-C(13) 125.63(19) 
N(8)-C(7)-C(12) 121.57(19) 
N(8)-C(7)-C(2) 114.15(17) 
C(12)-C(7)-C(2) 124.27(18) 
C(9)-N(8)-C(7) 119.07(18) 
C(9)-N(8)-Cu 126.74(14) 
C(7)-N(8)-Cu 114.14(13) 
N(8)-C(9)-C(10) 122.5(2) 
C(11)-C(10)-C(9) 118.5(2) 
C(10)-C(11)-C(12) 119.0(2) 
C(7)-C(12)-C(11) 119.38(19) 
N(14)-C(13)-C(18) 121.10(19) 
N(14)-C(13)-C(6) 114.00(18) 
C(18)-C(13)-C(6) 124.89(18) 
C(15)-N(14)-C(13) 119.22(18) 
C(15)-N(14)-Cu 126.29(14) 
C(13)-N(14)-Cu 114.37(14) 
N(14)-C(15)-C(16) 122.60(19) 
C(17)-C(16)-C(15) 118.2(2) 
C(18)-C(17)-C(16) 119.4(2) 
C(17)-C(18)-C(13) 119.5(2) 
C(4)-O(19)-C(20) 120.52(16) 
O(19)-C(20)-C(21) 103.99(17) 
N(22)-C(21)-C(20) 113.54(18) 
C(21)-N(22)-C(23) 109.52(16) 
C(21)-N(22)-C(27) 111.83(16) 
C(23)-N(22)-C(27) 107.93(17) 
N(22)-C(23)-C(24) 109.51(17) 
O(25)-C(24)-C(23) 111.10(19) 
C(24)-O(25)-C(26) 110.14(18) 
O(25)-C(26)-C(27) 112.28(19) 
N(22)-C(27)-C(26) 109.74(17) 
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Data for 12 
Formula [C21 H23 Au Cl N4 O]3(PF6), 2(C2 H3 N) 
Formula weight 1096.87 
Temperature 173(2) K 
Diffractometer, wavelength OD Xcalibur PX Ultra, 1.54184 Å 
Crystal system, space group Triclinic, P-1 
Unit cell dimensions a = 8.1371(4) Å 
 b = 14.6414(8) Å 
 c = 16.3452(9) Å 
Volume, Z 1824.59(18) Å3, 2 
Density (calculated) 1.996 Mg/m3 
Absorption coefficient 10.671 mm-1 
F(000) 1064 
Crystal colour / morphology Pale yellow thin plates 
Crystal size 0.36 x 0.28 x 0.01 mm3 
θ range for data collection 2.77 to 72.40° 
Index ranges -9<=h<=9, -17<=k<=18, -19<=l<=19 
Reflns collected / unique 13169 / 6946 [R(int) = 0.0460] 
Reflns observed [F>4ϭ(F)] 5873 
Absorption correction Analytical 
Max. and min. transmission 0.877 and 0.190 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6946 / 2711 / 729 
Goodness-of-fit on F2 1.053 
Final R indices [F>4ϭ(F)] R1 = 0.0539, wR2 = 0.1423 
R indices (all data) R1 = 0.0653, wR2 = 0.1514 
Largest diff. peak, hole 3.334, -1.567 eÅ-3 
Mean and maximum shift/error 0.000 and 0.003 
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Bond lengths [Å] and angles [°] for 12 
Au-N(1) 1.990(5) 
Au-N(14) 2.015(6) 
Au-N(8) 2.026(6) 
Au-Cl 2.2586(18) 
N(1)-C(2) 1.326(8) 
N(1)-C(6) 1.345(8) 
C(2)-C(3) 1.362(11) 
C(2)-C(7) 1.481(10) 
C(3)-C(4) 1.382(11) 
C(4)-O(19) 1.349(9) 
C(4)-C(5) 1.415(10) 
C(5)-C(6) 1.342(10) 
C(6)-C(13) 1.494(9) 
C(7)-C(12) 1.380(10) 
C(7)-N(8) 1.383(10) 
N(8)-C(9) 1.335(10) 
C(9)-C(10) 1.407(11) 
C(10)-C(11) 1.374(13) 
C(11)-C(12) 1.379(12) 
C(13)-N(14) 1.357(9) 
C(13)-C(18) 1.383(10) 
N(14)-C(15) 1.362(9) 
C(15)-C(16) 1.387(11) 
C(16)-C(17) 1.383(12) 
C(17)-C(18) 1.379(11) 
O(19)-C(20) 1.445(10) 
C(20)-C(21) 1.461(14) 
C(20)-C(21') 1.511(18) 
C(21)-N(22) 1.377(16) 
N(22)-C(23) 1.385(15) 
N(22)-C(26) 1.523(15) 
C(23)-C(24) 1.533(16) 
C(24)-C(25) 1.512(16) 
C(25)-C(26) 1.516(15) 
C(21')-N(22') 1.367(19) 
N(22')-C(23') 1.449(17) 
N(22')-C(26') 1.457(17) 
C(23')-C(24') 1.527(18) 
C(24')-C(25') 1.517(17) 
C(25')-C(26') 1.529(17) 
N(1)-Au-N(14) 81.1(2) 
N(1)-Au-N(8) 80.8(2) 
N(14)-Au-N(8) 161.8(3) 
N(1)-Au-Cl 177.89(14) 
N(14)-Au-Cl 99.41(18) 
N(8)-Au-Cl 98.72(18) 
C(2)-N(1)-C(6) 126.3(6) 
C(2)-N(1)-Au 117.3(4) 
C(6)-N(1)-Au 116.4(4) 
N(1)-C(2)-C(3) 118.0(6) 
N(1)-C(2)-C(7) 113.6(6) 
C(3)-C(2)-C(7) 128.4(6) 
C(2)-C(3)-C(4) 117.6(6) 
O(19)-C(4)-C(3) 114.8(7) 
O(19)-C(4)-C(5) 122.7(7) 
C(3)-C(4)-C(5) 122.5(7) 
C(6)-C(5)-C(4) 116.8(6) 
C(5)-C(6)-N(1) 118.7(6) 
C(5)-C(6)-C(13) 128.2(6) 
N(1)-C(6)-C(13) 113.1(6) 
C(12)-C(7)-N(8) 119.5(7) 
C(12)-C(7)-C(2) 125.1(7) 
N(8)-C(7)-C(2) 115.3(6) 
C(9)-N(8)-C(7) 121.2(6) 
C(9)-N(8)-Au 125.8(5) 
C(7)-N(8)-Au 112.9(4) 
N(8)-C(9)-C(10) 119.7(7) 
C(11)-C(10)-C(9) 119.9(7) 
C(10)-C(11)-C(12) 119.5(7) 
C(11)-C(12)-C(7) 120.1(8) 
N(14)-C(13)-C(18) 120.7(6) 
N(14)-C(13)-C(6) 115.4(6) 
C(18)-C(13)-C(6) 123.8(6) 
C(13)-N(14)-C(15) 120.5(6) 
C(13)-N(14)-Au 113.8(4) 
C(15)-N(14)-Au 125.6(5) 
N(14)-C(15)-C(16) 120.1(7) 
C(17)-C(16)-C(15) 119.5(7) 
C(18)-C(17)-C(16) 119.9(7) 
C(17)-C(18)-C(13) 119.3(7) 
C(4)-O(19)-C(20) 121.2(6) 
O(19)-C(20)-C(21) 108.4(10) 
O(19)-C(20)-C(21') 104.1(11) 
N(22)-C(21)-C(20) 123.2(11) 
C(21)-N(22)-C(23) 138.9(12) 
C(21)-N(22)-C(26) 118.0(9) 
C(23)-N(22)-C(26) 99.4(13) 
N(22)-C(23)-C(24) 108.9(11) 
C(25)-C(24)-C(23) 102.9(8) 
C(24)-C(25)-C(26) 103.8(8) 
C(25)-C(26)-N(22) 104.6(10) 
N(22')-C(21')-C(20) 120.4(13) 
C(21')-N(22')-C(23') 130.8(14) 
C(21')-N(22')-C(26') 129.2(14) 
C(23')-N(22')-C(26') 99.5(14) 
N(22')-C(23')-C(24') 106.3(14) 
C(25')-C(24')-C(23') 103.3(9) 
C(24')-C(25')-C(26') 103.2(9) 
N(22')-C(26')-C(25') 105.7(14) 
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A.8 MTS Assay Profiles 
 
Figure A-84: MTS assay profile for the platinum(II)-terpyridine complexes with the U2OS cell line. 
 
 
Figure A-85: MTS assay profile for the bi-metallic complexes with the U2OS cell line. 
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Figure A-86: MTS assay profile for the tri-metallic complexes with the U2OS cell line. 
 
 
Figure A-87: MTS assay profile for the pyridyl-phenanthroline platinum(II) complexes with the U2OS cell line. 
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Figure A-88: MTS assay profile for the phenyl-phenanthroline platinum(II) complexes with the U2OS cell line. 
 
Figure A-89: MTS assay profile for the platinum(II)-terpyridine complexes with the 293T cell line. 
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Figure A-90: MTS assay profile for the di-metallic complexes with the 293T cell line. 
 
 
Figure A-91: MTS assay profile for the tri-metallic complexes with the 293T cell line. 
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Figure A-92: MTS assay profile for the pyridyl-phenanthroline platinum(II) complexes with the 293T cell line. 
 
 
Figure A-93: MTS assay profile for the phenyl-phenanthroline platinum(II) complexes with the 293T cell line. 
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Figure A-94: MTS assay profile for the platinum(II)-terpyridine complexes with the GMO5757 cell line. 
 
 
Figure A-95: MTS assay profile for the di-metallic complexes with the GMO5757 cell line. 
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Figure A-96: MTS assay profile for the tri-metallic complexes with the GMO5757 cell line. 
 
 
Figure A-97: MTS assay profile for the pyridyl-phenanthroline platinum(II) complexes with the GM05757 cell line. 
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Figure A-98: MTS assay profile for the phenyl-phenanthroline platinum(II) complexes with the GM05757 cell line. 
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A.9 Flow Cytometry Population Profiles 
 
Figure A-99: Forward scatter - height (cell size) vs side scatter (cell texture) dot plot. The population of cells selected for 
study are shown by the gates. 
 
 
 
 
Figure A-100: Forward scatter - height vs forward scatter – area dot plot. The population of cells selected for study are 
shown by the gates. 
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Figure A-101: An example of a histrogram respresenting the different phases of the cell cycle for the cells in the chosen 
population. 
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